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Introduction and research questions
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1
The number of hip (THA) and knee (TKA) arthroplasties performed in the Netherlands is still 
rising. During the first five years of the Dutch LROI database (2007-2011) 105,455 primary 
hip arthroplasties and 79,272 primary knee arthroplasties were registered.1 As of June 2014 
about 150,000 TKA and 200,000 THA are registered. The projected increase until 2020 in 
prevalence of hip and knee arthroplasties will have important ramifications with regard to 
the number of joint arthroplasties expected and the subsequent increase in health care 
costs.2
Health care costs are expanding and in all areas solutions are being sought to decrease 
the national burden of health care. The changes of the last decennia in daily orthopaedic 
practice, especially the increase in not only the number of total joint arthroplasties, but also 
in faster postoperative rehabilitation is considerable. The introduction of fast-track surgery 
by means of clinical pathways for elective joint arthroplasties has reduced sin ome part 
the in-hospital inefficiency. Furthermore, techniques for reducing ‘surgical stress’ made a 
large change in the postoperative rehabilitation program.3 After surgical injury the body 
responds with profound changes in neural, endocrine and metabolic systems in addition to 
alterations in organ functions.4-6 These changes represent an universally conserved cellular 
defence mechanism of the body, but the stress-induced changes in postoperative organ 
function may also be implicated in the development of postoperative complications.5,7 Both 
pain and blood management are important issues, in order to reduce this surgical stress 
response, which could counteract fast postoperative rehabilitation.
PAIn MAnAgeMenT
In the last decades the focus in pain management was on the prevention of side effects, 
such as drowsiness or nausea. The implemented analgesia regime to enhance faster 
postoperative recovery and reduce morbidity to the patient was achieved with a multimodal 
approach.8,9 This approach should minimize stimuli at each nervous level (central and 
peripheral) and limit activation of the central nervous system. The use of a variety of 
medications at relatively low doses takes advantage of multiple pain modulators. Thus, the 
medication addresses several different steps along the pain pathway, which results in lower 
narcotic use and therefore fewer side effects that interfere with mobilisation.
Pre-emptive analgesia is a pillar in this concept, the medication is given before the 
surgical injury takes place, in order to block the transmission to the nervous system as 
early as possible.10-12 Better pain control and fewer side effects are present than when a 
single modality (i.e. opioids) is used.10-12 Although there is still debate on the concept of 
Thomassen.indd   11 30-10-2014   11:44:03
12 | Chapter 1
pre-emptive analgesia, more local analgesia techniques in THA and TKA were introduced 
in addition to the current gold standards of locoregional anaesthesia such as spinal or 
epidural.13 The beneficial effects of a femoral nerve block or local infiltration analgesia (LIA) 
in TKA have been widely studied in recent years.14-17 Different mixtures (content of the 
technique, composition of the LIA solution) and types of local infiltration (with or without 
catheter and its placement) are used around the world.15,18 Since LIA in THA and TKA has 
great effects on postoperative rehabilitation, it will also have implications on perioperative 
patient blood management. The impact of high-volume local infiltrations on the collection 
of shed blood for autologous blood transfusion is unknown.
Blood MAnAgeMenT
Total hip and knee arthroplasty surgery have significant perioperative blood loss; the 
combined visible and invisible blood loss is reported to be 1500 mL on average.19,20 This 
blood loss eventually causes a decrease in the postoperative haemoglobin (Hb) level of 
approximately 3 g/dL.19 Therefore blood transfusions are frequently reported after this 
type of surgery. Nevertheless, a large variation in perioperative transfusion rates have 
been reported, with up to 69% of patients being transfused, depending mainly on the used 
transfusion policy.21
During the last two decades great efforts have been made to change the practice of a 
liberal blood transfusion policy to a more restrictive policy.22-24 The awareness that the HIV 
and hepatitis virus could be transmitted through allogeneic blood transfusions in the early 
1980’s changed the attitude of both physicians as well as the public to the inherent risks 
of allogeneic blood. This also stimulated the emerging of a new discipline: ‘Transfusion 
Medicine’.25
The restrictive blood transfusion policy, i.e. awareness and a strict transfusion trigger 
(the so-called 4-5-6 (mmol/L) rule that is currently advised in the Netherlands) has led 
to a decrease in allogeneic blood transfusions by 30-40% in THA and TKA.26,27 Next to a 
restrictive blood transfusion policy several techniques for reducing the need for allogeneic 
blood transfusions became available. Alternatives for an allogeneic blood transfusion can 
be subdivided in two main groups: non-pharmaceutical interventions and pharmaceutical 
interventions.28,29
The non-pharmaceutical interventions consist of preoperative autologous donation, peri-
operative normovolaemic haemodilution, the use of a perioperative cell saver or post-
operative autologous blood retransfusion devices
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The pharmaceutical interventions comprise the pre-operative use of erythropoietin with 
(or without) iron supplementation, the perioperative use of anti-fibrinolytics such as 
tranexamic acid or fibrin glue.
Although we see a clear downward trend in transfusion needs, still many controversies 
are present about both the clinical effectiveness and the cost effectiveness of these 
alternatives. Although there is an awareness of transfusion medicine nowadays, the 
optimal algorithm for using these transfusion alternatives remains unclear. In addition, 
reported effects of many transfusion alternatives differ extensively leading to questions on 
methodology quality of PBM trials. Guyatt and co-workers developed several guidelines on 
this topic of quality assessment.30-32 Especially in surgical randomised clinical trials, bias is 
to a great extent determined by absence of concealment of allocation, blinding of patients 
(where possible) and outcome assessors and lost to follow-up.33-35 Evaluation of the quality 
of blood management trials comprises the second part of this thesis.
SCoPe oF THe THeSIS
Evaluation of postoperative patient pain management (PPM) and patient blood management 
(PBM) in elective total knee and total hip arthroplasty:
– Patient Pain Management (PPM)
• Postoperative analgesia in TKA patients with a more local technique, a femoralis 
block. What is an optimal dose in patients for an equipoise between pain and 
sufficient strength for postoperative rehabilitation (chapter 2)
• Patient safety in presence of local infiltration analgesia (LIA) and autologous blood 
reinfusion devices in total knee arthroplasty (chapter 3, 4)
– Patient Blood Management (PBM)
• An evaluation of two different transfusion alternatives was carried out in patients 
with specific haemoglobin values (chapter 5)
• A cost calculation for erythropoietin alpha in daily practice was made based on 
the cost saving data in literature and transfusion figures from two large teaching 
hospitals (chapter 6)
• Transfusion of shed blood collected with an autologous blood transfusion device 
is possible within 6 hours postoperative. Is there a difference in efficacy and an 
additional value of an autologous transfusion device (chapter 7)
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• A new intra- and postoperative cell saving device was tested in revision and primary 
THA with the hypothesis that it would reduce allogeneic blood transfusions in the 
postoperative phase (chapter 8)
– Two methodological aspects in PBM trials were investigated. Firstly, the aspect of blinding 
is important in the conduct of a clinical trial but is it also important to be blind for study 
results when evaluating risk of bias (chapter 9). Secondly, the heterogeneity in drainage 
trials is investigated because transfusion figures divers significantly. Which variables are 
of additional value when transfusion trials are being compared (chapter 10).
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Femoral nerve block using ropivacaine 0.025%, 0.05% 
and 0.1%: effects on the rehabilitation programmes 
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ABSTRACT
Femoral nerve blockade is recommended for analgesia following total knee 
arthroplasty. Following implementation of this type of postoperative analgesia in 
our hospital we found that active mobilization the day after surgery, may be difficult 
due to insufficient quadriceps muscle strength. We therefore designed a pilot 
study comparing the effect of ropivacaine 0.1%, 0.05% or 0.025% on the patient’s 
postoperative rehabilitation and analgesia. Three groups of 12 patients received 
bolus doses of ropivacaine via their femoral nerve catheters for postoperative 
analgesia. The ability to actively mobilize, quadriceps muscle strength, pain VAS-
scores and patient’s satisfaction were measured during the first three postoperative 
days. There were no significant differences in the patient’s ability to actively 
mobilize and the pain VAS-scores. The overall satisfaction of the patients with the 
pain treatment was significantly better (p=0.049) in the 0.1% compared with the 
0.025% group. This pilot study demonstrated no advantage associated with the use 
of a ropivacaine concentration less than 0.1%.
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InTRoduCTIon
Adequate postoperative pain control is important for rapid and optimal rehabilitation 
following total knee arthroplasty (TKA).1 A multimodal approach for postoperative pain 
management that reduces nociception at a local, spinal and cerebral level is recommended, 
because it achieves better pain control and less side effects than when a single modality 
(i.e. opioids) is used.2-3 In recent years several studies have indicated the beneficial effect of 
a femoral nerve blockade as part of a multimodal analgesia regime on postoperative pain 
and passive joint function following TKA.4-6 However, after incorporation of a femoral nerve 
catheter for bolus doses of 10 mL ropivacaine 0.1% in our postoperative pain protocol for 
TKA we received feedback from the nurses and physiotherapists that although analgesia 
appeared to be improved, a greater number of patients were unable to mobilize (i.e. walk) 
the day following surgery due to inadequate quadriceps muscle strength and diminished 
proprioception (i.e. sensation of joint position). Femoral nerve blockade produces a motor 
and sensory block of the anterior thigh muscles, i.e. quadriceps femoris, pectineous muscle, 
iliopsoas muscle and sartorius muscle and the skin on the anteromedial aspect of the thigh 
and knee. These factors may cause decreased muscle power and diminished proprioception 
and therefore interfere with the fast-track rehabilitation programme after TKA used in our 
institution. In this programme, patients are mobilised the morning after surgery and they 
follow an active rehabilitation schedule, which enables patients to be discharged home on 
the morning of the 5th postoperative day.
On the assumption that decreasing the concentration of ropivacaine used for femoral nerve 
blockade may improve the patient’s ability to follow the fast-track rehabilitation programme 
after TKA, we designed a pilot study using 0.1%, 0.05% or 0.025% ropivacaine bolus doses 
postoperatively. The purpose of this pilot study was to identify an optimal concentration 
of ropivacaine that provides good analgesia and patient’s satisfaction following TKA, whilst 
not interfering with the active mobilisation program.
MeTHodS
The local Ethical Committee approved the study. Patients scheduled for TKA, aged between 
18-80 years, without allergic or other contra-indications to the medication used in this 
study, were selected. Eligible patients, received verbal and written information on the 
study. One week before the scheduled surgery the patients gave written informed consent.
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Approximately 1hr prior to surgery the attending anaesthetist inserted a perineural 
femoral catheter (Pajunk with stimulating tip, Plastimed Benelux B.V., Velserbroek, The 
Netherlands) and administered 20 mL ropivacaine 0.2% using this catheter. Following 
confirmation of correct catheter position by the loss of skin sensibility and quadriceps 
weakness, 36 patients were randomly allocated, by the use of sealed envelopes, to one 
of three equally sized groups (i.e. 0.1%, 0.05% or 0.025% ropivacaine). The ward received 
blinded study medication for the postoperative bolus injections of ropivacaine in a 100 mL 
bottle with only the patient’s name and study number on it. Patients and investigators 
were blinded to the concentration of ropivacaine administered in the bolus injections on 
the ward.
Patients had the option of either general anaesthesia or spinal analgesia. Patients 
preferring general anaesthesia received propofol 1.5-2.5 mg.kg-1 and fentanyl 0.02 mg.kg-1 
for induction. Atracurium 0.3-0.5 mg.kg-1 was used to facilitate tracheal intubation. The 
patients’ lungs were mechanically ventilated using oxygen (40-60%) in air and sevoflurane 
at an end-tidal concentration of approximately 1.8%. At the discretion of the anaesthetist 
additional doses of fentanyl could be administered to suppress responses of the patient 
indicating inadequate anaesthesia. For spinal analgesia 15-20 mg bupivacaine 0.5% was 
administered at the interspace L2-3 or L3-4 using a 27-gauge 3.5-inch Whitacre spinal 
needle and a midline approach with the patient in a sitting position.
During the study period all patients received acetaminophen 1g four times daily, starting 
approximately 1hr before surgery and celecoxib 200 mg once daily, started in the recovery 
room. On arrival in the recovery room a continuous infusion of ropivacaine 0.1% 5mL.h-1 via 
the femoral catheter was started and was infused until 06.00 the following morning to ensure 
good analgesia during the first night after surgery. At 06.00 the infusion was discontinued 
and the patients received bolus injections of 10 mL ropivacaine at a concentration according 
to their study group (i.e. 0.1%, 0.05% or 0.025%). Four bolus injections were given on fixed 
times, i.e. first postoperative day at 06.00 (after discontinuation of the continuous infusion), 
11.00 (after mobilisation by the physiotherapist) and 22.00 and the second postoperative 
day at 06.00, to achieve a basic level of analgesia together with the acetaminophen and 
celecoxib. Apart from these fixed bolus injections, extra 10 mL doses of ropivacaine with 
a minimum time interval between doses of 30 min were given on patient request. If two 
consecutive doses of ropivacaine did not achieve adequate pain relief, 15 mg piritramide 
intramuscularly was administered as rescue medication. In the morning of the third 
postoperative day the femoral catheter was removed.
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One week before the scheduled surgery basic measurements of pain (VAS, a 100 mm 
horizontal line with the words ‘no pain’ at the left and ‘worst possible pain’ on the right) and 
quadriceps muscle strength were performed. Quadriceps muscle strength was measured 
by the physiotherapist using two methods: a qualitative measurement using a 6-point 
numerical rating scale (MRC scale7, Table 1) and a quantitative method for knee extension 
using a hand-held isometric force dynamometer (microFET2®, Hoggan Health Industries 
Inc., USA). The quantitative measurements of quadriceps muscle strength during the study 
were reported as a percentage of the baseline measurements 1 week before surgery.
Table 1 Qualitative 6-point rating of quadriceps muscle strength (MRC)7
level grading
0 No muscle action
1 Flicker of movement
2 Unable to overcome gravity
3 Able to overcome gravity
4 Able to overcome gravity and moderate resistance
5 Assessor unable to manually overcome the muscle power
Qualitative 6-point rating of quadriceps muscle strength
In the first two postoperative days the physiotherapist visited the patients at approximately 
10.00 and 14.30, the third day at 10.00 and the fourth day at 14.30 to measure the muscle 
strength and to determine if the patient had adequate muscle strength and sufficient 
proprioception to safely start the active training program. If patients had a MRC <3 or an 
inadequate sense of joint position they were not allowed to walk but followed a training 
programme in bed. At these time points the physiotherapist also tested the patient’s ability 
to passively flex the operated knee >90°. The rehabilitation programme after TKA, used in 
our institution, aimed at the rapid achievement of a functional level of recovery that enables 
patients to leave the hospital on the fifth postoperative day. The minimal discharge criteria 
were 40m walking with two crutches and ascending and descending stairs consisting of 
12 steps using one crutch and the handrail.
During the physiotherapy visits the patients recorded a pain VAS score at rest and on flexion 
of the knee in a diary. They also recorded a daily satisfaction score with the pain treatment 
(VAS, on a 100 mm horizontal line for satisfaction with the words ‘extremely dissatisfied’ at 
the left and ‘excellent’ on the right) for the first three postoperative days. The nursing staff 
recorded the use of rescue medication (piritramide) in the diary.
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Statistics
Our primary aim was to reduce the number of patients not able to participate in active 
mobilisation due to insufficient muscle power defined as a MRC score <3, while still 
maintaining an adequate pain relief. Previous testing indicated a mean (SD) MRC of 2.2 
(1.02) the day after surgery while using ropivacaine 0.1%. A sample size of 12 per group was 
calculated to detect a clinical relevant increase of the mean MRC of 1.5 between the groups 
at a two-sided 0.05 significant level with a power of 80%.
Data are presented as mean ± SD, median with interquartile ranges (IQR), numbers or 
percentages. Student’s t-test was used for comparison of the means of continuous variables. 
One-way analysis of variance (ANOVA) was used for ordinal data (e.g. VAS-scores, patient’s 
satisfaction with pain therapy), if indicated followed by a Kruskal-Wallis test. Categorical 
data (e.g. ASA physical status, type of anaesthesia) were analysed using chi-squared test 
with Yates correction or two-tailed Fisher’s exact test where appropriate. A p-value <0.05 
was considered statistically significant.
ReSulTS
The groups were comparable for gender, age, body mass index, ASA physical status and 
type of anaesthesia (Table 2). Table 3 shows the qualitative and quantitative measurements 
of quadriceps muscle strength in the operated leg and the patient’s ability to flex the knee. 
There were no significant differences in the number of patients per group with permission 
(MRC >3) to active mobilise during the study period. In fact, more patients in the group 
0.1% were able to mobilise on the first postoperative day (0.1%: 0.05%: 0.025% = 7: 6: 5, 
NS).
Table 2 Demographic and anaesthetic characteristics
group 0.025% 0.05% 0.1%
n (male/female) 12 (4/8) 12 (5/7) 12 (4/8)
Age (years) 68.5 (4.9) 68.3 (8.3) 71.5 (8.6)
Body mass index 28.3 (4.7) 29.9 (6.0) 29.1 (4.3)
ASA physical status I/II 4/8 2/10 5/7
Spinal/general 11/1 11/1 11/1
Data presented as mean (SD) or frequency data
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Table 3 Measurements of quadriceps muscle strength and flexion of the knee
group 0.025% 0.05% 0.1%
day 1
10.00 MRC 2 (2-2.3) 3 (2-3) 2 (1.8-3)
% 15 (22) 10 (15) 11 (13)
14.30 MRC 2.5 (2-3) 3 (2-3) 3 (2-3.3)
% 21 (25) 22 (18) 23 (21)
Flexion >90° 3/12 2/12 1/12
day 2
10.00 MRC 2.5 (2-3) 3 (2-3) 3 (2.8-3)
% 11 (12) 16 (14) 30 (28)*
14.30 MRC 3 (2-3) 3 (2.5-3) 3 (2-3.3)
% 21 (25) 25 (25) 30 (29)
Flexion >90° 4/12 7/12 10/12*
day 3
10.00 MRC 3 (3-3) 3 (3-3) 3 (3-4)
% 24 (19) 29 (19) 33 (25)
Flexion >90° 7/12 8/12 10/12
day 4
14.30 MRC 3.5 (3-4) 3 (3-3.8) 3.5 (3-4)
% 31 (20) 36 (31) 35 (21)
Flexion >90° 8/12 10/12 12/12
*Difference between 0.025% group and 0.1 group significant (p<0.04)
Qualitative measurements (MRC, median (IQR)), quantative measurements (expressed as mean % (SD) of the 
measurement 1 week before the surgery). Flexion is the number of patients with a passive range of motion of 
the operated knee >90°/total number of patients.
By the end of the third postoperative day all patients had permission to walk with a walking 
frame. The quantitative strength measurements in the operated leg declined sharply from 
the pre-operative values in all groups on the first postoperative day and recovered only 
partially (31-36%) (Table 3) in the days until discharge from the hospital. Apart from the first 
measurement (10.00) (Table 3) on the second day there were no significant differences in 
the quantitative power measurements between the groups. Except for the measurement 
at 10.00 on the first postoperative day (r=0.63, p=0.01), the Pearson correlation between 
the qualitative and quantitative strength measurements on the other data collection points 
was poor and not significant (r=0.20-0.26). From day 2 more patients in group 0.1% had a 
passive range of motion of the operated knee >90° compared with the other two groups. 
All patients in group 0.1% reached this milestone in the rehabilitation programme on the 
fourth postoperative day (Table 3). The difference in knee flexion between group 0.1% and 
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0.025% was significant on the second postoperative day. All patients achieved the discharge 
criteria on the fourth postoperative day and went home the following morning.
There were no significant differences in the median VAS scores for pain in rest and during 
flexion of the knee and the median VAS score for patient’s satisfaction with the pain 
treatment between the groups on the separate data collection points (Table 4).
Table 4 Median (IQR) VAS pain score in rest (VASR ) and knee flexion (VASM ) and patient’s daily 
satisfaction with the pain treatment (VASS, 0 = poor and 100 is excellent)
group 0.025% 0.05% 0.1%
1 week preop
VASR 6 (5-42) 4 (3-7) 5 (4-17)
VASM 7 (6-37) 9 (3-35) 5 (2-52)
day 1
10.00 VASR 36 (12-46) 40 (25-47) 34 (21-44)
VASM 38 (26-58) 41 (25-50) 36 (23-47)
VASS 37 (20-75) 66 (54-73) 58 (46-81)
14.30 VASR 17 (5-43) 11 (7-29) 13 (9-17)
VASM 29 (10-48) 27 (14-35) 22 (14-30)
day 2
10.00 VASR 31 (17-46) 20 (16-27) 22 (10-48)
VASM 37 (24-46) 40 (24-71) 37 (20-64)
VASS 45 (26-78) 70 (51-79) 79 (70-90)
14.30 VASR 10 (5-15) 10 (5-21) 15 (7-17)
VASM 26 (19-35) 39 (18-60) 28 (24-43)
day 3
10.00 VASR 11 (9-20) 15 (9-23) 12 (7-36)
VASM 24 (16-46) 20 (11-43) 38 (22-49)
VASS 70 (40-90) 73 (63-82) 83 (64-86)
day 4
VASR 10 (4-21) 16 (8-19) 15 (9-42)
VASM 24 (13-34) 42 (17-55) 25 (11-58)
There were no significant differences between the groups in VAS pain scores. VASS over the whole study period 
(day 1-3) was significantly better in group 0.1% compared to group 0.025% (ANOVA, p=0.049).
However, the overall patient’s satisfaction was consistently better in the group 0.1%. 
Measured over the entire study period (day 1-3) this difference was significant compared 
with the group 0.025% (Table 4). Moreover, the median number of extra bolus doses 
ropivacaine on request of the patient tended to be higher in the 0.025% group (NS, Table 5) 
and the mean decrease of the VAS score 30 min after the bolus injection was significantly 
Thomassen.indd   26 30-10-2014   11:44:04
Femoral nerve block using ropivacaine | 27
2
lower compared with the 0.1% group. Also the median (IQR) number of rescue piritramide 
injections were higher in patients of the 0.025% group compared with the 0.1% group, 
although this difference did not reach statistical significance (p=0.056).
Table 5 Number of extra bolus doses ropivacaine, decrease in VAS pain scores 30 min after a bolus 
dose of ropivacaine and the number of rescue piritramide injections during the study 
group 0.025% 0.05% 0.1% p (0.025% vs 0.1%)
Extra bolus doses 10 (6-11) 6 (4-11) 6 (5-8) NS
Decrease VAS pain 8 (11.7) 13 (13.3) 16 (15.9) 0.01
Piritramide injections 2 (1-4) 0 (0-2) 1 (1-1) 0.056
The number of extra bolus doses ropivacaine presented as median (IQR), the decrease in VAS pain scores 30 min 
after a bolus dose of ropivacaine presented as mean (SD) and the median (IQR) number of rescue piritramide 
injections during the study (day 1-3).
dISCuSSIon
In recent years several studies have indicated the beneficial effect of femoral nerve 
blockade on analgesia and the rehabilitation programme following TKA.4-6,8-10 The principal 
aim of these studies was to detect improvement of postoperative pain control, reduction 
of opioid use and the associated side effects after TKA.
Although quadriceps muscle weakness is often mentioned as a potential disadvantage 
for early ambulation of the patient2,3,5,11, most studies do not comment further on this 
since their rehabilitation programmes in the first postoperative days were mostly in bed 
using a continuous passive motion machine and active walking was postponed until the 
second or third postoperative day or even later.4-6,8-10 Salinas et al. also using the microFET® 
dynamometer, reported a quantitative decrease in quadriceps motor strength to 6 ± 16% 
from baseline motor strength in 17 healthy volunteers who had a continuous femoral block 
with ropivacaine 0.2% 10 mL.h-1 for 4 hours and an initial bolus injection of 10 mL lidocaine 
1%.1 Eight hours after stopping the infusion they had recovered only to 58 ± 40% of their 
baseline power. Apart from the femoral nerve block itself, TKA surgery has a significant 
negative effect on quadriceps muscle strength of the operated leg.5,12 In 14 consecutive 
patients after TKA without a postoperative regional technique in our institution the mean 
(SD) muscle strength in the operated leg declined to 33% (18) the day after surgery and 
recovered to 54% (30) on the fourth postoperative day (B.J.W. Thomassen, unpublished 
data). In the present study quantitative strength measurements declined to 15-23% of the 
baseline on the first postoperative day and recovered to 31-36% the day before discharge 
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(Table 3). There were no apparent differences in quantitative muscle strength between 
the groups and no indication of higher values in the groups with a lower concentration of 
ropivacaine that might become significant if we had included more patients in our study.
Barrington et al. using the same 6-point rating scale for qualitative muscle strength 
measurement as in our study (Table 1), reported that only 6 of 53 patients had a 
score >3 on the first day after TKA in their femoral nerve block group using bupivacaine 
0.2% at 0.1 mL.kg-1.h-1 with a PCA bolus of 0.05 mL.kg-1.5 They also found significantly 
greater quadriceps muscle blockade in their femoral nerve blockade group on the second 
postoperative day compared with the group of patients with epidural analgesia with a 
continuous infusion of ropivacaine 0.2% plus fentanyl. In the present study there were no 
significant differences in qualitative muscle strength measurements between the groups. 
However, this study was designed to detect a substantial difference in qualitative strength 
measurements and lacked the power to find smaller but probably clinically less relevant 
differences. The median qualitative strength score in all groups ranged between 2 and 3 
(Table 3) on the first postoperative day and consequently only half of the patients had 
permission to actively mobilise with a walking frame that day. However, all patients with 
a slow start at ambulation made up the difference in the days thereafter and met the 
discharge criteria by the end of the fourth postoperative day.
In this study we used a qualitative 6 point rating scale (Table 1) and a quantitative (isometric 
muscle force dynamometer) method to evaluate quadriceps muscle strength and found a 
poor correlation between these two measurements. Zaric et al. in a study with epidural 
ropivacaine in 30 healthy volunteers also observed that qualitative strength measurements 
(modified 4-point Bromage scale) decreased far less and later than expected on basis of 
the quantitative measurements and at the recovery of the Bromage score from grade 1 
to 0, only 22-40% of the muscle force for knee extension, assessed by the quantitative 
method, had recovered.13 However, they did find a close relationship between the sensory 
blockade (pinprick) and the quantitative strength measurements. Although the use of 
force dynamometry allows for more precise quadriceps strength measurements, than the 
normally used qualitative rating scale, caution in the interpretation of early postoperative 
measurements after TKA is warranted, because maximal isometric quadriceps contraction 
may be painful in the first postoperative days and lead to erroneously low values.11,13,14
There were no significant differences between the groups in the VAS pain scores at rest 
and during flexion of the knee (Table 4). However, the patients in the 0.025% group tended 
to use more piritramide rescue medication and the VAS scores for satisfaction with the 
pain treatment were significantly better in the 0.1% group (Table 4). In view of the fact 
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that all patients met the discharge criteria on the end of the fourth postoperative day, 
although several of them could not participate in the active mobilisation (i.e. walking) in 
the first postoperative days, we consider to investigate the effect of a higher ropivacaine 
concentration (i.e. 0.15%, 0.2%) on our fast track rehabilitation programme, as these 
concentrations were reported as superior for analgesia and may not lead to a longer 
hospital stay.6,10
In conclusion, this pilot study indicated no apparent advantage in decreasing the 
concentration of ropivacaine administered as bolus injections via the femoral nerve 
catheter below 0.1% on the patient’s ability to actively participate in the rehabilitation 
programme after TKA. In fact, the lowest studied concentration (i.e. 0.025%) resulted in 
a lower patient’s satisfaction with the pain treatment, while not improving recovery after 
TKA.
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ABSTRACT
We investigated the safety of LIA (local infiltration analgesia) combined with 
retransfusion of drained blood. Total knee arthroplasty patients received two 
peri-articular injections during surgery followed by continuous infusion, both with 
ropivacaine (567 mg). Ropivacaine plasma concentrations were determined in 
blood samples taken at 0, 3, 6 and 24 hours postoperatively. The collected shed 
blood was not retransfused, instead retransfusion was modelled by estimating the 
cumulative plasma concentrations at 6 hours postoperative. Total and unbound 
ropivacaine plasma concentrations ranged respectively from 0.08 to 1.9 mg/L 
and 0.003 to 0.11 mg/L. An average of 13.1 ± 3.7 mg unbound ropivacaine would 
have been returned to the patient. The estimated cumulative ropivacaine plasma 
levels showed that instant retransfusion would have led to plasma levels below 
0.26 mg/L. It appears to be safe to transfuse autologous blood in combination with 
LIA. However, before drawing definite conclusions formal measurement of actual 
concentrations is required.
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InTRoduCTIon
Recovery after total knee arthroplasty (TKA) is hampered by postoperative pain when not 
adequately dealt with.20 A multimodal approach that reduces nociception is recommended 
to achieve maximum efficacy in pain control. As part of a ‘multimodal approach’ local 
infiltration technique with local anaesthetics, local infiltration analgesia (LIA), has been 
introduced. Large case series have been performed with satisfactory results for pain 
relief and despite the high volume, the frequency of side effects of the local infiltration 
techniques was low.13,17
Several LIA variations have been described in the last decades, with different routes of 
administration, types of anaesthetics, and the combination of intra-operative infiltrations 
with postoperative catheters. At the moment there is non-uniformity with regard to the 
preferred technique. Kohan and Kerr described their LIA technique using a catheter for 
postoperative single-shot local anaesthetic administration after 15 to 20 hours.13 Bianconi 
et al. favoured the LIA technique when compared to systemic analgesia because of less 
postoperative pain, opioid use reduction and shorter hospital stay.3
Several authors have studied the effectiveness of autologous retransfusion drains. Moonen 
et al. and Cheng et al. found a reduction in allogeneic blood transfusions in knee- and hip 
arthroplasty.7,16 However, Amin et al. and Abuzakuk et al. found no effect of retransfusion 
drains.1,2 Despite the discussion about the effectiveness of wound drains in general, in our 
hospital, as in many clinics worldwide retransfusion of drained blood is still standard care 
and independent of the haemoglobin level in many hospitals.
A combination of LIA and retransfusion of shed blood involves the risk of reinfusing 
potentially high concentrations of local anaesthetics. Ropivacaine (Naropin®, AstraZeneca) 
is most frequently used in LIA, because of its enhanced safety profile compared to other 
long-acting local anaesthetics.12,25 Parker et al. reported the safe combination of both 
techniques in case of single shot LIA. However, no continuous wound catheter was present 
and no unbound ropivacaine plasma concentrations were analysed.19-20 Most of the plasma 
binding of local anaesthetics is due to association with α-1-acid glycoprotein (AAG). In 
this case, unbound ropivacaine plasma concentration interacts with receptors to produce 
pharmacological or toxicological effects after systemic administration. That is why the 
unbound ropivacaine plasma concentration is of particular importance since side effects 
and complications are largely attributable to this fraction.
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This study was designed to determine ropivacaine plasma concentrations in the patient and 
in shed blood after local (continuous) infiltration and to estimate cumulative ropivacaine 
plasma concentrations assuming retransfusion of shed blood.
MeTHodS
This experimental prospective study protocol was approved by the local Medical Ethics 
Committee (CCMO no. NL25137.098.08) and registered in the Dutch trial registry (NTR1784). 
After written informed consent had been obtained, twenty primary TKA patients were 
enrolled in the study. Inclusion criteria were age from 18 till 90 years, ASA 1-2, haemoglobin 
(Hb) levels above 7.5 mmol/L and normal renal function (Modified diet in renal disease 
equation (MDRD)) value above 48 mL/min. Before surgery two intravenous cannulae were 
inserted into a vein of both arms, one for routine monitoring of the patient during surgery 
and one (controlateral side) in order to obtain blood samples. All patients received lumbar 
spinal anaesthesia with 15 mg bupivacaine 0.5%. Two orthopaedic surgeons performed 
the operations according to standard procedure. Cemented cruciate retaining components 
(PFC Sigma, DePuy, Johnson&Johnson) were placed and patella resurfacing was done when 
necessary.
A solution consisting of 50 mL ropivacaine 0.75% (=375 mg) (AstraZeneca, Sweden), 50 mL 
NaCl 0.9% and 0.5 mL of 1:1000 epinephrine was injected in the peri-articular tissues. 
The solution was equally divided in two 50 mL syringes and injected with 22 gauge spinal 
 needles. Before placement of the final implants the posterior capsule and deep peri- 
articular tissues were infiltrated with the first syringe. The second syringe was used to 
infiltrate the synovium of the suprapatellar pouch, quadriceps and patellar tendons and 
subcutaneous tissue surrounding the incision.
Additionally, near the end of the operation the Solace™ Infusion System (Apex medical, San 
Diego) was inserted and connected. This single use elastomeric type pump was filled with 
270 mL ropivacaine 0.2% without epinephrine, which was attached to two small catheters, 
each producing 2 mL/h, which were placed intraarticular and subfascial. A total of 96 mL 
ropivacaine 0.2% (=192 mg) was infused during the first 24 hours after surgery.
Furthermore, a Bellovac autologous blood transfusion (ABT) drain (AstraTech, Sweden) was 
placed intra-articularly.
Blood samples were taken at the conclusion of surgery (T=0) before the Solace infusion 
system and drain were opened and 3, 6 and 24 hours after the first sample. At 6 hours, the 
drain was disconnected and two samples were taken out of the blood bag: one before and 
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one after passage through the filter cascade. Shed blood was not returned to the patient. 
The 6-hour sampling time was taken because this is the maximum time allowed for blood 
collection in autologous retransfusion drains.
All samples were centrifuged at 3000 rpm for 10 minutes and plasma was stored at minus 
80 degrees Celsius. The wound drain and Solace infusion catheters were removed after 
24 hours.
During hospitalisation haemoglobin levels (Hb) were measured preoperatively and post-
operatively on day 1 and 3.
Analyses
Total and unbound ropivacaine concentrations were measured with liquid chromatography-
mass spectrometry (LC-MSMS, Agilent Technologies 6410 Triple Quad).4 The accuracy and 
intermediate precision of these analyses were respectively 2.2-4.4% and 2.0-2.9%.
The free ratio of ropivacaine for each patient (Psfr) was calculated by dividing the unbound 
concentration by the total concentration.
Subsequently we modelled the theoretical maximum unbound ropivacaine plasma 
concentration if the shed blood would have been instantly returned to the patient. We 
estimated circulating plasma volume per patient according to the formulae of Lemmens 
et al.15 and the patient specific haematocrit (preoperative) values. Next, we estimated the 
theoretical maximum unbound ropivacaine plasma concentration as follows:
((Rbel x Vbel x Psfr6) + (Rpl6 x pat specific circulating plasma volume)) / (pat specific 
circulating plasma volume + Vbel). (Rbel = unbound ropivacaine concentration in mg/L in 
the retransfusion device after blood passage through the filter cascade, Vbel = volume of 
shed blood in L, Psfr6 = patient specific free ratio of ropivacaine at 6 hours postoperatively, 
Rpl6 = unbound ropivacaine plasma concentration in mg/L at 6 hours postoperatively)
In this calculation we assume that a part of the unbound ropivacaine in the shed blood 
will instantly bind to AAG upon retransfusion. Psfr6 determines the amount of ropivacaine 
remaining unbound.
Statistics
The continuous data are presented as the number of subjects, mean, standard deviation 
(SD), minimum and maximum values, and categorical data expressed as frequencies and 
percentages. Normally distributed data are presented as mean ± SD; in case of non-normal 
distribution median and range are used.
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Spearman’s correlations were calculated to examine a potential relationship between 
patients’ characteristics (age, BMI and renal clearance) and ropivacaine concentrations in 
plasma. Data were analysed using SPSS 17.0 (SPSS for Windows, Chicago: SPSS Inc.).
ReSulTS
Twenty consecutive eligible patients undergoing elective TKA were enrolled in the study 
(Table 1). The first and second local analgesia block were given respectively 43 and 
63 minutes (on average) after start of surgery (SD: 10 min). The catheter for continuous 
infusion was unclamped 57 minutes (SD: 11 min) after the first block was given. The first 
sample was taken 34 minutes (SD: 9 min) after the second intraoperative injection.
Table 1 Patient demographic data 
Mean ± Sd (range)
Age (years) 71.3 ± 7.5 (58-84)
Body Mass Index (kg/m2) 27.1 ± 3.5 (21-37)
Renal clearance (MDRD) (mL/min) 69.7 ± 11.8 (48-86)
Male / female 15 (75%) / 5 (25%)
ASA classification (1/2) 4 (20%) / 16 (80%)
Left / right 7 (35%) / 13 (65%)
Patella resurfacing (yes/no) 11 (55%) / 9 (45%)
MDRD = modification of diet in renal diseases
ASA = American Society of Anaesthesiologists
Mean total and unbound ropivacaine plasma concentrations are shown in Table 2, on 
average the free fraction of ropivacaine was 4.8% (SD: 0.7%).
The plasma values at 6 hours postoperatively ranged for total ropivacaine from 0.54 to 
1.69 mg/L and unbound ropivacaine 0.03-0.11 mg/L at 6 hours postoperatively. The Cmax 
(peak concentration) of the total ropivacaine plasma concentration was 1.89 mg/L found at 
24 hours postoperatively, for unbound ropivacaine plasma concentration Cmax was 0.11 mg/L 
at 6 hours postoperatively. Both values were found in different patients. The Cmax for the 
total ropivacaine plasma concentration was found in 13 patients at 24 hours postoperatively, 
others had their maximum at 3 hours (n=2) and 6 hours (n=5) postoperatively. The Cmax for 
unbound ropivacaine plasma concentration was found in half of the patients at 6 hours, 
5 patients had Cmax at 3 hours and 5 patients at 24 hours postoperatively.
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A negative correlation was found between age and BMI (r=-0.458) and the differences in 
Cmax time points. Furthermore, no significant relationship was found between the time 
window, the single-shots and the sampling points.
The median shed blood volume was 600 mL (range: 303-869 mL). In one case the exact 
amount could not be measured, the missing value was imputed from the mean volume of 
the shed blood in all other patients, which was 591 mL.
There was a small difference in the total and unbound ropivacaine concentration before 
and after filtration of the shed blood, respectively 33.05 vs. 32.7 mg/L for the total 
concentration. We used the filtered total ropivacaine concentration for modelling the 
cumulative concentration; because the filtered shed blood would be returned to the 
patient.
The ropivacaine concentrations in shed blood were much higher in comparison to the 
plasma levels. The unbound ropivacaine fraction (mean ± SD) in shed blood (68.8 ± 4.6%) 
was higher as compared to plasma (4.8 ± 1.1%).
When the shed blood would have been returned to the patient an average of 13.1 ± 3.7 mg 
(range: 6.2-18 mg) unbound ropivacaine would have been administered intravenously.
We estimated the cumulative ropivacaine plasma concentration when the shed blood 
would have been returned to the patient. This model showed a mean unbound ropivacaine 
plasma concentration after retransfusion of the shed blood of 0.26 ± 0.11 mg/L (range: 
0.12-0.58 mg/L).
Haemoglobin levels showed the expected decrease during the first postoperative days 
in all patients. The average pre-operative Hb value was 9.1 mmol/L (SD: 0.5 mmol/L), on 
day 1 and 3 Hb values were respectively 6.9 mmol/L (SD: 0.6 mmol/L) and 6.6 mmol/L (SD: 
0.8 mmol/L). None of the patients received an allogeneic blood transfusion.
Table 2 Total and unbound ropivacaine concentrations in plasma and shed blood
unbound Total Fraction
T0 0.014 ± 0.009 (0.003-0.036) 0.302 ± 0.177 (0.078-0.698) 4.5 ± 0.6 (3.1-5.3)
T3 0.042 ± 0.019 (0.019-0.086) 0.798 ± 0.254 (0.448-1.434) 5.1 ± 0.9 (3.3-7.1)
T6 0.050 ± 0.022 (0.025-0.105) 0.888 ± 0.299 (0.539-1.689) 5.8 ± 2.2 (3.4-12.6)
T24 0.040 ± 0.015 (0.017-0.078) 1.028 ± 0.328 (0.467-1.886) 3.9 ± 0.6 (2.7-5.1)
ABT before 23.05 ± 5.72 (11.95-32.69) 33.049 ± 6.539 (18.445-41.773) 69.1 ± 4.7 (62.2-78.5)
ABT after 22.61 ± 5.72 (10.33-31.87) 32.69 ± 6.777 (16.385-41.300) 68.5 ± 4.5 (59.9-77.2)
Unbound and total values are shown in mg/L as mean ± SD (range). The fraction is unbound concentration in % 
of the total concentration. Values under timepoints (T) 0, 3, 6 and 24 hours represents plasma.
ABT (Autologous Blood Transfusion) before and after represents shed blood before and after filtration.
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dISCuSSIon
LIA is a relatively simple technique where significant opiate sparing effects have been 
described.9,11 The combination with a retransfusion drain is performed in several hospitals 
however questions were raised with respect to its safety. Before addressing efficacy we 
need to examine the issues of safety. We combined these two modalities with special focus 
on the unbound ropivacaine plasma concentration, since the unbound fraction is mainly 
responsible for systemic toxicity. We expected that the cumulative modelled unbound 
ropivacaine plasma concentration at 6 hours postoperatively would be well below the 
threshold for systemic toxicity stated by Knudsen et al.14 They performed a study on 
healthy volunteers receiving ropivacaine intravenously. Based on the arterial sampling a 
threshold for CNS (central nervous system) toxicity is apparent at mean (min-max) unbound 
ropivacaine plasma concentration in the order of 0.56 mg/L (range: 0.34-0.85 mg/L).14 
Without retransfusion we found unbound ropivacaine plasma concentrations of 0.05 ± 0.02 
mg/L (95% CI: 0.04-0.06 mg/L) at 6 hours postoperative.
It is important to base the safe limits on the unbound ropivacaine plasma concentrations 
since this concentration is related to systemic pharmacodynamic effects and toxicity. Two 
studies used LIA intraoperatively with ropivacaine in dose up to 400 mg generating unbound 
ropivacaine plasma concentrations well below the threshold for systemic toxicity. 6,8,14
Four studies have so far been published where shed blood has been collected postoperatively 
and analysed for ropivacaine content.4,10,18,21 In these studies, the total amount of ropivacaine 
in the shed blood collected was found to be low, <27 mg, in comparison to doses used 
in regional anaesthesia. In one of these studies doses up to 490 mg were used.21 In our 
study we found a maximum total ropivacaine concentration in shed blood of 41.3 mg. The 
reason for this slightly higher value might be explained by our study design. We started 
the postoperative wound infusion immediately after the end of surgery in difference with 
all the other published studies where the wound infusion started after six hours, e.g after 
finalisation of drain blood collection.
No investigation has so far been published measuring the change in unbound ropivacaine 
following retransfusion of shed blood. However, in one study the change in total 
ropivacaine was measured.18 The estimated mean maximum dose of ropivacaine reinfused, 
obtained from the product of drain volume and concentration, was approximately 
1.3 mg (range: 0.4-2.6 mg). The mean total ropivacaine plasma concentration increased 
slightly, 0.03 μg/mL, from 0.79 μg/mL to a mean value of 0.82 μg/mL after completion of 
retransfusion.18 In our study the total amount of ropivacaine in shed blood was 32.7 mg 
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(range: 16.4-41.3 mg). Considering a worst case scenario where shed blood with 41.3 mg 
ropivacaine would be reinfused our values would be 32 times (41.3/1.3) higher than 
by Parker et al.18 Theoretically this would with our study results generate a blood level 
increase of total ropivacaine with 32 x 0.03 mg = 0.95 mg/L, when the shed blood had been 
reinfused.
The major determinant of systemic toxicity in local anaesthetics is the unbound concentration 
in plasma. It is known that AAG, the protein responsible for ropivacaine binding, has high 
inter- and intra-individual variability and therefore concentrations and binding capacity 
can largely differ over time and between patients. Furthermore, AAG concentrations are 
influenced by surgery, myocardial infarction and inflammatory processes.24 Essving et al 
noted that even though the total plasma concentration showed increasing values, the free 
fraction decreases with time.8 This is in line with the fact that ropivacaine is mainly bound 
to AAG. The AAG availability has been associated with an increase in the protein binding 
of ropivacaine during long-term infusion after surgery.5,23 This is also seen in our study 
were the mean unbound ropivacaine fraction decreases after 24 hours. In our study mean 
unbound ropivacaine fraction was 4.8% in the included ASA I and II patients. This is lower 
than reported by Knudsen et al., which may be explained by the fact that our patients had 
more co-morbidity.14
In two previously published studies the unbound ropivacaine fraction was measured.4,8 
The unbound ropivacaine fraction in the different studies varied between 2.2 and 8.8%. 
In our study we found unbound ropivacaine fraction in plasma at six hours to be 5.8% 
(range: 3.4-12.6%). Applying the highest fraction on the theoretically generated total 
plasma level increase of 0.95 mg/L would generate unbound ropivacaine, if reinfused, of 
12.6% x 0.95 mg/L = 0.12 mg/L. Adding this maximum calculated increase to the highest 
reported unbound ropivacaine plasma concentration generates a maximum unbound 
ropivacaine plasma concentration of 0.105 + 0.12 = 0.225 mg/L, a concentration well below 
the threshold for systemic toxicity of 0.56 mg/L.14 Also the model we used with all specific 
data from each patient (e.g. plasma volume, shed blood volume and free fraction) showed 
a mean unbound ropivacaine plasma concentration after retransfusion of the shed blood of 
0.26 ± 0.11 mg/L (range: 0.12-0.58 mg/L). In both models we assume instant retransfusion 
and instant binding. In daily practice however, an erythrocyte concentrate is normally 
reinfused in half an hour or more, so even lower unbound ropivacaine values are likely.
Regarding the shed blood collected, the median total drainage loss of 600 mL was similar to 
the reported amounts in the study of Vendittoli et al.22 Vendittoli et al. noted that drainage 
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loss was not significantly different between patients with single morphine consumption or 
in combination with peri-articular infiltration.22
In conclusion, data so far indicate that intraoperative local infiltration analgesia with 
ropivacaine for hip and knee arthroplasty can safely be combined with autologous blood 
reinfusion, even if a postoperative ropivacaine wound infusion at low rates starts directly 
after the end of surgery. Nonetheless, the safety issues have to be warranted by actual 
administration of the shed blood collected.
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ABSTRACT
The authors hypothesized that it is safe to combine local infiltration analgesia 
(LIA) in total knee arthroplasty (TKA) with a retransfusion drain since ropivacaine 
concentrations would not exceed the arterial toxicity threshold concentrations of 
4.3 mg/L for total and 0.56 mg/L for unbound ropivacaine.
Twenty-two patients scheduled for primary TKA were included. During surgery 
three peri-articular injections with ropivacaine (300mg) were given. Plasma and 
shed blood samples were taken at 0, 1, 3, 6, 7 and 24 hours postoperatively.
At 6 hours postoperatively, the total ropivacaine plasma concentration ranged from 
0.26 to 1.53 mg/L and unbound ropivacaine from 0.03 to 0.12 mg/L. At 7 hours, the 
total ropivacaine plasma concentration ranged from 0.19 to 1.71 mg/L and unbound 
ropivacaine from 0.02 to 0.09 mg/L. In the collected shed blood, a total of 0.27 to 
12.8 mg (median 3.73 mg) unbound ropivacaine was present. Reinfusion would lead 
to an addition of 3.73 mg (median) unbound ropivacaine that would be reinfused into 
the patient. The calculated (modelled) estimation regarding the maximum unbound 
ropivacaine plasma concentration showed a median value of 0.114 mg/L (IQR: 0.09, 
0.12 mg/L). All concentrations were well below reported toxicity thresholds.
The combination of LIA and reinfusion presented herein are considered safe. However, 
differences in pain protocol lead to changes in the safety evaluation. Compared with 
previous studies, the technique of administration is of greater importance for the 
effect on unbound ropivacaine because of unknown mechanisms.
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InTRoduCTIon
As part of a multimodal approach, local infiltration anaesthesia (LIA) has been introduced. 
Large case series have been described with satisfactory results for pain relief and despite 
the high concentration, side effects of local infiltration techniques occur infrequently.1,2
The combination of LIA with autologous blood transfusion, that is postoperatively giving 
back the patient’s own blood collected in a transfusion bag during the first 6 hours after 
surgery, might lead to infusion of considerable amounts of local anaesthetics. In this respect, 
continuous infusion issues, plasma concentrations and toxicity are clinical pharmacological 
issues that have to be considered in the safety evaluation of intra-operative local infiltration 
techniques with ropivacaine in hip and knee arthroplasty combined with autologous blood 
transfusion.
In plasma, ropivacaine is mainly bound to α-1-acid glycoprotein (AAG) which is an acute-
phase protein whose concentration has been shown to increase in response to surgical 
stress.3 As ropivacaine is eliminated by hepatic metabolism, with an intermediate to low 
extraction ratio, its rate of elimination should, theoretically, depend on the unbound 
ropivacaine concentration in plasma.4-6 The total plasma clearance is expected to vary with 
changes in the unbound fraction, i.e. a postoperative increase in the AAG concentration will 
decrease the free fraction (due to increased protein binding), which will decrease the total 
clearance and result in a relative increase in total plasma concentrations.6,7 This is important, 
as it is the unbound plasma concentration that is related to systemic pharmacodynamic 
effects and toxicity. Since the rate of diffusion across a membrane is proportional to the 
unbound drug concentration, the rapid appearance of systemic central nervous system and 
cardiovascular toxicity of local anaesthetics is determined by the unbound concentration as 
opposed to the total plasma drug concentration.
Only six small studies have been published about (possible) reinfusion following total knee 
arthroplasty (TKA) with LIA using ropivacaine.8-13 Hitherto, reinfusion was studied in two 
studies with different doses (200 mg vs. 150 mg), additional bolus injections (twice vs. none) 
and even other comparators such as tourniquet usage and hip and knee arthroplasty.9,10
The aim of this study was to determine the safety of LIA in combination with a retransfusion 
drain. Total ropivacaine plasma concentrations should not exceed 4.3 mg/L (arterial) as 
these are associated with toxicity; as for the unbound ropivacaine plasma concentrations 
– supposing a protein binding of 87% – concentrations greater than 0.56 mg/L (arterial) are 
associated with toxicity.14 Since protein binding may vary considerably between and within 
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subjects, we measured total and unbound ropivacaine plasma concentrations as well as 
ropivacaine concentrations in the retransfusion device.
MeTHodS
Our regional ethical committee approved the study (CCMO no. NL33364.098.10) and the 
trial was registered in the Dutch trial registry (NTR2677). Patients planned for a primary 
TKA with preoperative haemoglobin (Hb) concentrations above 7.5 mmol/L were eligible 
for participation in the study. Other inclusion criteria were age between 18 and 90 years, 
American Society of Anaesthesiologists (ASA) classification 1 or 2, lumbar spinal anaesthesia 
(L2-3 or L3-4 level with 3 mL of bupivacaine 0.5%), an estimated GFR with the modification 
of diet in renal disease (MDRD) formula >48mL/min. Patients gave their informed consent 
after having received oral and written information.
An intravenous cannula was inserted into a vein of each arm, one for routine monitoring 
of the patient during surgery and one (antecubital) in order to obtain blood samples. One 
orthopaedic surgeon performed all operations according to standard procedure. Cemented 
cruciate retaining components (PFC Sigma, DePuy, Johnson&Johnson, Warsaw, IN) were 
placed and patella resurfacing was done when necessary. A tourniquet was used during 
surgery which was inflated to 300 mmHg. Tourniquet was released after skin closure and 
compressive bandaging. Peroperative and postoperative surveillance of the patient was 
performed by routine cardiac monitoring which took place for at least 3 hours after surgery.
Three syringes each containing 50 mL ropivacaine 0.2% (Fresenius Kabi, Hamburg, 
Germany) and 0.33 mg epinephrine were injected with an 18-gauge spinal needle. Before 
placement of the final implants the posterior capsule and deep peri-articular tissues were 
infiltrated with the first syringe. The second syringe was used to infiltrate the capsule and 
the borders of the incised quadriceps and patellar tendons, infra-patellar ligament and 
possible remnants of the fat pad. The third syringe was used to infiltrate the subcutaneous 
layer around skin incision.
At the end of surgery an autologous blood transfusion (ABT) drain (Bellovac ABT, AstraTech, 
Mölndal, Sweden) was placed intra-articular in the knee joint. The drain was opened at the 
recovery unit after the first blood sample was taken (T=0). At 1, 3, 6, 7 and 24 hours after 
the first sample another blood sample was taken from the patient. At 1, 3 and 6 hours the 
drainage bag was disconnected, volume noted and a sample was taken. All samples were 
drawn with EDTA tubes and samples were centrifuged at 3000 rpm for 10 minutes, plasma 
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samples were then stored at -70°C until LC-MSMS analysis. The Bellovac ABT drain was 
removed after 24 hours.
A standardised pain therapy protocol was used (Table 1). The Visual Analog Scale (VAS) for 
pain was asked before blood samples were taken.
Table 1 Pain treatment protocol




1000 mg Acetaminophen (IV)
4 mg Ondansetron (IV) 
Infiltration of 150 mL ropivacaine 2 mg/mL / 1 mg/mL epinephrine
4 hours after surgery
1000 mg Acetaminophen (oral)
8 hours after surgery
300 mg Gabapentin
1000 mg Acetaminophen (oral)
day 1 after surgery
300 mg Gabapentin
200 mg Celecoxib
1000 mg, 4 times daily Acetaminophen (oral)
Following days
200 mg, once daily Celecoxib (till 2 weeks postoperative) 
1000 mg, 4 times daily Acetaminophen (oral)
escape medication
200 mg, once daily Celecoxib 
1000 mg, 4 times daily Piritramide (IM)
4 mg, 2 times daily Ondansetron (IV) (except for surgery day)
IM = intramuscular, IV = intravenous
Escape medication is taken in case a patient experiences to much pain (VAS > 4)
Analyses
The main analyses of this study consisted of total and unbound ropivacaine plasma 
concentrations in the different patients’ and shed blood samples. Ropivacaine 
concentrations were measured with liquid chromatography-tandem mass spectrometry 
(LC-MSMS,  Agilent Technologies 6410 Triple Quad, Agilent, Amstelveen, Netherlands).8 
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The accuracy of the ropivacaine analyses was 2.2-4.4% and intermediate precision was 2.0-
2.9%.12
The free ratio of ropivacaine for each patient was calculated by dividing the unbound 
ropivacaine plasma concentration by the total ropivacaine plasma concentration of the 
different samples (Psff = patient specific free fraction).
Subsequently, the theoretical maximum unbound ropivacaine plasma concentration was 
modelled if the blood from the retransfusion device would have been instantly returned to 
the patient. Circulating plasma volume per patient was estimated according to the blood 
volume formulae of Lemmens et al., patient specific (preoperative) haematocrit value and 
body weight.15 Next, the theoretical maximum unbound ropivacaine plasma concentration 
was estimated as follows:
((Rbel x Vbel x Psff6) + (Rpl6 x pat specific circulating plasma volume)) / (pat specific circulating 
plasma volume + Vbel). (Rbel = unbound ropivacaine plasma concentration in mg/L in the 
retransfusion device after blood passage through the filter cascade, Vbel = volume of shed 
blood in L, Psff6 = patient specific free fraction of ropivacaine at 6 hours post operatively, 
Rpl6 = unbound ropivacaine plasma concentration in mg/L at 6 hours post operatively).
In this calculation the assumption that most of the unbound ropivacaine present in the 
blood collected in the retransfusion device would instantly bind to plasma protein upon 
reinfusion was made.
Pharmacokinetic analysis
Individual pharmacokinetic parameters for ropivacaine were calculated with the MW/Pharm 
pharmacokinetic software package (version 3.70, Medi/Ware, Netherlands). MW/Pharm 
consists of Bayesian modelling software and uses an ‘a priori’ population pharmacokinetic 
model.16 Using Bayesian techniques the model was fitted to the measured ropivacaine data. 
‘A priori’ pharmacokinetic parameters were taken from our previous study12 and consisted 
of an one-compartment open model with a metabolic clearance (CLm) of 11 ± 5.98 L/h, 
fraction excreted unchanged in the urine (fr) of 1%, volume of distribution 0.5099 ± 0.3674 
L/kg LBMc, (LBMc is Lean Body Mass corrected), absorption constant from the site of 
injection 0.0313 ± 0.0114 h-1 and a lag time until absorption of 0.1267 ± 0.1364 h. When 
modelling the data, the fraction excreted unchanged was fixed to the literature value of 
0.01 because of lack of data on renal elimination.17
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Statistics
Continuous data are presented as the number of subjects, mean, standard deviation, 
minimum and maximum concentrations. Categorical data expressed as frequencies and 
percentages. Data were tested for normality. Normally distributed data are presented as 
mean ± standard deviation; in case of a non-normal distribution median and inter-quartile 
range (IQR) was used.
Data were analysed using SPSS 17.0 (SPSS for Windows, SPSS Inc. Chicago, IL, USA).
ReSulTS
A total of 24 consecutive patients were enrolled in the study, 22 patients were included in 
the final analysis. Two patients were excluded because no blood samples could be drawn.
The average age was 67.7 ± 9.8 years, body mass index (BMI) was 27.8 ± 3.4 kg/m2. The 
majority of patients was male (59%) and were operated upon the right knee (64%) with 
patella resurfacing in 9 cases (41%). Eighty-six percent of the patients had American Society 
of Anaesthesiologist (ASA) classification 2, eGFR ranged between 63 and 109 mL/min 
(average 81.5 mL/min). The average length of hospital stay was 3.69 ± 0.98 days. The three 
LIA blocks were given on average respectively 47, 66 and 76 minutes after start of surgery. 
The first sample was taken 50 minutes (SD: 9 min) after the first intra-operative injection.
Table 2 Total and unbound ropivacaine concentrations in plasma 
unbound Total Fraction
T=0 0.009 (0.006-0.013) 0.106 (0.081-0.192) 6.498 (5.596-8.288)
T=1 0.016 (0.014-0.022) 0.269 (0.209-0.375) 6.581 (5.762-7.544)
T=3 0.032 (0.027-0.043) 0.466 (0.428-0.609) 6.791 (5.870-7.432)
T=6 0.043 (0.036-0.050) 0.585 (0.455-0.663) 7.538 (6.208-9.272)
T=7 0.045 (0.003-0.062) 0.593 (0.189-1.708) 7.560 (6.706-9.622)
T=24 0.024 (0.017-0.039) 0.433 (0.278-0.578) 6.195 (4.777-7.094)
Unbound and total values are shown in mg/L as median (IQR), fraction is unbound concentration in % of the total 
concentration.
Mean total and unbound ropivacaine plasma concentrations are shown in Tables 2 and 3. 
The plasma concentrations 6 and 7 hours postoperatively are important for the potential 
reinfusion of shed blood. Plasma concentrations 6 hours postoperatively ranged from 0.26 
to 1.53 mg/L for total ropivacaine and from 0.03 to 0.12 mg/L for unbound ropivacaine. 
At 7 hours the concentrations were 0.19 to 1.71 mg/L for total ropivacaine and 0.02 to 
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0.09 mg/L for unbound ropivacaine. Lowest total and unbound ropivacaine plasma 
concentrations were found in patient 20 at T=0 and were respectively 0.023 and 0.003 
mg/L. In the same person the highest concentrations were found in shed blood at T=1, 
141.98 mg/L for total ropivacaine and 111.49 mg/L for unbound ropivacaine. The highest 
unbound ropivacaine plasma concentration was found at T=6 (0.12 mg/L) and the highest 
total ropivacaine plasma concentration was 1.80 mg/L (at T=24), both in the same person.
The time points where patients reached peak concentrations varied widely. For total 
ropivacaine peak plasma concentrations were reached at 3 hours (8 patients), 6 hours 
(5 patients), 7 hours (5 patients) and 24 hours (4 patients). The unbound ropivacaine plasma 
concentrations reached their peak at 3 hours (6 patients), at 6 hours (7 patients), at 7 hours 
(7 patients) and 2 patients at 24 hours.
Table 3 Total and unbound ropivacaine concentrations in shed blood 
Volume unbound Total Fraction
T=1 ABT 100 (60-225) 15.793 (9.634-24.666) 27.462 (18.996-42.725) 57.731 (54.214-59.762)
T=3 ABT 190 (100-250) 3.772 (2.237-8.083) 9.751 (7.963-17.317) 39.969 (28.046-46.052)
T=6 ABT 200 (100-234) 2.774 (1.269-3.380) 8.049 (5.373-9.551) 31.841 (22.445-36.939)
Volume presented in mL. Unbound and total values are shown in mg/L as median (IQR), fraction is unbound 
concentration as % of the total concentration.
The median of postoperative shed blood volume was the sum of the 4 time points (1, 3, 6 and 
24 hours postoperative) and was 707 mL (IQR: 403, 909 mL). The median of postoperative 
shed blood (collected blood until 6 hours postoperative) that would be returned to the 
patient was 463 mL (IQR: 306, 669 mL).
When the shed blood would have been returned to the patient, the volume and 
concentrations collected during the first 6 hours are important (Table 3). In the cumulative 
collected shed blood from the first 6 hours a total of 0.27 to 12.8 mg (median 3.73 mg) 
unbound ropivacaine was present. The median unbound amount per time point (1, 3 and 
6 hours postoperatively) was, respectively, 2.18 mg (IQR: 1.21, 3.51 mg), 0.73 mg (IQR: 0.36, 
1.4 mg) and 0.44 mg (IQR: 0.15, 0.69 mg). The amount of blood collected was quite equal 
during these time points but unbound ropivacaine concentrations decreased significantly 
from T=1 to T=3 and T=6. Reinfusion would lead to an addition of 3.73 mg (median) unbound 
ropivacaine to the patient’s blood.
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The calculated (modelled) estimation, assuming reinfusion, regarding the maximum 
unbound ropivacaine plasma concentration showed a median value of 0.11 mg/L (IQR: 
0.09, 0.12 mg/L).
Pharmacokinetic analyses are presented in Table 4. Mean metabolic clearance in the 
pharmacokinetic analyses was, 12.41 ± 6.32 L/h. The Ka and Tlag were 0.05 ± 0.11 hr and 
0.16 ± 0.11 hr respectively. The volume of distribution for ropivacaine averaged 0.61 ± 
0.36 L/kg.
Table 4 Pharmacokinetic data
Patient no Clm (l/h) Vd (l/kg) Ka (hr) Tlag (hr)
1 12.03 0.17 0.02 0.06
2 10.45 0.55 0.04 0.27
3 23.85 0.65 0.05 0.11
4 25.05 1.31 0.53 0.15
5 22.54 0.32 0.02 0.19
6 12.4 0.74 0.041 0.21
7 22.46 0.76 0.04 0.44
8 10.06 1.25 0.03 0.10
9 3.45 0.37 0.04 0.03
10 6.07 0.51 0.04 0.13
11 10.76 0.27 0.03 0.04
12 9.03 0.17 0.02 0.06
13 7.55 0.97 0.03 0.22
14 9.49 0.88 0.03 0.15
15 7.97 0.19 0.02 0.23
16 5.25 0.48 0.04 0.12
17 19.68 0.24 0.04 0.37
18 14.29 0.62 0.03 0.08
19 14 0.39 0.03 0.19
20 9.73 1.37 0.02 0.34
21 8.07 0.58 0.03 0.06
22 8.93 0.75 0.03 0.04
Mean ± SD 12.41 ± 6.32 0.61 ± 0.36 0.05 ± 0.11 0.16 ± 0.11
Variance 50.91 59.44 197.78 69.26
CLm = metabolic clearance. Vd = volume of distribution. Ka = absorption rate intramuscular. Tlag = time till 
absorption. Renal elimination was fixed at a literature value of 0.01 of the creatinine clearance.17
Routine cardiac monitoring peroperative and 3 hours postoperatively did not show any 
remarkable changes that could be addressed to ropivacaine toxicity. None of the patients 
experienced any adverse events attributable to the LIA procedure during hospitalisation 
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and until 6 weeks postoperative. Furthermore, no non-specific adverse events, such as 
headache, were experienced by the patients during and after the procedure.
Additionally, the VAS scores were good for all patients. The first two patients with too much 
pain (VAS >4) were reported at 3 hours postoperative. The patients that reported too much 
pain at the following time points were successfully treated with the escape medication 
mentioned in the pain protocol.
dISCuSSIon
There is sufficient evidence that LIA is safe and can reduce postoperative pain following 
TKA.18 We studied the safety of LIA in combination with a retransfusion drain. Total and 
unbound concentrations of ropivacaine were used as surrogate parameters for safety. The 
individual unbound ropivacaine plasma concentrations at 6 hours postoperative are below 
the published arterial toxicity threshold of 0.56 mg/L, and no cardiac symptoms related 
to ropivacaine or other adverse effects were observed in all patients studied.14 Cardiac 
symptoms of ropivacaine toxicity were measured by peroperative and postoperative 
surveillance of the patient, monitoring took place for at least 3 hours after surgery.
If we should add 3.73 mg unbound ropivacaine (via shed blood) and assume instant binding, 
unbound ropivacaine plasma concentrations would rise by a median of 0.11 mg/L. Also the 
maximum unbound ropivacaine plasma concentration (0.44 mg/L) does not exceed the 
toxic threshold especially if we take into account the elimination of ropivacaine between 6 
and 7 hours postoperative.
We previously performed a similar study with a slightly different design. In the former 
study patients received LIA with two syringes of 50 mL ropivacaine 0.375% and continuous 
infiltration after surgery during the next 24 hours. Plasma samples were taken at the 
same time points, excluding T=1 and T=7 and shed blood was only collected at 6 hours 
postoperative.12 The sample handling, laboratory and ropivacaine analysis were performed 
by the same persons and the same validated analytical technique, only some samples were 
stored longer than others which is inherent to the inclusion of eligible patients. Also the 
pharmacokinetic data analysis was performed by the same person with the same software. 
However, both studies revealed some contradictions which could not be explained by 
difference in study design alone.
The mean free fraction in the current study (7.3%) was higher than the population average 
of 5% and even significantly higher than the 4.8% in the former study.12 This difference 
could not be explained by the included patients, because both patient groups were equal 
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in co-morbidity, ASA classification and medication usage. In the former study, continuous 
infusion was given in the first 24 hours postoperative which could lead to saturation 
of AAG. It is known that AAG, the protein responsible for ropivacaine binding, has high 
inter- and intra-individual variability and therefore concentrations and binding capacity 
can largely differ over time and between patients. Furthermore, AAG concentrations are 
influenced by surgery, myocardial infarction and inflammatory processes.3 In the study by 
Essving et al. it is noted that even though the total plasma concentration showed increasing 
 concentrations, the free fraction decrease with time.19 This is in line with the fact that 
ropivacaine is mainly bound to AAG, and AAG availability has been associated with an 
increase in the protein binding of ropivacaine during long-term infusion after surgery.7,20 
This is also seen in both studies performed, where the mean unbound ropivacaine fraction 
decreased after 24 hours.
Secondly, the unbound and total ropivacaine concentrations at T=0 were lower in the 
current study despite the higher concentration of ropivacaine given at that time point (300 
mg versus 150 mg). The fluid management during surgery showed no differences between 
both studies. In the former study an average of 1300 mL (median 1500 mL) was given, in the 
current study an average of 1227 mL (median 1250 mL) was infiltrated perioperatively. All 
patients received intravenous Sodium chloride and Ringers solution. Also the intraoperative 
sedation (propofol) beside the spinal anaesthesia during surgery could potentially explain 
the differences between the two groups. The intravenously given fat emulsion (vehicle for 
propofol) is prone to absorb ropivacaine.21 However, in both groups the same number of 
patients, 14 versus 13 respectively in the current and former study group received propofol 
infusion (same dose) during surgery.
Thirdly, we had expected that the ropivacaine concentrations in the shed blood would 
be much lower because no continuous infusion with ropivacaine was given in the current 
study. But the median unbound concentrations differed only 1.8 mg per litre in shed blood 
between the two studies.
The pharmacokinetic data analyses had some remarkable findings. The metabolic clearance 
was much lower than expected, 12.4 L/hr (13.6 L/hr previous study) compared to the 26 L/
hr as expected from literature. The volume of distribution of ropivacaine (0.61 L/kg current 
and 0.63 L/kg previous study) was comparable with literature value (0.67 L/kg).17 The lower 
absorption rates were to be expected because the injection site was intra-articular and 
intramuscular and furthermore ropivacaine was combined with epinephrine which causes 
a contraction of the blood vessels which leads to slower release from the injection site.
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There is not much data to compare our results with, the studies that focus on ropivacaine 
infusion and injection site do not focus on specific pharmacokinetics and pharmacodynamics.
Two studies focus on the pain intensity after intra- versus extraarticular continuous 
infusion.22,23 One study has shown that after synovial procedures, where an extensive raw 
surface is created, there is an increased absorption of bupivacaine. Furthermore tourniquet 
inflation seems to reduce absorption, however longer tourniquet ischemia may lead to 
enhanced post-ischemic reperfusion with enhanced systemic absorption. In our studies no 
differences in tourniquet inflation and duration was seen. Cederholm et al. investigated 
the different concentrations of ropivacaine in combination with or without epinephrine on 
the skin blood flow.24 They found a reduction of skin blood flow compared to saline. This 
reduction was more pronounced with lower concentrations of ropivacaine (<0.5%: tested 
1%, 0.5%, 0.375%, 0.125% and 0.063%). All the above factors except for the concentrations 
in the LIA injections were equal, 0.375% in 100 mL (375 mg) and 0.2% in 150 mL (300 mg) 
in both studies.
Six other small studies have so far been published where blood has been collected 
postoperatively in wound drains and analysed for ropivacaine.8-13 The ropivacaine doses 
for LIA ranged between 150 and 400 mg. Only in three studies shed blood was returned 
to the patients after LIA with ropivacaine. In comparison with the other studies the total 
ropivacaine amount in shed blood found in the current study was higher (median 8.2 mg, 
range: 1.3-19.5 mg) than in the other studies (range: 0.28-7 mg). The only other study that 
looked at unbound ropivacaine concentrations had a lower unbound ropivacaine plasma 
concentration (<0.038 mg/L) than the 0.043 mg/L unbound ropivacaine in the current study 
without reinfusion. The mean calculated unbound plasma concentration after potential 
reinfusion was 0.11 mg/L. This is remarkable because our ropivacaine concentrations in 
shed blood (range: 0.27-12.8 mg) are comparable with the ranges found by Breindahl et al. 
(range: 0.49-7.2 mg), but our plasma concentrations are much higher.9 Also, no explanation 
could be found when comparing study data in which the same retransfusion systems are 
being compared.
Furthermore, it is quite extraordinary that the unbound ropivacaine plasma concentration 
that is related to systemic pharmacodynamic effects and toxicity is scarcely measured in 
studies, because total and unbound concentrations are related to each other.
Limitations of our study include the assumption of reinfusion that has not actually been 
performed out of safety considerations. Also this study has no large groups of patients 
studied and furthermore pain protocols were not completely comparable with the first study 
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performed. Additionally to the performed laboratory analysis actual AAG concentrations 
would have give us more insight in the apparent anomalies in free-fraction.
Conclusion
Based on unbound ropivacaine concentrations and the absence of signs of ropivacaine 
related cardiotoxicity, the combination of LIA and reinfusion presented herein can be 
considered as safe. However, as seen in the comparison of this study with the former study 
performed by this same group, differences in pain protocol lead to unexplainable changes in 
the pharmacokinetic evaluation. The mode of administration is of greater importance than 
expected which is difficult to explain because of an unknown gradient/hydrostatic effect in 
the human body. The pharmacokinetic analysis showed that the results are unpredictable 
because they depend upon unknown variables.
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ABSTRACT
This prospective randomised clinical trial evaluated the effect of alternatives 
for allogeneic blood transfusions after total hip replacement and total knee 
replacement in patients with preoperative haemoglobin levels between 10.0 g/dL 
and 13.0 g/dL. A total of 100 patients were randomly allocated to the Eprex (pre-
operative injections of epoetin) or Bellovac groups (postoperative retransfusion of 
shed blood). Allogeneic blood transfusions were administered according to hospital 
policy.
In the Eprex group, 4% of the patients (two patients) received at least one allogeneic 
blood transfusion. In the Bellovac group, where a mean 216 mL (0 to 700 mL) shed 
blood was retransfused, 28% (14 patients) required the allogeneic transfusion 
(p=0.002). When comparing Eprex with Bellovac in total hip replacement, the 
percentages were 7% (two of 30 patients) and 30% (nine of 30 patients) (p=0.047) 
respectively, whereas in total knee replacement, the percentages were 0% (0 of 
20 patients) and 25% (five of 20 patients) respectively (p=0.042).
Preoperative epoetin injections are more effective but more costly in reducing the 
need for allogeneic blood transfusions in mildly anaemic patients than postoperative 
retransfusion of autologous blood.
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InTRoduCTIon
Operations for major joint replacement frequently require blood transfusion. The potential 
risks involved have stimulated the search for alternatives, such as preoperative injections 
of epoetin alpha and postoperative cell saving.1-8 In spite of algorithms to reduce allo geneic 
blood transfusions,it is not known which intervention or combination of measures is most 
successful.9
Preoperative injections of epoetin alpha have been shown to reduce the need for allogeneic 
blood transfusion by increasing the preoperative haemoglobin (Hb) level in patients 
whose baseline lay between 10.0 g/dL and 13.0 g/dL.2,4 One prospective randomised 
study4 showed that only 12% of patients treated with injections of epoetin alpha received 
at least one blood transfusion, compared with 46% in the control group. Postoperative 
retransfusions with autologous blood have been shown to reduce the requirements for 
allogeneic transfusion in patients who did not have preoperative anaemia. A prospective 
randomised study concluded that patients treated with a postoperative cell saving system 
had a significant reduction in transfusions of allogeneic blood compared with controls,7 
as evidenced by an absolute risk reduction from 19% to 6%. However, in that study, all 
patients had preoperative Hb levels between 13.0 g/dL and 14.5 g/dL.
After a Pubmed search (MeSH terms Blood Transfusion, Autologous, Erythropoietin, 
Recombinant) we found no randomised studies which compared preoperative injections of 
epoetin and postoperative cell saving.10 We therefore carried out a prospective randomised 
trial designed to evaluate the use of a relatively cheap postoperative retransfusion system 
in patients with preoperative Hb levels between 10.0 g/dL and 13.0 g/dL, compared with 
using expensive preoperative injections of epoetin alpha. Our aim was to compare the 
differences in the need for allogeneic blood transfusions in both groups.
MeTHodS
Between June 2006 and October 2007, all patients scheduled for elective total hip 
replacement (THR) or total knee replacement (TKR) for primary osteoarthritis (OA) with a 
pre operative Hb level between 10.0 g/dL and 13.0 g/dL were selected for the trial. Patients 
with haematological diseases, coagulation disorders, or with known malignancy or infection 
were excluded. Informed consent was obtained, and the study was approved by the local 
hospital ethics committee.
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A total of 100 patients were enrolled and all were randomly allocated to the Eprex or 
Bellovac groups by block randomisation and sealed envelopes which were labelled with 
a consecutive case number from 1 to 100. Patients in the Eprex group received 40,000 IU 
of epoetin alpha (Eprex, Janssen-Cilag BV, Tilburg, The Netherlands) in each injection. Four 
subcutaneous injections were given weekly, beginning three weeks before with the final 
injection immediately after operation. The injections were supported by supplementary 
oral iron (ferrofumerate 200 mg three times daily), beginning three days before the first 
injection and finishing the day before operation.
To prevent bias, a retransfusion system (Bellovac ABT, AstraTech AB, Mölndal, Sweden) 
was employed in both groups, but only those in the Bellovac group had an autologous 
retransfusion. At the end of the operation a deep drain was connected to the retransfusion 
system after closure of the wound. This system comprises a suction bellows connected 
to a transfusion bag with a 40-μm filter. The filtered blood was returned either when the 
bag was full (500mL) or six hours postoperatively. The amount of blood collected and 
retransfused was recorded.
Patients undergoing THR received an ABG-II system (Stryker, Waardenburg, The 
Netherlands), cemented or uncemented depending on their age and bone quality. 
Those undergoing TKR received a cemented Vanguard prosthesis (Biomet, Dordrecht, 
The Netherlands). Five different surgeons, all experienced in joint replacement, did the 
operations. In TKR, a tourniquet was used and was released after wound closure.
Patients on anticoagulants (acenocoumarol or acetylsalicylate) stopped these five 
days before the operation. All patients received low molecular weight heparin for 
thromboembolic prophylaxis, starting after surgery and continuing for six weeks.
In order to evaluate the increase in Hb levels caused by injections of epoetin alpha, the Hb 
levels in the Eprex group were measured on the day of admission. As part of the routine 
preoperative investigations, Hb levels in the Bellovac group were also obtained on the day 
of admission. After operation the Hb levels were measured on the first and third days in 
both groups.
Allogeneic blood transfusions were administered according to hospital policy (Table 1). 
Postoperatively, the anaesthetist determined the Hb transfusion trigger, depending on 
the American Society of Anaesthesiologists (ASA) classification and the course of the 
operation.11 The anaesthesiologist was independent but not blinded, as all prescribed 
medications, including epoetin alpha and ferrofumerate, were recorded. The preoperative 
Hb levels were different in the two groups, thereby making blinding difficult. All allogeneic 
blood transfusions and complications were recorded according to the classification of 
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Parvizi et al.12 The rehabilitation programme conformed to a standard policy, with discharge 
from hospital planned for five days after operation. The length of follow-up varied from 
two to 18 months.
Before the study, a sample size calculation was performed based on retrospective data. 
A reduction of 10% in allogeneic blood transfusions by using a retransfusion system in 
patients with a preoperative Hb level between 10.0 g/dL and 13.0 g/dL, compared with 
controls from the past, was considered to be the smallest clinical difference. With the 
α level set to 0.05 and the power at 0.80, it was calculated that 50 patients were needed in 
each group. The results were analysed statistically using Fisher’s exact test for testing the 
proportions of those receiving allogeneic blood transfusions. All other continuous variables 
were analysed with Student’s t-test. A p-value <0.05 was considered significant. Patients 
were evaluated according to the intention-to-treat principle.
Table 1 Transfusion triggers
Haemoglobin level (g/dl)
number op patients
ASA score eprex group Bellovac group
8.1 ASA 2, 1 25 17
8.9 ASA 3, 2 # 17 26
9.7 ASA 4, 3 ## 8 7
ASA, American Society of Anesthesiologist11
# = significant blood loss during surgery (>500 mL); ## = minor complications during surgery for example, 
temporary deflections on electrocardiogram
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ReSulTS
Of the 50 patients in each group (Table 2), all were ASA grades 2 or 3 and there were 
no statistical differences between the groups in terms of age, gender, height, weight, pre-
operative Hb level, type of surgery or postoperative transfusion trigger.
Table 2 Patient and surgical characteristics
Characteristic eprex group (n=50) Bellovac group (n=50)
Age (years) 73 (49-88) 75 (59-88)
Gender (male/female) 9 / 41 6 / 44
Height (cm) 164 (150-176) 163 (154-174)
Weight (kg) 71 (53-101) 76 (51-106)
Preoperative Hb at screening (g/dL) 12.4 (10.6-13.0) 12.4 (10.8-13.0)
Type of surgery (THR / TKR) 30 / 20 30 / 20
Type of THR (uncemented/hybrid/cemented) 8 / 6 / 17 7 / 7 / 16
Type of anaesthesia (spinal / general) 43 / 7 41 / 9
Postoperative transfusion trigger (g/dL) 8.5 (8.1-9.7) 8.7 (8.1-9.7)
Data are reported as mean (range). THR = total hip replacement; TKR = total knee replacement. There were no 
significant differences between both groups.
There was one failure of inclusion in a patient randomly assigned to the Eprex group who 
received preoperative injections of epoetin alpha and then a postoperative retransfusion 
of 400 mL. One patient in the Eprex group suffered a thrombosis in the superior sagittal 
sinus with an Hb level of 15.6 g/dL after the second injection of epoetin alpha. No further 
epoetin injections were administered and the operation was postponed for six months 
until the patient had recovered completely. Both patients were evaluated according to the 
intention-to-treat principle.
Primary THR was performed in 60 patients and primary TKR in 40 patients. In most cases 
(84 patients, 84%) spinal anaesthesia was used. The remainder had general anaesthesia. 
The intra-operative blood loss was similar in both groups, being 395 mL in the Eprex and 
381 mL in the Bellovac group (p=0.75).
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The mean transfusion triggers in the Eprex and Bellovac groups were 8.5 g/dL (range: 8.1-
9.7 g/dL) and 8.7 g/dL (range: 8.1-9.7 g/dL) respectively (Table 2). A mean of 216 mL (range: 
0-700 mL) were retransfused in the Bellovac group, 131 mL (range: 0-500 mL) in THR and 
341 mL (0 to 700) in TKR. In one patient, retransfusion was not carried out as the quality 
of shed blood was considered dubious owing to premature disconnection of the drain to 
the collection bag. This patient was included according to the intention-to-treat principle.
Table 3 Cost comparison per patient in Euro’s
eprex group Bellovac group
Epoetin alpha injections 1,831.68 None
Ferrofumerate tablets 302.22 None
Bellovac ABT retransfusion system None 84.70
Allogeneic blood transfusion 12.04 80.24
Total costs per patient 2,145.94 164.94
Data are reported as costs per patient in both groups. The costs of the used treatment were based on the 
recommended prices of the manufacturers. The cost of allogeneic blood per patient was based on the percentage 
of patients receiving allogeneic blood combined with the number of units erythrocyte concentrates transfused 
per patient. The cost of one erythrocyte concentrate was € 200.60.
In the Eprex group two patients (4%) received at least one allogeneic blood transfusion, 
compared with 14 (28%) in the Bellovac group (p=0.002). When comparing Eprex with 
Bellovac in THR, these results were 7% (2 of 30) and 30% (9 of 30), respectively (p=0.047), 
whereas in TKR they were 0% and 25% (5 of 20) (p=0.042). The number of units erythrocyte 
concentrates per transfused patient was 1.5 (3/2) in the Eprex group and 1.4 (20/14) in 
the Bellovac group. None of the patients randomly assigned to the Bellovac group with 
a postoperative transfusion trigger of 8.1 g/dL needed allogeneic blood. The costs of 
treatment in both groups and the costs of allogeneic transfusions are presented in Table 3.
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Table 4 Clinical complications
Complication eprex group (n=50) Bellovac group (n=50)
Systemic major 
Cerebral thrombosis in the sagittal sinus 1 (2)
Perforated sigmoid colon 1 (2)
Systemic minor
Nausea 1 (2) 1 (2)
Diabetes mellitus instability 1 (2)
Urinary retention 1 (2)
Urinary track infection 1 (2)
local major
Peri-prosthetic fracture 1 (2)
local minor
Haematoma 1 (2) 2 (4)
Prolonged wound discharge 3 (6) 3 (6)
Superficial wound infection 1 (2)
Total 8 (16) 10 (20)
Data are reported as number (%) of patients with complications in both groups. The one patient in the Bellovac 
group with a “Local major” complication includes a patient with a periprosthetic fracture due to a fall one month 
after primary THR. A revision of the stem was performed. There were no significant differences between both 
groups.
The preoperative levels of Hb were a mean of 12.4 g/dL (range: 10.6-13.0 g/dL) in the Eprex 
group and 12.4 g/dL (range: 10.8-13.0 g/dL) in the Bellovac group (Figure 1). The Hb level 
immediately before operation after the injections in the Eprex group increased by a mean 
of 2.5 g/dL to 14.9 g/dL (range: 13.0-16.6 g/dL). On the first day after operation the mean Hb 
level had decreased to 11.4 g/dL (range: 9.0-13.8 g/dL) in the Eprex group and to 9.7 g/dL 
(range: 7.6-12.1 g/dL) in the Bellovac group. By the third day the levels had decreased to 
11.2 g/dL (range: 8.4-13.7 g/dL) in the Eprex group and to 9.5 g/dL (range: 7.2-11.1 g/dL) in 
the Bellovac group. These reductions were significantly different between the groups on 
the first (p=0.011) and third (p=0.012) days after operation.
The incidence of clinical complications was similar between the groups (Table 4). Four 
patients in the Eprex and five in the Bellovac had haematomas and prolonged wound 
discharge. In the latter group one patient with a superficial wound infection needed 
debridement without removal of the prosthesis.
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Figure 1 Perioperative Hb level
The level of haemoglobin (Hb) in both groups preoperatively and at one and three days 
postoperatively, § indicates statistical significance.
dISCuSSIon
Most hospitals use restrictive transfusion triggers because they are aware of the risks 
and complications of allogeneic blood.13,14 In addition, other interventions to reduce the 
use of allogeneic blood are in use, and it is not known which is the most successful.1-8 
Post operative cell saving using a retransfusion system is relatively inexpensive, whereas 
pre operative injections of epoetin alpha are approximately 15 times more expensive.5-8 
Changing treatment from injections of epoetin to cell saving in patients with preoperative 
Hb levels between 10.0 g/dL and 13.0 g/dL would reduce the cost to the health system. 
Although its efficacy has already been demonstrated in patients without preoperative 
anaemia, the effectiveness of a retransfusion system in patients with mild anaemia before 
operation can be disputed.6-8 The analysis of the costs showed that in such patients the use 
of injections of epoetin supported by ferrofumerate tablets increased the cost per patients 
compared with the retransfusion system. Although this was only based on direct costs, 
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actual comparisons of cost-effectiveness between the groups is hardly possible, as the 
indirect costs were not measured.
In this study, 28% of patients in the Bellovac group needed allogeneic blood, compared with 
46% of the control group in the study of Weber et al.4 Comparing these results, the absolute 
risk reduction would be 18%. Although some patients in the Bellovac group still needed 
allogeneic blood transfusions, their reduction of these was probably due to the retransfusion 
of shed blood. Our absolute risk reduction in allogeneic blood transfusion of injections of 
epoetin compared with postoperative cell saving is 24%. Thus, in every 4.2 patients treated 
with preoperative injections of epoetin alpha, one allogeneic transfusion was prevented 
compared with treatment with a retransfusion system.
The average amount of retransfused shed blood (216 mL) in the Bellovac group was small 
compared with published values.5,6,15 A possible confounding factor is the position of the 
drain. Some of our surgeons preferred the subfascial position in THR, which appeared to 
influence the amount of collectable blood compared with placement in the joint. Therefore, 
retransfusion of different amounts of shed blood may influence the increase in the systemic 
postoperative Hb level and hence the need for allogeneic transfusion. More studies are 
needed in this respect.
Both options for allogeneic transfusion involved complications. In the Eprex group a patient 
with an Hb level of 15.6 g/dL after the second injection of epoetin suffered thrombosis of 
the superior sagittal sinus. This serious event raised the question whether epoetin was 
related to thromboembolic complications, in line with suggestions that such problems 
might arise from an additional influence on coagulation activation.16,17 However, other 
studies, including large randomised clinical trials, observed no differences in adverse 
events between epoetin and controls.2,4,18,19 Hence, the thromboembolic complication in 
our patient, although recognised in the literature, could not be proven to be related.
Patients with preoperative Hb levels >14.5 g/dL have less chance of receiving allogeneic 
blood than do mildly anaemic patients with a preoperative Hb <13.0 g/dL.20 Treating these 
patients enhances the level of Hb. In our study, the average increase in Hb was 2.5 g/dL to 
an absolute of 14.9 g/dL, agreeing with earlier reports.2,4 After primary THR and TKR the 
mean total blood loss to the third postoperative day causes a fall in Hb of approximately 
3.0 g/dL.21
The average reduction in Hb in patients in our Eprex group was 3.5 g/dL on day 1 and 
3.7 g/dL on day 3, compared with the preoperative level. Severe blood loss was needed 
before an allogeneic blood transfusions was given. Conversely, in the Bellovac group, the 
average reduction in Hb was 2.7 g/dL and 2.9 g/dL, respectively. Because the postoperative 
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levels of Hb were significantly lower, less blood loss was needed before allogeneic 
blood was given to these patients. Our finding that none of the Bellovac patients with a 
postoperative transfusion trigger of 8.1 g/dL needed allogeneic transfusion may imply that, 
being even more restrictive, fewer patients in the Bellovac group would need allogeneic 
blood. Therefore, further randomised trials on this topic are justified.
In conclusion, preoperative injections of epoetin are more effective in reducing the need 
for allogeneic blood transfusions in mildly anaemic patients with preoperative Hb levels 
of 10.0 g/dL to 13.0 g/dL compared with postoperative retransfusion of autologous shed 
blood in major joint arthroplasty, but are more expensive.
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ABSTRACT
Hospitals were critized in many ways (medical care and patient safety), so different 
stakeholders jointly started the project ‘Zichtbare Zorg Ziekenhuizen’ (ZZZ; ‘Visible 
Care Hospitals’). This project has developed indicator sets for over eighty disorders. 
The goal of this project was to collect data from hospitals in a uniform manner. 
Transfusion of allogeneic blood is one of the indicators that provides information 
about the quality of actual hip- and knee replacement surgery and the treatment 
around it. However, there exists a flaw in the system that needs to be further 
discussed. Namely, hospitals can positively influence this indicator without having 
to bear the costs of the investments.
Thomassen.indd   78 30-10-2014   11:44:07
Allogeneic blood indicator is not unambiguous  | 79
6
InTRoduCTIon
Annually different quality lists are presented that rank hospitals by the level of care offered. 
These lists are different regarding ranking because each list has its own parameters for 
scoring quality of care. To create more uniformity the project ‘Zichtbare Zorg Ziekenhuizen’ 
(ZZZ; ‘Visible Care Hospitals’) was initiated. The aim of the ZZZ is to gather quality 
information from hospitals in a standardized format to allow for a comparison of quality of 
care to be made. ZZZ strives to collect the information through one channel and to support 
the hospitals in this action through the same organisation. The indicator sets of ZZZ are 
composed of the following parties: Consumers’ Union, The Health Care Inspectorate (IGZ), 
The Dutch Federation of University Medical Centres (NFU), The Federation of Patients and 
Consumer Organisations in the Netherlands (NPCF), The Dutch Federation of Hospitals 
(NVZ), The Dutch Nurses and Carers (V&VN), The Council of Medical Physicians (OMS), The 
Association of Health Care Insurers (ZN) and the scientific professional associations.
Human mistakes
ZZZ’s main goal is to give insight into the quality of treatment of 80 disorders. In 2010, 
twenty-three disorders had a so-called indicator set. In 2011, twenty-two new indicator 
sets were developed. All these sets are based on medical guidelines and comprise the 
complete treatment process. For orthopaedic surgery the indicator sets ‘total hip and 
knee arthroplasty’ have existed for some years already (in 2011 divided in two different 
sets) and different steps of the treatment process are visualized in these sets.1,2 The 
following indicators are defined: complication registry, Dutch Arthroplasty Register, deep 
infections, preoperative antibiotic prophylaxis, preoperative thrombosis prophylaxis, and 
allogeneic blood transfusions. Allogeneic blood transfusions are part of this set due to the 
risks associated with allogeneic blood transfusions. Possible risks include: Hepatitis, HIV/
AIDS, transfer of infectious diseases and also human mistakes by administration of blood 
products.3 A part of patients is not possible to exclude, despite all efforts for extensive and 
better precautions. Besides that, an allogeneic blood transfusion could have a negative 
influence on the immune system. Several methods have been introduced to decrease the 
use of allogeneic blood transfusions. In 2004 the Dutch homologous blood transfusion 
guidelines were developed. The introduction of a stricter indication regime for allogeneic 
blood transfusion, the so-called 4-5-6 rules (the numbers indicate haemoglobin (Hb) levels 
in mmol/L), had an important revolutionary effect. The indications for allogeneic blood 
transfusions are very clear. The health status of the patient, ASA classification (American 
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Society of Anaesthesiologists) and cardiopulmonal changes due to the surgery are taken 
into account.
Blood saving techniques
Besides a restrictive blood regime other blood-saving techniques are possible in joint 
arthroplasties. Important features to account for during surgery include careful haemostasis 
and maintaining patients’ normothermia. Before surgery, autologous blood donation is 
possible and patients with a moderate anaemia (Hb < 8.1 mmol/L) could be treated with 
erythropoietin alpha (epo). During surgery, cell saving (washed and unwashed systems) 
and fibrin glue are possibilities. Furthermore, after surgery blood loss could be measured 
in the first six hours after surgery and retransfused to the patient. These measures are all 
part of the DRG (Diagnosis-related group, in Dutch DBC: diagnosis treatment combination). 
Hospitals have to make their own decisions regarding cost-effectiveness of various blood 
saving techniques. Erythropoietin alpha treatment is an exception because the treatment 
costs are part of the extramural care. The treatment consists of four injections with a total 
price of €1440,-. This treatment option in fact, leads to an omission in the indicator. Hence 
hospitals could positively influence the indicator allogeneic blood transfusions without 
being responsible for the costs.
Calculation example
To illustrate the discrepancy above we analysed data from two large teaching hospitals. 
We retrospectively analysed collected data about allogeneic blood transfusions in primary 
total hip and knee arthroplasties, operated during 2008 or 2009. A total of 2077 joint 
arthroplasties (1189 total hip arthroplasties and 888 total knee arthroplasties) were 
performed. In this group 249 patients (12%) received an allogeneic blood transfusion. 
We checked if the allogeneic blood transfusions were given correctly in combination 
with another blood saving technique (if applicable). The transfusions were identified as 
‘incorrect’, ‘possible incorrect’ and ‘correct’. This classification followed the 4-5-6 rule 
in combination with patients’ health status, Hb level of transfusion, number of bags 
transfused, increase in Hb level and patients’ complaints.
In 78 percent the allogeneic blood transfusion was given correctly, possible incorrect in 16% 
of the cases and 5% was incorrectly given. These figures indicate that continuous training, 
education and refreshment courses have an additional value to minimize the amount of 
allogeneic blood transfusions.
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Four injections
Depending on preoperative Hb values we determined if patients were eligible for 
receiving erythropoietin alpha preoperatively to reduce the number of allogeneic blood 
transfusions. Of the 249 patients, 165 patients (66%) would receive erythropoietin alpha if 
this was standard practice in these hospitals. Thus, patients with a haemoglobin level below 
8.2 mmol/L should receive four erythropoietin alpha injections. On average, one in five has 
a haemoglobin level below 8.2 mmol/L. In our case, this would lead to 415 indications for 
erythropoietin alpha. Erythropoietin alpha is currently offered by Janssen-Cilag and Sandoz. 
If standard practice this should cost €598.000,- for the patient cohort under investigation.
Research has concluded that after erythropoietin alpha treatment the incidence of allo-
geneic blood transfusion should decrease by 75 percent.4 In our case, the preoperative 
moderate anaemic patients with an allogeneic blood transfusion would decrease from 
165 to 41 patients. Theoretically, we could have reduced the amount of allogeneic blood 
transfusions from 249 to 125 patients if erythropoietin alpha injections were standard 
practice in these hospitals. Not all allogeneic blood transfusions can be prevented, so 
the costs for these transfusions should be added to the sum of the erythropoietin alpha 
treatment.
The costs for allogeneic blood transfusions are €53.550,-, for 125 patients who receive an 
average of 2.1 packed cells (€204,- per packed cell). The total costs would be €651.550,-. 
In the current situation, where erythropoietin alpha is not the standard of care, the costs 
would be lower, €106.672,- (249 patients with an average of 2.1 packed cells multiplied 
by €204,-). If erythropoietin alpha would be introduced as standard treatment of care the 
costs would be increase by factor 6.
dubious validity
Indicators have led to more unambiguous reporting of health care quality. Transparency, 
quality improvement and more efficiency in health care are important features of indicators. 
Besides that data validity is questioned. Due to the absence of data verification, the 
allogeneic blood transfusion indicator is also positively influenced by misuse of costs from 
other health care bodies. It is probable that hospitals provide socially-desirable answers 
because no data verification has been performed. The indicator sets are based on the 
guidelines of the scientific professional associations. Acceptable percentages are known 
and specified by the professional bodies. This is visible from the reports of all combined 
data from hospitals and independent treatment centres.4 Of the 97 hospitals, 92 hospitals 
reported their allogeneic blood transfusion data. These percentages show that 28% of 
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the hospitals have no allogeneic blood transfusions in total hip- and knee  arthroplasties. 
This can be concluded since they score 100% on the question ‘percentage surgeries in which 
patients received no allogeneic blood transfusion in the perioperative setting in the case 
of total hip and knee arthroplasties’. The literature over the last decade regarding blood 
management in combination with the retrospective data from this research has shown that 
a percentage of 100% is unrealistic.
Additional information
Since each hospital tries to find solutions to reduce health care costs, the standardisation 
regarding implementation of erythropoietin in total joint arthroplasties remains a challenge. 
Research has concluded that erythropoietin is an effective way to prevent allogeneic blood 
transfusions, with less adverse events.5 However, the costs related to its use are high. For 
this reason hospitals think differently about the usefulness of this product. There is no 
doubt about the indicator sets and the fact that erythropoietin could be helpful in blood 
management. The most important message of this research is that hospitals can improve 
their indicator set with funds from the extramural setting. It may be necessary to add 
additional questions to the indicator regarding allogeneic blood transfusion. In this case it 
may be helpful to provide information regarding the alternatives used in practice since it is 
possible to have higher ranking, while others pay for the alternative used. It is debateable 
whether erythropoietin alpha will still be prescribed in this magnitude if it became part of 
the DRG.
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ABSTRACT
We hypothesised there was no clinical value in using an autologous blood transfusion 
(ABT) drain in either primary total hip (THR) or total knee replacement (TKR) in 
terms of limiting allogeneic blood transfusions when a modern restrictive blood 
management regime was followed. A total of 575 patients (65.2% men), with a mean 
age of 68.9 years (range, 36 to 94 years) were randomised in this three-arm study to 
no drainage (group A), or to wound drainage with an ABT drain for either six hours 
(group B) or 24 hours (group C). The primary outcome was the number of patients 
receiving allogeneic blood transfusion. Secondary outcomes were post-operative 
haemoglobin (Hb) levels, length of hospital stay and adverse events.
This study identified only 41 (7.1%) transfused patients, with no significant 
difference in distribution between the three groups (p=0.857). The mean pre-
operative Hb value in the transfused group was 12.8 g/dL (range, 9.8 to 15.5 g/dL) 
versus 14.3 g/dL (range, 10.6 to 18.0 g/dL) in the non-transfused group (p<0.001, 
95% confidence interval: 1.08 to 1.86 g/dL). Post-operatively, the median of 
re-transfused shed blood in patients with a THR was 280 mL (Interquartile range 
(IQR) 150 to 400 mL) and in TKR patients 500 mL (IQR 350 to 650 mL) (p<0.001).
ABT drains had no effect on the proportion of transfused patients in primary THR 
and TKR. The secondary outcomes were also comparable between groups.
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InTRoduCTIon
The basis for modern patient blood management (PBM) is the application of a restrictive 
blood transfusion protocol combined with measures to reduce the need for peri-operative 
allogeneic blood transfusion.1 Pre-operatively, erythropoietin injections combined with 
autologous blood donation can be used, although the use of the latter has declined in 
this millennium.2 Intra-operatively tranexamic acid administration, cell saving of salvaged 
blood, and intra-operative blood volume dilution are other options in PBM.3 Post-
operatively, autologous blood transfusion (ABT) of shed blood along with clear transfusion 
thresholds are also used.4-6 The optimal combination for particular patients and their cost 
effectiveness is still debated. Nevertheless, the largest benefit in modern PBM appears to 
be the introduction of a restrictive blood transfusion threshold in most hospitals.5,7
The use of wound drains in primary joint replacement is still controversial. Parker et al. 
reported in their meta-analysis that no conclusive evidence for the use of closed suction 
surgical drains in primary joint replacement but ABT drains were not included in their 
analysis.8 With ABT drains the shed blood that accumulates in the suction bottles is re-infused 
into the patient within the first six hours. However, their usefulness in total hip (THR) or total 
knee (TKR) replacement is still uncertain. This is largely due to methodological difficulties 
in reporting, such as differences between studied groups, absence of randomisation, no 
formal power analysis, lack of controls, the use of varying end points, different transfusion 
thresholds and the use of different blood reinfusion devices.9-12 The rate of drainage from 
a wound is important when determining the beneficial effect of ABT drains. An ABT drain 
removed at six hours post–operatively potentially achieves satisfactory early drainage 
while minimising overall blood loss, but any blood drained after six hours is discarded if 
these devices are still in situ.13
We initiated a multi-centre, prospective, randomised, single-blinded controlled trial on the 
effect of autologous blood transfusion at two postoperative time intervals (removal at six 
or 24 hours) compared to a control group (no wound drainage) in primary THR and TKR 
surgery, in the presence of a restrictive transfusion threshold. The primary outcome was 
the assessment of the requirement for allogeneic blood transfusions.
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MeTHodS
The trial was undertaken in the Netherlands in two hospitals using the Bellovac ABT System 
(WellSpect Healthcare, Mölndal, Sweden), a wound blood reinfusion device. All consecutive 
patients planned for primary THR or TKR between November 2010 and November 2012 
were eligible for the study. The study population consisted of 322 THRs and 253 TKRs, 
undertaken in 575 patients (Table 1, Figure 1). The primary goal was to compare the need 
for allogeneic blood transfusion in a) patients with no wound drainage (group A), b) in 
patients who received autologous blood reinfusion from their drain after six hours at which 
stage this drain was removed (group B) and c) in patients who received autologous blood 
reinfusion from their drain after six hours but drain removal after 24 hours (group C).
The medical ethics committee approved the study (NL27458.098.10), and all patients 
provided written informed consent before enrolment. The study was registered in the 
Dutch trial registry (NTR2501).
Table 1 Patient characteristics
group A group B group C
N 190 191 194
Age (yrs) Mean (range)* 68.9 (43-89) 69.5 (36-90) 68.2 (42-94)
BMI (kg/m2) Mean (range)† 28.2 (20.1-41.8) 28.2 (17.8-47) 28.1 (19.3-43.9)
Gender n (%) Female 132 (69.5) 123 (64.4) 120 (61.9)
Male 58 (30.5) 68 (35.6) 74 (38.1)
ASA n (%) I 24 (12.6) 25 (13.1) 28 (14.4)
II 149 (78.4) 141 (73.8) 146 (75.3)
III 17 (8.9) 25 (13.1) 20 (10.3)
Surgery n (%) THR 103 (54.2) 103 (53.9) 116 (59.8)
TKR 87 (45.8) 88 (46.1) 78 (40.2)
Anaesthesia n (%) Spinal 140 (73.7) 146 (76.4) 143 (73.7)
General 50 (26.3) 45 (23.6) 51 (26.3)
Pre-operative Hb (g/dL) Mean (range)‡ 14.2 (9.8-17.9) 14.2 (10.6-17.1) 14.2 (10.6-18.0)
Erythropoietin n (%) n=17 4 (2.1) 7 (3.7) 6 (3.1)
Surgical approach for THR 
(n = 332)
SL 50 51 50
PL 48 45 62
AS 5 7 4
ASA, classification according to the American Society of Anaesthesiologist18; BMI, Body Mass Index; Hb, 
haemoglobin; THR, total hip replacement; TKR, total knee replacement; SL, straight lateral; PL, posterolateral; 
AS, anterior supine.
*, p-value 0.411; one-way ANOVA test
† p-value 0.939; one-way ANOVA test
‡ p-value 0.790; one-way ANOVA test
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Included paents (n = 575) 
MCH = 434 
LLZ = 141 
Group C (n = 190), ITT 
THA = 103 
TKA = 87 
Group 6 (n = 191), ITT 
THA = 103 
TKA = 88 
Group 24 (n = 194), ITT 
THA = 116 
TKA = 78 
Incorrect treatment (n = 25) 
3 = no drain instead of drain, because of clinical problems 
1 = 6 hours instead of 24 hours, because of device problems by 
reinfusion 
21 = 24 hours, because this was roune before study conduct 
Group C (n = 193), AT 
THA = 106 
TKA = 87 
Group 6 (n = 170), AT 
THA = 92 
TKA = 78 
Group 24 (n = 212), AT 
THA = 124 
TKA = 88 
Figure 1 Flowchart
Group A, no wound drainage; group B, 6 hour drainage for six hours and removal of the drain; 
group C, wound drainage for six hours and removal of the drain 24 hours postoperatively. MCH, 
Medical Center Haaglanden; LLZ, Lange Land Hospital, AT, As Treated; ITT, Intention to Treat; THR, 
Total Hip Replacement; TKR, Total Knee Replacement.
Exclusion criteria were inability to give informed consent, patients with bleeding disorders, 
a religious objection to the concept of blood transfusion, and patients where bone grafting 
was expected during THR. Performance of a TKR without a tourniquet, previous major 
operations such as a tibial osteotomy or THR undertaken for post-traumatic secondary 
osteoarthritis, also resulted in exclusion. All surgical procedures were performed according 
to the surgeons’ preference, using their customary approach. Each surgeon involved in the 
trial undertook a minimum of 50 joint replacements annually. There were three different 
approaches to THR: straight lateral (SL), posterolateral (PL) and anterior supine (AS). For 
TKRs a straight midline skin incision and medial parapatellar arthrotomy was used. The 
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tourniquet in TKR was released after skin closure and the application of compressive 
bandaging.
The re-infusion drains were used in groups B and C according to the manufacturer’s 
instructions for post-operative autologous blood collection and re-infusion. The collected 
shed blood was returned to the patient in both re-infusion groups irrespective of their 
haemoglobin (Hb) level. In group B, the ABT drain was removed after six hours. In group C, 
the re-infusion drainage bottle was replaced with a low-vacuum Bellovac drain (WellSpect 
Healthcare, Mölndal, Sweden) after the first six hours, and then removed during the first 
post-operative morning (between 18 to 24 hours post-operatively).
Erythropoietin (Eprex, Janssen Pharmaceutical Companies of Johnson & Johnson, Tilburg, 
The Netherlands) was routinely used in one of the two hospitals in anaemic patients with a 
pre-operative Hb level below 13 g/dL (n=17). Three subcutaneous injections (40,000 IU of 
erythropoietin alpha in each injection) were given weekly, beginning three weeks before 
surgery with iron supplementation. Patients who used anticoagulation stopped these seven 
to ten days pre-operatively so that their INR was ≤1.8 before surgery.
All patients received thrombo-prophylaxis with low weight molecular heparin after surgery 
and continued until six weeks post-operatively. All patients received a single dose of 
cephalosporin prior to incision and two more doses within 24 hours postoperative, which 
was part of the routine protocol in use in both hospitals. Rehabilitation followed the 
standard procedure specific to each hospital. In general, patients’ mobilisation started on 
the first post-operative day and planned discharge was between the second and fourth 
post-operative day.
The primary outcome was the proportion of post-operative patients receiving an allogeneic 
blood transfusion. The secondary outcomes were post-operative Hb values, measured 
peri-operative blood loss, transfusion volumes, length of hospital stay and adverse events, 
especially wound problems. All adverse events were coded according to Parvizi et al.14 Intra-
operative blood loss was only calculated for the THRs, as TKRs were undertaken with a 
tourniquet. Protocol violations regarding allogeneic transfusion were noted and recorded.
Eligible patients were consecutively randomised to receive either no drain (group A) or a 
Bellovac ABT System for re-infusion of shed blood (group B or C). Stratification of patients was 
carried out per clinic because each clinic has its own surgical technique and post-operative 
clinical procedures. Variable block sizes were used to ensure three balanced groups with 
an additional unknown randomisation factor. A computer generated randomisation plan 
was sealed in opaque envelopes by an independent person with randomisation performed 
in the operating theatre, but deferred until wound closure, to prevent changes in surgical 
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behaviour being introduced. Each patient’ actual randomisation was checked against the 
randomisation list, inclusion date, surgery date and demographic data to ensure correct 
implementation and strict consecutive allocation.
The decision to transfuse allogeneic blood was taken according to the restrictive Dutch 
transfusion threshold regime (Table 2) known as the “4-5-6 (mmol/L) flexi norm”.15
For all transfusions the indication was registered. Allogeneic blood transfusion was only 
given when the Hb level exceeded 8 g/dL if the patient was symptomatic from their 
anaemia, such as experiencing tachycardia and/or hypotension. Each allogeneic transfusion 
was evaluated (correct or probably incorrect) at the end of the study by certain authors 
(BT, PdH, HK and PP). The decision, if a transfusion was given correctly was based on pre-
transfusion Hb, comorbidity, Hb increase after transfusion and day of transfusion. All 
outcome measures were collected prospectively and analysed as applicable by personnel 
unaware of the treatment allocation.
Table 2 The transfusion threshold15
Hb level, 6.4 g/dl
ASA 1
ASA 2 and 3, and uncomplicated surgery
Hb level, 8 g/dl
ASA 2 and 3, and significant blood loss during surgery (more than 500 mL)
Hb level, 9.6 g/dl 
ASA 2 and 3, and minor complications during surgery (i.e. ST deviation on electrocardiogram)
ASA 4
ASA, classification according to the American Society of Anesthesiologists18
Statistical analysis
Sample size calculation. The use of allogeneic blood in THR and TKR patients (i.e. percentage 
transfused patients) in the presence of a restrictive transfusion threshold (Table 2) was 
estimated to be 19%.17 The expected transfusion rate in the re-infusion group was estimated 
to be 7%.16,17 Therefore, the expected mean difference in transfusion rate was 12%. With a 
5% significance level, two-sided hypothesis and 90% power, a total of 184 patients would 
be required in each group. Allowing for a drop-out rate of 3%, a total of 190 patients per 
group would be required.
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Analyses were based on an intention-to-treat (ITT) principle, analysed in the assigned 
group. To assess the effect of the actual treatment (i.e. re-infusion of shed blood) an “As 
Treated” (AT) analysis was also performed.
For data which were not normally distributed median and interquartile range (IQR) 
were presented. Demographic and baseline data were based on the results from the PP 
procedure. Conclusions related to effectiveness and efficacy were explored by using the 
AT analysis set. Risk for variability due to the multi-centre study design, with for example 
differences in routines for hospital stay and discharge, was mitigated by use of stratification.
Pearson’s chi squared test was used to test frequencies of categorical response variables. 
The non-parametric Kruskal-Wallis test was used to analyse differences in continuous 
response variables between the treatment groups. A p-value < 0.05 was considered 
statistically significant. Tables with descriptive data were generated and hypotheses tested 
using statistical software PASW Statistics version 20.0 (IBM SPSS Statistics for Windows, 
Chicago, Illinois).
ReSulTS
According to the ITT principle, 25 (4%) patients did not receive the treatment as randomised, 
and were analysed as AT. The three groups were comparable with regards to mean age, body 
mass index (BMI) and American Society of Anaesthesiologists (ASA) classification.18 The 
three different surgical approaches used for THR (151 SL, 155 PL and 16 AS), were equally 
divided between the transfusion subgroups (Table 1). In 188 of 202 (93%) TKR patients who 
received spinal anaesthesia, it was a combination of spinal and epidural anaesthesia (CSE).
In total 41 patients (7.1%) received an allogeneic blood transfusion of packed cells (mean 
2.1 units, range 1 to 6). We did not identify any significant difference in the requirement of 
allogeneic transfusion (Table 3).
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Table 3 Transfusion per analysis
group A group B group C Total p-value$
ITT 190 191 194 575
Transfused patients (%) 12 (6.3) 14 (7.3) 15 (7.7) 41 (7.1) 0.857
THR* 8 (7.8) 5 (4.9) 12 (10.3) 25 (7.8) 0.317
TKR* 4 (4.6) 9 (10.2) 3 (3.8) 16 (6.3) 0.173
AT 193 170 212 575
Transfused patients (%) 12 (6.2) 12 (7.1) 17 (8) 41 (7.1) 0.780
THR# 8 (7.5) 4 (4.3) 13 (10.5) 25 (7.8) 0.248
TKR# 4 (4.6) 8 (10.3) 4 (4.5) 16 (6.3) 0.230
ITT, intention-to-treat; THR, total hip replacement; TKR, total knee replacement; AT, as treated.
$ Pearson Chi-square
* calculated from 322 THR (103, 103, 116 for respectively group A, B, C) and 253 TKR patients (87, 88, 78 for 
respectively group A, B, C).
# calculated from 322 THR (106, 92, 124 for respectively group A, B, C) and 253 TKR patients (87, 78, 88 for 
respectively group A, B, C).
Patients who required an allogeneic transfusion had significantly different pre-operative Hb 
levels compared with the non-transfused patients (p<0.001, independent samples t-test; 
95% confidence interval (CI): 1.08 to 1.86 g/dL). The mean pre-operative Hb value in the 
transfused group was 12.8 g/dL (9.8 to 15.5 g/dL) versus 14.3 g/dL (9.8 to 15.5 g/dL) in the 
non-transfused group. The mean Hb level increased from 8.3 g/dL (6.3 to 9.8 g/dL) before 
transfusion to 10.3 g/dL (8.4 to 12.2 g/dL) after allogeneic transfusions. The evaluation 
whether those allogenic transfusions were justifiable, showed that in 15 of the 41 (37%) 
transfusions were probably incorrect based on the pre-study defined criteria. The 
distribution between group A, B and C was six, five and four patients, respectively.
The length of hospital stay was similar between all groups (p=0.15; Kruskal-Wallis test) with 
a median of four days (three nights) (IQR group A and B: 4 to 6 and IQR group C: 4 to 5). The 
median intra-operative blood loss in THR patients was 350 mL (IQR: 250 to 500 mL), with 
no differences between the groups (p=0.095; Kruskal-Wallis test).
A total of 385 patients were randomised for post-operative autologous re-infusion. Due to 
insufficient shed blood collection (<80 mL, n=38) or problems with the Bellovac ABT System 
(n=4), 42 patients (11%) did not receive autologous blood reinfusion. The median amount 
of re-infused autologous blood was 350 mL (IQR: 200 to 500 mL). The volume of autologous 
blood re-infused between procedures was: THR median 280 mL (IQR: 150 to 400 mL), TKR 
median 500 mL (IQR: 350 to 650 mL), which was significantly different (p<0.001; Mann-
Whitney U test) between the two joint types.
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Table 4 All adverse events
group A group B group C
N 190 191 194
Systemic complications - major 14* 14* 10
Acute renal failure 1 1 -
Hypotensive crisis 1 - 1
Deep (THR / TKR) infection† 4 5 2
Myocardial infarction 1 - -
Pulmonary embolus 1 2 1
Tachyarrhythmia 6 5 6
Transient ischemic attack - 1 -
Systemic complications - minor 14‡ 24‡ 25‡
Anaemia 7 11 8
Deep venous thrombosis 1 - 2
Mental status change 2 2 4
Pneumonia - 2 2
Urinary problems 3 4 2
Others 1 5 7
local complications - major 5 6 1
Dislocation§ 4 4 -
Peripheral nerve injury 1 2 1
local complications - minor 19 18** 22
Drain hole oozing na 4 4
Haematoma 2 - 2
Persistent wound drainage 9 5 6
Skin blisters 6 3 6
Superficial wound infection 1 3 1
Others 1 3 3
NA, not applicable; THR, total hip replacement; TKR, total knee replacement.
* one patient in group A and two patients in group B with a double adverse event in this category.
†all patients underwent debridement for infection.
‡ There was one patient (group A) and two patients (group B and C) that had a double adverse event in this 
category. One patient in group B had three adverse events in this category.
§ two patients had two dislocations within six weeks, one patient underwent revision surgery for recurrent 
dislocation within these six weeks.
** one patient in group B had a double adverse event in this category.
Within the first six post-operative weeks of the study period, 147 (26%) patients (91 hips 
and 56 knees) presented with a total of 172 adverse events; three patients had three 
adverse events and 18 patients had two adverse events (Table 4). Of these, 13 patients had 
a re-operation on the THR or TKR surgical site. In 12 patients a debridement due to deep 
wound infection was carried out. One patient underwent revision surgery for recurrent 
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dislocations of her THR. Of the adverse events 22 patients were re-admitted to the hospital, 
which included the 13 re-operated patients. The other seven patients were re-admitted for 
observation of an adverse event.
dISCuSSIon
Only 41 (7%) patients received an allogeneic transfusion with no differences between the 
re-infusion and control groups in either THRs or TKRs. Post-operative Hb values, length of 
hospital stay and adverse events were comparable between the three groups. It appeared 
that the Bellovac ABT System had no effect on these outcome variables.
Previous studies have only compared closed suction drainage with no drainage in THR.19 Our 
allogeneic blood transfusion rates were between 6% and 8% in all groups and considerably 
lower than in most other studies.9-11 The low allogeneic blood transfusion rate could possibly 
be explained by the fact that both centres have applied a strict modern transfusion regime 
for several years.5 Although the current study was powered on the assumption of higher 
transfusion rates, the actual transfusion rate did not differ between the three groups. 
A larger sample size might detect a smaller difference in transfusion rate, but this would 
probably not be clinically relevant.
The need for ABT drains in total joint replacement has been repeatedly questioned. Our 
data are supported by other studies but neither had a control group where no drainage is 
used.9,10 Only one study compared ABT drainage and re-infusion with closed suction drainage 
or with no drainage.20 The strength of that study was the inclusion of only uncemented 
THRs operated through one approach (direct anterior). A major limitation, however, was 
that their primary endpoint of the difference between pre- and post-operative Hb values 
did not take into account the treatment differences such as allogeneic blood transfusion 
post-surgery and the drains in that study were in situ for 48 hours.
Other studies on ABT drains found an allogeneic transfusion reduction ranging from 40% in 
favour of no drainage to 86% in favour of the autologous drain groups.10,12,15,21 These studies 
were relatively small with 20 to 80 patients in each group looking at either one or both of 
THRs and TKRs.
Most reports on blood management trials state the protocol used for allogeneic blood 
transfusion decisions. However, the issue of whether the patients were symptomatic or not 
make it difficult to interpret the significance of the allogeneic blood transfusion volumes 
given. Our secondary outcome measures, such as length of hospital stay and amount of 
re-infused autologous blood, showed no differences as with other studies.4,11,12
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Our study has some limitations. Erythropoietin was used in only one of the participating 
hospitals and could have a possible impact. Pre-operative Hb levels are known to be of 
significance when dealing with transfusions in the post-operative phase.22 In all, 17 patients 
(3%) of the study population received erythropoietin. This was 15% of eligible erythropoietin 
patients. It is noteworthy that five patients with pre-operative erythropoietin usage still 
had Hb level below 12.9 g/dL at surgery, but none of these patients received an allogeneic 
blood transfusion.
Our study was also limited in that the decision whether or not to use allogeneic transfusions 
was not blinded. After evaluating the decision to transfuse, on basis of pre- transfusion 
Hb, comorbidity, Hb increase after transfusion and the day of transfusion, in 15 of the 
41 patients the allogeneic blood transfusion was of questionable value. However, this was 
only based on retrospective evaluation of the medical data, which could not identify any 
patient who justifiably received blood. If the strict transfusion rules were followed the 7.1% 
transfusion rate could theoretically be lowered to 4.5%.
Finally, 25 (4%) of the patients did not receive the treatment as randomised. This was 
mainly because the standard hospital protocol before the study started called for the drain 
to be left in situ for 24 hours. Twenty-one cases had the drain in situ for 24 hours. In the 
other four patients, three patients received no drain and one patient had a drain in situ for 
6 hours instead of 24 hours.
This large study has demonstrated that ABT drains have no beneficial effect on the post-
operative transfusion requirements in THR and TKR in hospitals with a restrictive transfusion 
protocol.
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ABSTRACT
There are risks related to blood incompatibility and blood-borne diseases when using 
allogeneic blood transfusion. Several alternatives exist today, one of which, used 
for autologous blood salvage perioperatively, is the Sangvia Blood Management 
System. This study was designed to investigate the efficacy of the system and to add 
data to previously reported safety results.
Two hundred sixteen patients undergoing primary or revision total hip arthroplasty 
(THA) were enrolled in this randomized, controlled, assessor-blinded multicenter 
study. Randomization was either autologous blood transfusion (Sangvia group) or 
no use of autologous blood (Control group), both in combination with a transfusion 
protocol for allogeneic transfusion. Patients were followed during hospital stay 
and at two months after discharge. The primary outcome was allogeneic blood 
transfusion frequency. Data on blood loss, postoperative hemoglobin/hematocrit, 
safety and quality of life were also collected. The effectiveness analysis including 
all patients showed an allogeneic blood transfusion rate of 14% in both groups. 
The efficacy analysis included 197 patients and showed a transfusion rate of 9% 
in the Sangvia group as compared to 13% in the Control group (95%CI -0.05-0.12, 
p=0.502). A mean of 522 mL autologous blood was returned in the Sangvia group 
and lower calculated blood loss was seen 1095 mL vs 1285 mL in the Control group 
(95%CI 31-346, p=0.018). No differences in postoperative hemoglobin was detected 
but a lower hematocrit reduction after surgery was seen among patients receiving 
autologous blood. No relevant differences were found for safety parameters or 
quality of life.
General low use of allogeneic blood in THA is seen in the current study of the 
Sangvia system used together with a transfusion protocol. The trial setting is under- 
powered due to premature termination and therefore not able to verify efficacy for 
the system itself but contributes with descriptive data on safety.
Trial registration
Clinicaltrials.gov NCT00822588




In major orthopedic procedures, there is considerable blood loss during and after surgery 
which causes acute postoperative anemia and often leads to a rising need for allogeneic 
blood transfusions. Allogeneic blood transfusion is not a risk-free therapy, as it is associated 
with potential risks of matching errors, down-modulation of the immune system, increased 
infection rate, absence of clotting factors and transmission of infectious diseases, which 
may result in poorer postoperative outcomes and higher mortality.1-8 In addition, some 
patients refuse to have an allogeneic blood transfusion for religious reasons and allogeneic 
blood is a limited and increasingly expensive resource.9 To minimize these disadvantages, a 
variety of alternative interventions has been developed to reduce the need for allo geneic 
transfusions. These interventions are generally either agents to diminish blood loss (e.g. 
tranexamic acid), agents that promote red blood cell production (e.g. erythropoietin) 
or techniques for re-infusing the patient’s own blood (e.g. cell salvage).10-16 A systematic 
review of previously studied cell salvage systems suggested that their use is efficacious 
in reducing the need for allogeneic transfusion in cardiac and orthopaedic surgery even 
though it concluded that the methodology was poor.17
Both ‘filtered’ and ‘washed’ cell salvage systems are commonly used and known 
 contraindications are mainly related to the quality of the collected blood. While it is 
known that salvaged blood is laden with complement split products, interleukins, various 
inflammatory mediators and fat particles the clinical implication of these factors is not 
clear.18-21
This study was designed to evaluate the clinical efficacy of a new device for cell salvage, 
i.e. the SangviaTM Blood Management System (Astra Tech AB, Mölndal, Sweden), by using a 
scientifically sound research methodology. The study was also done to further investigate 
the safety aspect of ‘filtered’ cell salvage and to confirm previously reported safety findings 
for this new device for cell salvage.20,21
MeTHodS
This was an international multicenter, prospective, assessor-blinded, randomized, controlled 
trial with an adaptive statistical study design. Six European hospitals were involved, located 
in The Netherlands (three clinics), Spain, Norway and Austria. The protocol for this trial 
and supporting CONSORT checklist are available as supporting information; see CONSORT 
checklist S1 and Study protocol S2.
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Participants
For inclusion in the study, patients had to be scheduled for primary or revision total hip 
arthroplasty and be classified as American Society of Anesthesiology (ASA) class I, II or 
III. The following criteria excluded the patients from participation in the study: Exclusion 
due to ethical concern included previous randomization in this study, involvement in the 
planning and/or conduct of this study, and participation in an interfering study. Exclusion 
due to safety concerns included current symptoms of hemophilia and contraindications 
for autologous blood use, i.e. hyperkalaemia, current systemic infection or local infection 
in the operation field or impaired renal function (elevated creatinine/clearance levels), 
known malignancy in the last five years and expected use of cytotoxic drugs. Exclusion 
due to expected impact on outcome included untreated anemia (hemoglobin (Hb) level 
<11 g/dL), revision total hip arthroplasties with expected serious bone grafting, and use 
of other alternatives for blood conservation such as recombinant erythropoietin, fibrin 
sealant, aprotinin and other autologous blood transfusion.
Use of tranexamic acid was allowed if routinely used in the individual clinic and thus equally 
distributed between the treatment groups. The decision for tranexamic acid use had to be 
made before randomization.
ethics
Written informed consent was obtained from all participating patients. The study was 
approved by applicable local ethics committees before its initiation and was conducted 
in accordance with the Declaration of Helsinki, ICH/Good Clinical Practice, and regulatory 
requirements. The following ethics committees approved the study: Medisch-ethische 
commissie at Onze lieve vrouwe gasthuis (reference WO 09.033), METC Zuidwest Holland 
(reference 09-031), Medisch Centrum Haaglanden (reference RVB/RZ/1444), Reinier de 
Graaf Groep (reference CZ/CS/2009-086), CEIC-IMAS (reference YA-DRA-0001, version 2.0, 
date 12/01/2009), Det medisinske fakultet Regional komite for medisinsk og helsefaglig 
forskningsetikk Helseregion Midt-Norge (reference 4.2009.421), Ethik-kommission der 
Medizinischen Universität Wien und des Allgemeinen Krankenhauses Der stadt Wien AKH 
(reference 011/2009).
Interventions
Prior surgery patients scheduled for primary or revision total hip arthroplasty (THA) were 
randomized to receive either autologous blood transfusion (Sangvia group) or no use 
of autologous blood (Control group) in combination with using a transfusion protocol 
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limiting allogeneic blood transfusions to patients with hemoglobin (Hb) values below 
8.5 g/dL or significant clinical symptoms of anemia. Surgery was performed by orthopedic 
surgeons following their routine procedures. The Sangvia group used the SangviaTM Blood 
Management System (Astra Tech AB, Mölndal, Sweden) for surgery. The system was used 
according to the manufacturer’s instructions for both intra-operative and postoperative 
autologous blood collection and transfusion. Details about the system are published in 
Kvarström et al. and Stachura et al.20,21 Postoperative drains were used in both groups to 
standardize postoperative routines and minimize differences between the two treatment 
groups, i.e. the Sangvia drain for postoperative autologous blood collection and transfusion 
in the Sangvia group and a regular postoperative low-vacuum drain (BellovacTM, Astra Tech 
AB, Mölndal, Sweden) in the Control group. Both drainage systems were used until the first 
postoperative morning. Before patient recruitment started ten systems were used to train 
operating room staff at each of the study sites.
Rehabilitation followed the standard procedure at each specific hospital.
outcomes
The primary outcome measure was allogeneic blood transfusion frequency, given as a 
relative percentage, and measured at the day of discharge. Allogeneic blood transfusions 
were also described by the number of transfusion decisions taken for a patient, the 
transfusion volume and the calculated transfusion index (total number of units per 
transfused patient).
Secondary outcome measures included blood loss, postoperative Hb and hematocrit (Hct), 
safety and quality of life. The intra-operative blood loss was estimated by the surgeon 
by evaluating intra-operative cell saving volumes, waste suction volumes and weighing 
gauzes. The research assistant estimated blood loss after surgery based on drain volumes. 
The sum of intra- and postoperative blood loss represents the total value of estimated 
blood loss. In addition to the estimated values, blood loss was calculated on the basis of 
blood volume and Hct values, i.e. calculated blood loss (mL) = [Total blood volume (mL) x 
(Hct
pre-op – Hctpost-op)] / [(Hctpre-op + Hctpost-op)/2]. Total blood volume was calculated in liters by 
the formula (0.3669 x height (m3)) + (0.03219 x weight (kg)) + 0.6041 for men and (0.3561 x 
height (m3)) + (0.03308 x weight (kg)) + 0.1833 for women.22,23
Safety data included vital signs (heart rate, blood pressure, temperature), laboratory 
variables (potassium, sodium, creatinine and Glomerular Filtration Rate) and adverse 
events classified by severity and causality. Quality of life was assessed by the EuroQol (EQ-
5D) health status questionnaire.24,25 All patients were followed during surgery and their 
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hospital stay with outcome measures collected pre-operatively, at three hours, on one, 
two and four days after surgery, and on the day of discharge. A final check-up to fill out the 
EQ-5D questionnaire was done two months after surgery.
Sample size
The study used an adaptive statistical design where a preplanned interim analysis on half of 
the population was done to confirm or reject sample size estimations. The null hypothesis 
tested for rejection was if the allogeneic transfusion frequency was equal in the Sangvia 
and in the Control group. The initial sample size calculation (power 90%, 5% two-sided 
level of significance) was based on the literature and normal use of allogeneic blood in the 
Control group was estimated to be 21%.13,26-28 The expected value for transfusion frequency 
in the Sangvia group was estimated to be around 7% based on an expected added value 
to previous reported findings from postoperative autologous systems.13 The sample size 
necessary for detection of the expected difference in transfusion frequency was calculated 
to be 260 patients.29 A further 40 patients were planned to be included to adjust for non-
evaluable patients or drop-outs.
Randomization
Eligible patients were consecutively randomized to receive either autologous blood 
transfusion, by the SangviaTM Blood Management System (Sangvia group), or to no use of 
autologous blood (Control group).
Treatment allocation was stratified by hospital and type of surgery, i.e. primary or revision 
arthroplasty. For randomization a block size of 4 and allocation distribution 1:1 were 
used. For each hospital, a separate randomization list was generated by a computer and 
implemented in a web-based login system. The randomization plan and generated list were 
only known to study personnel not involved in clinical procedures.
The principal investigator/study coordinator randomized the patients as close as possible 
prior to surgery in the web-based login system. In the majority of cases this was an 
investigator not involved in surgery. Each patient’s actual randomization was checked 
against the randomization list, inclusion date, surgery date and demographical data to 
ensure correct implementation and strict consecutive allocation.
Blinding
To mitigate the risk of bias, the decision for allogeneic blood transfusion was taken on 
the basis of a transfusion trigger, a Hb value <8.5 g/dL, by an assessor unaware of the 
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treatment group. The majority of the clinics used a representative from the blood bank for 
the decision. In acute situations, i.e. during surgery, the decision had to be taken by the 
surgeon/anesthesiologist who was aware of the treatment allocation. For all transfusions, 
indication was registered and for allogeneic blood transfusions with Hb values above 8.5 g/
dL, the requirement was for the patient to have clinical symptoms, i.e. signs of anemia, such 
as tachycardia and/or hypotension. Secondary outcome measures were collected 
prospectively and analyzed as applicable by independent laboratory personnel unaware 
of the treatment allocation. Clinical variables such as vital signs, evaluated by personnel in 
contact with the patient, could not be blinded during the first postoperative day due to the 
differences in drains used in the Sangvia and Control groups.
Statistical methods
Analyses were made on both an Intention To Treat (ITT) and a Per Protocol (PP) principle. 
Demographic and baseline data were based on the results from the ITT procedure. 
Conclusions related to effectiveness were explored by using the ITT analysis set, and those 
related to efficacy were based on the results in the PP analysis set. Conclusions related 
to safety and quality of life were also based on the ITT analysis set. The risk for variability 
due to the multicenter study design, with for example differences in routines for hospital 
stay and discharge, was mitigated by use of stratification. Thus the results of the statistical 
analyses do not present data for each individual clinic.
The Fisher Exact test was used to test frequencies of dichotomous response variables. The 
non-parametric Wilcoxon Rank Sum rank test was used to analyze differences in continuous 
response variables between the treatment groups. P-values <0.05 were considered 
statistically significant. In addition, 95% confidence intervals (CI) were calculated based on 
independent sample t-test (equal variances assumed) and presented for comparative data. 
No correction for multiplicity was made since hypotheses were considered statistically 
independent.
Tables with descriptive data were generated and hypotheses tested using statistical 
software PASW Statistics version 18.0 (IBM® SPSS® Statistics).
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ReSulTS
Participant flow
The pre-planned interim analysis was performed in 135 patients, 66 in the Sangvia group 
and 69 in the Control group, and concluded that the transfusion rate in the Control group 
was 12% instead of the expected 21%. Accordingly, the study was at risk of being under-
powered and inconclusive and was prematurely stopped. This resulted in 227 enrolled 
patients instead of the planned 300. Randomization was done before surgery, and thus 
all enrolled patients were randomized. Some of the exclusion criteria could only be 
completely verified after randomization just before, during or after surgery, e.g. local 
infection in the operation field. Only limited demographical and no follow up data were 
collected for patients for whom exclusion criteria were identified after randomization but 
before surgery. Of the 227 patients, this was applicable in 11 patients who were excluded 
due to withdrawn consent (five patients), exclusion criteria fulfilled (two patients with an 
ongoing local infection, one patient with a missing creatinine value) and three patients 
whose surgery was rescheduled after the study was prematurely discontinued. These 
patients were registered and are presented in Figure 1 but are not represented in any of the 
analyses due to lacking data. Thus, treatment was allocated and data were collected from 
a total of 216 patients (ITT analysis), 106 in the Sangvia group and 110 in the Control group.
Major protocol deviations were detected in some patients after treatment, and for that 
reason two analysis sets were identified, i.e. ITT and PP (Figure 1). Although it is recognized 
that the ITT analysis set should include all patients intended for treatment the actual ITT 
analysis set in this study was limited to all treated patients due to missing follow-up data 
for patients excluded before treatment allocation. The PP analysis set excluded 19 patients 
for whom major protocol deviations were detected. Ten patients were excluded from the 
PP analysis in the Sangvia group; other autologous blood devices were used by mistake in 
four cases, erythropoietin was given by mistake in one case, a preoperatively creatinine 
level outside the normal range was detected late for one case and no treatment was given 
due to technical and management difficulties in four cases. Nine patients were excluded 
from the PP analysis in the Control group; other autologous blood was given by mistake 
in five cases, preoperatively creatinine level outside normal range was detected late for 
one case, a preoperatively Hb level below the exclusion criteria was detected late for 
one case, a history of malignancy was detected late for one case and incorrect treatment 
allocation was used by mistake in one case, i.e. Sangvia was used. The PP analysis consisted 
of 197 patients, 96 in the Sangvia group and 101 in the Control group.















Control (ITT)  
n=110
 
Sangvia (PP)  
n=96
 
Control (PP)  
n=101  
Exclusion before surgery (n=7)
 
 
- Surgery outside study period (n=2)
 
- Withdrawn consent (n=4)
 
- Exclusion criteria fulfilled (n=4)
 
Exclusion before surgery (n=4)
- Surgery outside study period (n=1) 
- Withdrawn consent (n=1)
 
- Exclusion criteria fulfilled (n=2)
 
Major protocol deviaons (n=10)  
 - Exclusion criteria fulfilled (n=6)  
- No treatment (n=4)  
Major protocol deviaons (n=9)  
 - Exclusion criteria fulfilled (n=8)  
 - No treatment (n=1)
Figure 1 Study patient flow and definition of analysis sets
Recruitment
Patients were enrolled in the study between May 2009 and April 2010. The last patient 
completed the trial in May 2010.
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Table 1 Patients characteristics
Sangvia Control p-value1
N 106 110
Age (years) Mean (SD) 67 (11) 65 (12) 0.163
BMI Mean (SD) 27.3 (4.6) 27.5 (4.6) 0.509
Sex n (%) Female 76 (72) 70 (64)
Male 30 (28) 40 (36) 0.245
ASA n (%) I 28 (26) 31 (28)
II 59 (56) 66 (60)
III 19 (18) 13 (12) 0.402
Surgery n (%) Primary 100 (94) 104 (95) 
Revision 6 (6) 6 (6) 1.000
Anesthesia n (%) Spinal 63 (60) 63 (57)
General 40 (38) 42 (38)
Combined 2 (2) 5(5) 0.826
Pre-op Hb (g/dL) Mean (SD) 13.87 (1.16) 13.98 (1.16) 0.474
Pre-op Hct (%) Mean (SD) 41 (4) 42 (3) 0.346
BMI = Body Mass Index
1Mann-Whitney U/Wilcoxon rank sum test: Exact Sig. (2-tailed) was used to give an indication of the size of 
chance imbalances between the treatment groups.
Baseline data
The study population was found to be homogeneous with a mean age of 66 years old, 
BMI of 27.4 and a majority (68%) of female patients of ASA class I (27%) or II (58%). Patient 
characteristics seemed to be similar in the Sangvia and Control groups (Table 1). One clinic 
routinely used tranexamic acid, five patients received it, two in the Control group and three 
in the Sangvia group. All except four patients in the Sangvia group received autologous 
blood transfusion, collected either intra-operatively and/or postoperatively, and a mean of 
522 mL was transfused (PP analysis).





The ITT analysis showed a generally low allogeneic blood transfusion frequency of 14% in 
both groups (95% CI -0.09-0.10, p=1.00) and efficacy was studied in the PP analysis where 
nine of 96 (9%) patients needed an allogeneic blood transfusion in the Sangvia group and 13 
of 101 (13%) in the Control group. The 4% difference between the groups was not statistically 
significant (95% CI -0.05-0.12, p=0.502), the power for detecting it was 14%. A total of 
15 transfusion decisions were taken for the nine patients transfused in the Sangvia group 
and 26 for the 13 patients transfused in the Control group (PP analysis). The transfusion 
volume among the patients receiving allogeneic blood was 756 mL (2.3 units), transfusion 
index =2.33 in the Sangvia group and 856 mL (2.5 units), transfusion index =2.54 in the 
Control group (PP analysis). Corresponding values from the ITT analysis were 24 transfusion 
decisions for 15 patients transfused, 735 mL (2.3 units) and transfusion index =2.33 in the 
Sangvia group and 29 transfusion decisions for 15 patients transfused, 834 mL (2.6 units), 
transfusion index =2.60 in the Control group. None of the differences measured were found 
to be statistically significant. Of the 30 patients that were transfused (53 transfusions), 
only 4 patients (5 transfusions) underwent revision surgery. Five transfusions were given 
during surgery without a known Hb value. For 28 transfusions the transfusion trigger of 
<8.5 g/dL was reached. The other 20 transfusions were given based on clinical symptoms. 
The transfusion percentage per center showed a large variance, ranging from 4% to 52% 
(4%, 9%, 11% twice, 20%, 52%).
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Table 2 Estimated and calculated blood loss per treatment group
Sangvia Control 95% CI, p-value1
ITT analysis set
estimated blood loss (ml)
Intra-operative Mean (SD) 479 (329) 517 (305) -124-48, 0.239
Postoperative 0-6h Mean (SD) 305 (188) 292 (182) -40-66, 0.696
Postoperative 6-24h Mean (SD) 220 (126) 212 (171) -36-52, 0.186
Total Mean (SD) 931 (486) 927 (431) -119-127, 0.947
PP analysis set
Calculated blood loss (ml)
3 hours after surgery Mean (SD) 923 (407) 952 (419) -147-89, 0.667
Postoperative day 1 Mean (SD) 1104 (418) 1140 (449) -159-87, 0.385
Postoperative day 2 Mean (SD) 1145 (436) 1296 (500) 17-285, 0.063
Postoperative day 4 Mean (SD) 1095 (480) 1285 (562) 31-349, 0.0175
1Mann-Whitney U/Wilcoxon rank sum test: Exact Sig. (2-tailed), 95% CI based on independent sample t-test, 
equal variances assumed.
Secondary outcomes
The results of the estimated and calculated blood loss are presented in Table 2. The PP 
analysis showed that the total estimated blood loss was 914 mL in the Sangvia group and 
921 mL in the Control group (95% CI -31-117, p=0.879). Corresponding values from the ITT 
analysis were 931 mL in the Sangvia group and 927 mL in the Control group (95% CI -119-
127, p=0.947). A smaller calculated blood loss was seen in the Sangvia group at days 2 and 4 
compared to the Control group (PP analysis); 1145 mL vs. 1296 mL on day 2 (95% CI 17-285, 
p=0.063) and 1095 mL vs. 1285 mL on day 4 (95% CI 31-349, p=0.018). No early differences 
were seen at three hours (923 mL vs. 952 mL, 95% CI -147-89, p=0.667) or at day 1 (1104 
mL vs. 1140 mL, 95% CI -159-87, p=0.385) after surgery. Corresponding values from the ITT 
analysis were 935 mL vs. 970 mL three hours after surgery (95% CI -155-85, p=0.251), 1081 
mL vs. 1160 mL on day 1 (95% CI -199-41, p=0.066), 1148 mL vs. 1311 mL on day 2 (95% CI 
36-290, p=0.013) and 1104 mL vs. 1284 mL on day 4 (95% CI 26-334, p=0.009).
The Hb and Hct values are presented in Table 3 as relative change from screening 
(PP analysis). For the Hb values, lower reduction was seen in the Sangvia group but no 
statistically significant differences were detected in a comparison of the two treatment 
groups. Corresponding values from the ITT analysis set were 2.53 g/dL vs. 2.58 g/dL at three 
hours (95% CI -0.35-0.25, p=0.963), 3.03 g/dL vs. 3.14 g/dL at day 1 (95% CI -0.40-0.18, 
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p=0.322), 3.13 g/dL vs. 3.41 g/dL at day 2 (95% CI -0.57-0.01, p=0.074) and 3.05 g/dL vs. 
3.30 g/dL at day 4 (95% CI -0.60-0.10, p=0.123).
Regarding the change in Hct percentages, the reduction in the Sangvia group was 
significantly lower than in the Control group on day 4 (95% CI -2-0, p=0.02). Corresponding 
values from the ITT analysis set were 8% vs. 8% at three hours (95% CI -1-1, p=0.996), 9% 
vs. 9% at day 1 (95% CI -1-1, p=0.337), 9% vs. 10% at day 2 (95% CI -2-0, p=0.068) and 9% vs. 
10% at day 4 (95% CI -2-0, p=0.017).
Table 3 Hb and Hct change from screening per treatment group (PP analysis set)
Sangvia Control 95% CI, p-value1
Hb (g/dl)
3 h after surgery Mean (SD) 2.53 (0.98) 2.54 (1.12) -0.31-029, 0.735
1 day after surgery Mean (SD) 3.11 (1.04) 3.10 (1.11) -0.29-0.31, 0.809
2 days after surgery Mean (SD) 3.14 (1.06) 3.38 (1.06) -0.54-0.06, 0.130
4 days after surgery Mean (SD) 3.06 (1.16) 3.31 (1.22) -0.61-0.11, 0.141
Hct (%)
3 h after surgery Mean (SD) 8 (3) 8 (3) -1-1, 0.687
1 day after surgery Mean (SD) 9 (3) 9 (4) -1-1, 0.802
2 days after surgery Mean (SD) 9 (3) 10 (4) -2-0, 0.140
4 days after surgery Mean (SD) 9 (4) 10 (4) -2-0, 0.021
1Mann-Whitney U/Wilcoxon rank sum test: Exact Sig. (2-tailed), 95% CI based on independent sample t-test, 
equal variances assumed.
Laboratory parameters and vital signs showed no differences in overall heart rate and 
temperature between the two treatment groups at any time point (ITT analysis). The blood 
pressure measurements however indicated that there was a smaller reduction in blood 
pressure during surgery in patients in the Sangvia group, i.e. difference of 8 mmHg in 
systolic blood pressure (95% CI 4-12, p=0.005) and 6 mmHg in diastolic blood pressure (95% 
CI 3-9, p=0.001), as compared to the Control group (ITT analysis). The difference in diastolic 
blood pressure also seemed to persist on day 1 (difference 3 mmHg: 95% CI 0-6, p=0.027), 
day 2 (difference 5 mmHg: 95% CI 1-9, p=0.009), day 3 (difference 6 mmHg: 95% CI 2-10, 
p=0.005) and day 4 (difference 8 mmHg, 95% CI 3-13, p=0.001) after surgery (ITT analysis). 
All mean/median values for sodium, potassium, creatinine and Glomerular Filtration Rate 
were within normal reference intervals of 135-145 mmol/L, 3.5-5.0 mmol/L, 62-95 μmol/L 
and 55-134 mL/min/1.73m2, respectively, and no differences were detected between the 
groups at any time point (ITT/PP analysis).
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The assessment with the EQ-5D questionnaire showed an expected general improvement 
in mobility, self-care, usual activity, pain and anxiety in both groups (ITT analysis). After 
two months, problems in mobility, self-care, usual activity, pain and anxiety were reported 
for 48%, 28%, 38% 46% and 10%, respectively, in the Sangvia group and for 52%, 27%, 
54%, 47% and 10%, respectively, in the Control group. The median general improvement in 
health status was from 70 to 80 on the Visual Analogue Scale (VAS) in both groups.
Adverse events
Forty-three of 106 (41%) patients in the Sangvia group and 46 of 110 (42%) patients in the 
Control group had one or more adverse events (difference 1%: 95% CI -0.14-0.12, p=0.891), 
leading to a total of 141 adverse events. The numbers of patients with one, two or three 
reported adverse events were coded and are compared in Table 4. Twelve patients (11%) 
in the Sangvia group reported 14 adverse events that were classified as either possibly or 
probably/definitely device related. The following adverse events were classified as possibly 
related: 1x anaemia, 2x headache/vertigo/nausea, 2 x pain during transfusion, 2x seroma, 
2x wound leakage, 1x wound swelling, 1x hematuria, 1x saturation depression and 1x high 
heart beat. In addition, one reported wound leakage was classified as probably/definitely 
device related.
Seven serious adverse events occurred in both groups (difference 1%, 95% CI -0.06-0.07, 
p=1.00). One patient in the Control group died 13 days after surgery. All other events were 
serious due to prolongation of hospitalization. Table 5 list all serious adverse events per 
treatment group collected in the study. To further explore the correlation between adverse 
events and autologous blood transfusion special attention was paid to reported adverse 
events among patients with the highest transfusion volumes in the Sangvia group (i.e. 75% 
percentile, representing transfusion volume >669 mL). These are listed in Table 6. One 
reported serious adverse event (i.e. vasovagal episode) was found in one patient with a 
total transfusion volume of 700 mL. No indications were otherwise seen of more severe 
adverse events with increasing transfusion volume.
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Table 4 All (serious) adverse events coded according to WHO-ART
Sangvia Control
 n 106 110
Adverse events per system-organ class1 n events
Skin and appendages disorders 1 1 1
Musculo-skeletal system disorders 1 3 1
Central & peripheral nervous system disorders2 1 7 1
2 1 0
Psychiatric disorders 1 1 3
Gastro-intestinal system disorders 1 8 7
2 4 3
Metabolic and nutritional disorders 1 3 0
Cardiovascular disorders, general 1 4 9
Heart rate and rhythm disorders 1 3 2
Respiratory system disorders 1 3 2
Red blood cell disorders 1 2 3
Platelet, bleeding and clotting disorders 1 0 1
Urinary system disorders 1 3 3
Body as a whole - general disorders3, 4 1 13 18
2 4 1
3 1 1
Resistance mechanism disorders 1 3 4
Number of patients with 1, 2 or 3 reported adverse events per system organ class.
1System organ class according to WHO Adverse Reaction Terminology (WHO-ART) was used for coding by means 
of Primary System according to the Adverse Event Dictionary Version 029 (equivalent to MedDRA).
2Reported AEs were dizziness, headache, nausea, myoclonus, vertigo, restless legs, and needling sensation 
during transfusion.
3Body as a whole – general disorders include for example postoperative complications (e.g. wound seroma and/
or redness and hip joint dislocation), peripheral edema, pain and death.
4There was one reported death in the Control group, which occurred 13 days after discharge.
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Table 5 Reported serious1 adverse events 
Adverse event Sangvia Control
Cardiac insufficiency 1 0
Dehydration 1 0
Hip dislocation/luxation 1 1
Lung embolism 0 1
Paralytic ileus 1 0
Periprosthetic fissure (intra-op) 0 1
Saturation depression 1 0
Death 0 1
Infection hip 0 1
Suspected infection (positive bacterial culture) 1 0
Wound infection 0 1
Wound leakage 1 1
Total 7 7
1Serious definition according to ICH/Good Clinical Practice as any untoward and unintended response that 
results in death, is immediately life-threatening, requires in-subject hospitalization or prolongation of existing 
hospitalization, results in persistent or significant disability or incapacity, is a congenital abnormality or birth 
defect or is an important medical event that may jeopardize the patient or may require medical intervention to 
prevent one of the outcomes listed above.
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700 2 1 Needling stings in skin during blood transfusion
Delirium
700 1 2 Nausea
Vomiting






750 1 1 Leg pain 3 weeks after surgery
800 1 0
825 1 0
850 1 3 Oedema of scrotum and both legs 
Seroma





1050 2 1 Pain in the leg
Anaemia bleeding




1400 1 2 Abscess perianal with purulent secretion
Seroma
2720 1 3 Hematuria
Muscle cramp in upper thigh
Wound leakage
1The Sangvia transfusion volume was divided by percentile, i.e. 25% = 306 mL, 50% = 475 mL and 75% = 669 mL.
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dISCuSSIon
Interpretation
In our assessor–blinded, randomized, controlled, parallel-group trial that included 216 
patients, a low use of allogeneic blood was seen when the Sangvia Blood Management 
System was used together with a transfusion protocol. The trial setting was not able to 
verify efficacy with regards to allogeneic transfusion frequency for the system itself, but 
a lower calculated blood loss and lower hematocrit reduction was seen four days after 
surgery among patients receiving autologous blood. The study contributes descriptive data 
on safety, and no safety issues were discovered with the use of the new device. Further 
large-scale, randomized, controlled trials are warranted to continue to investigate the 
safety and efficacy of the device.
Carless et al. conducted a systematic review to investigate the effectiveness of cell salvage 
in orthopedic, cardiac and vascular surgery.17 Overall, the findings showed that cell salvage 
reduces the need for transfusions of donated blood in cardiac and orthopedic surgery. 
These conclusions were drawn with the remark that the methodological quality of the 
trials was poor and that the findings may be biased in favor of cell salvage.17 This is why 
large trials of high methodological quality that assess the relative effectiveness, safety and 
cost-effectiveness of cell salvage are necessary. Although the quality of the current study 
design was strengthened by using an independent and blinded transfusion trigger assessor, 
we cannot rule out potential bias as allogeneic transfusions were also allowed for clinical 
symptoms and transfusion decisions were taken by clinicians aware of treatment allocation 
in acute situations during surgery. Blinding is a cornerstone of therapeutic assessment 
to mitigate the risk of bias and previous studies have shown larger treatment effects in 
cases of un-blinded endpoint assessment.30 However, blinding patients, care providers and 
outcome assessors is difficult to achieve when surgery techniques are being studied, and 
unblinding may thus occur more often in such studies.31 The results of the current study, 
based on blinded laboratory analyses, show some efficacy benefits with lower calculated 
blood loss and hemaocrit reduction, supporting the use of cell salvage. However, efficacy 
with regard to allogeneic blood transfusion needs to be further verified in a larger trial 
setting.
Our study seems to confirm previously reported safety results with the Sangvia Blood 
Management System and proposes that it might be safe to use in orthopedic surgery even 
though it is recognized that the study was not primarily powered for safety conclusions.20,21 
This speculation is based on the fact that laboratory variables collected for safety analysis 
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did not show any differences between the two groups and all stayed within the reference 
ranges, and that the majority of reported adverse events were non-severe. In addition, no 
general safety issues were raised when investigating reported adverse events and both 
treatment groups had very similar adverse event profiles, as shown in Table 4. Furthermore, 
no indications were seen of more severe adverse events with increasing transfusion volume 
when examining the adverse events reported from patients that received the highest 
transfusion volumes with Sangvia, as shown in Table 6.
limitations and generalizability
Our study is strengthened by using an independent and blinded transfusion trigger 
assessor. Blinding is a cornerstone of therapeutic assessment to mitigate the risk of bias. 
For instance, previous studies have shown larger treatment effects in cases of un-blinded 
endpoint assessment.30 Blinding patients, care providers and outcome assessors when 
assessing a non-pharmacological trial is more difficult than in pharmacological trials, which 
is why blinding is not always appropriate and unblinding may occur more often.31
The primary limitation of the study relates to low power since an adaptive interim analysis 
concluded that the allogeneic transfusion rate in the Control group was much lower (12%) 
than the expected 21% and the study was prematurely discontinued. The results of the 
PP analysis showed a transfusion rate of 9% in the Sangvia group and 13% in the Control 
group, indicating a 4% difference between the groups (95% CI -0.05-0.12, p=0.502). This 
difference was not statistically verified, however, and the power for detecting it, if true, 
was only 14%. A new study, performed in the same trial setting and having the aim to 
detect a potential difference at the 4% level, with a power of 90% and a two-sided level of 
significance of 5%, would require at least 2572 patients. The ITT analysis did not indicate 
any differences in transfusion rate between the treatment groups (14% in both groups, 95% 
confidence interval -9-10, p=1.00). However, this analysis set should be used with care when 
drawing efficacy conclusions because it included patients with major protocol deviations 
(e.g. Sangvia was used in the Control group and epoetin alfa and other autologous blood 
transfusion were used with a potential impact on the need for allogeneic blood transfusion).
As described in the participant flow in the results section it is worth to mention once again 
that the data presented in the ITT analysis was limited to all treated patients due to missing 
follow-up data for patients excluded before treatment allocation. It is recognized that this 
is not per definition a formal ITT analysis since it should include all patients intended for 
treatment, for our study that means also the ones that did not make it into the operating 
room. Thus, our study may have skewed results due to post-randomisation bias. This 
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illustrates the more complicated nature of surgical randomized trials and stresses the need 
for randomization as close as possible to the intervention or control treatment preventing 
this limitation in our study and subsequent difficulties in analysing the results using formal 
ITT analysis.
Accordingly, any potential differences in the efficacy of the intervention would be weakened 
and unlikely to be discovered in the ITT analysis set owing to the low power of the study. 
However, the ITT is interesting in exploring the effectiveness of the treatment, although 
it is difficult to relate to the reason why there are differences in the results of the ITT 
and PP analyses, i.e. they may either relate to poor treatment efficacy or poor treatment 
implementation.
The low allogeneic transfusion frequency found in the study affects the generalizability 
of the results. First, the literature refers to the use of transfusion trigger protocols in 
transfusion medicine but it is likely that this was used more strictly in the current clinical 
trial setting than in normal practice based on the facts that an assessor-blinded study design 
was used and allogeneic transfusion frequencies found in the literature were much higher 
than those observed in the study.12,26 Second, the study population was homogeneous with 
regard to demographic and baseline variables but generally healthier than the expected 
target population of the study. For example, the patients were young (mean age of 66 years) 
and healthy (ASA class I in 27% of the cases) and very few revision hip arthroplasties were 
included (only 6%). The latter was prominent in one clinic that primarily included ASA class 
I patients with high pre-operative Hb levels since the epoetin alfa guideline at the hospital 
restricted the inclusion of patients with lower Hb levels. Third, there were some indications 
of selection bias toward uncomplicated surgery in the study. For example, no revision hip 
arthroplasties were included at one clinic. In summary, the present results were based on a 
population that was challenging in terms of studying efficacy improvements.
Further limitations of the study relate to the generalizability of the results. For instance, 
the inclusion and exclusion criteria regarding hemoglobin values were very strict, i.e. a 
Hb level above 11 g/dL and no use of epoetin alfa. The latter excluded patients with a 
pre-operative hemoglobin value between 11 g/dL and 13 g/dL in centers using a routine 
regimen of epoetin alfa. Salido et al. showed that pre-operative hemoglobin values have a 
predictive value for the need for allogeneic blood transfusions why it could be expected to 
be easier to detect efficacy differences in centers without implemented blood management 
programs.32 Furthermore, some patients were excluded from the PP analysis as a result 
of poor protocol implementation, e.g. other autologous blood devices and erythropoietin 
were used by mistake. Although study personnel were trained before the study was 
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started, it can be concluded that this was not sufficient to avoid major protocol deviations 
in the study. This was especially true for clinics that had to change their normal practice to 
adapt to the standardized clinical study protocol. More emphasis should thus be placed on 
training before initiating future clinical studies in this area.
overall evidence
Our study was not able to draw general conclusions on efficacy, but the safety data propose 
that the Sangvia Blood Management System may be safe to use in orthopedic surgery. Both 
these aspects need to be further investigated in large-scale clinical research. It could also 
be interesting to compare the cost-effectiveness with other therapy options. For instance, 
a comparison could be made with a preoperative alternative such as epoetin alfa in a non-
inferiority design. Epoetin alfa is paid in most countries by other health care resources than 
the hospital budget, and thus cost effectiveness should focus on the whole health care 
community. It would also be interesting to conduct a clinical efficacy trial for the Sangvia 
Blood Management System in patients with a higher allogeneic transfusion rate risk, e.g. 
revision surgery, and/or in patients with low pre-operative Hb values, with a special focus 
on the methodological quality, and as utilized in the presented study.17,33
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Should assessors be blinded to study results 
when judging risk of bias?
A randomised study of withholding study results of blood management 
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ABSTRACT
Blinding is one of the methodological safeguards and has impact on the effect sizes 
measured. We aimed to evaluate the impact of blinding assessors for study results 
when judging risk of bias.
Studies were randomly allocated in a blinded or non-blinded fashion for study results 
to four assessors. Four assessors all received blinded and non-blinded studies. We 
focused our search in standard databases to human, English-language, randomised 
controlled trials and studies published between January 2000 and September 
2010. Presence of bias (i.e. randomisation, blinding and selection) with the Jadad 
and Chalmers instruments was evaluated in 132 articles. Agreement between the 
assessors of the same kind (blinded or non-blinded for study results) was measured 
with a Kappa (κ) coefficient. By measuring a sum score per instrument we estimated 
the blinding effect in this study design.
The assessors blinded for study results had higher κ values on all items (0.66, 
0.51, 0.42, 0.54) compared to the non-blinded assessors (0.60, 0.50, 0.35, 0.21). 
Furthermore, the agreement between the assessors of the same kind on the Jadad 
items (κ range, 0.5-0.66) was higher than on the Chalmers items (κ range, 0.21-0.54). 
Articles received a higher sum score, 3.66 versus 3.38 points and 2.23 versus 2.13 
points on respectively Jadad and Chalmers, from the assessors blinded for study 
results compared to the non-blinded assessors. Despite the statistically significant 
data, the differences found are marginal and therefore probably methodologically 
irrelevant.
Blinded assessors were more optimistic about the study quality, as measured by 
Jadad and Chalmers scales, compared to assessors with access to study results. 
However, it remains questionable if this difference is methodologically relevant 
when performing a systematic review. Further research has to be performed to 
evaluate its impact when conducting a systematic review, especially in studies 
regarding the screening of methodological quality.
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BACKgRound
Quality of studies is a multi-dimensional concept that is related to the validity of the study 
findings. These findings are a result of study design; conduct and analysis of a trial; its 
clinical relevance; and the quality of reporting.1 Literature shows that poor study design 
frequently results in positive findings or larger effect sizes.2-4 Moher et al. reported 
statistically significant differences in effect sizes in studies with a high or unclear risk of 
bias compared with those studies with a low risk of bias.5 As a consequence, the quality of 
the primary studies can influence the magnitude of the effect in a SR or MA. Therefore, it 
is important to downgrade the quality of evidence if a study shows major limitations, if the 
results are inconsistent or when the evidence is indirect or imprecise.6
The three generally accepted and most relevant methodological safeguards for internal 
validity are randomisation, blinding persons for the intervention and selection (i.e. 
limitation of the occurrence of withdrawals, attrition bias).7 Despite these three important 
methodological aspects, the diversity in instruments for scoring methodological quality 
is large. As concluded by Jüni et al. there is a considerable heterogeneity in available 
instruments, and the scoring on each tool has also influence.8 Since assessors that score 
the quality of articles can be biased as well, agreement among assessors is frequently 
evaluated in SRs or Mas.9-11 Hartling et al. studied the interrater reliability on the risk 
of bias tool introduced by the Cochrane Collaboration and concluded that a clear and 
detailed guidance is necessary. Due to the low agreement this could have implications for 
interpretation of a SR.11 Scoring articles in a slightly different way/manner or with different 
instruments may even result in contrary conclusions in a systematic review. Morissette et 
al. did a methodological review comparing the difference in risk of bias assessment when 
the assessment is blinded or non-blinded for basic study characteristics (authors name, 
journal etc.) and concluded that there is discordance but that the effort to conceal is 
probably disproportionate.12
We considered that blinding for study results could be important as well. To evaluate the 
latter we conducted an experiment in which assessors were either blinded or non-blinded 
for study results when evaluating the risk of bias in studies. We hypothesized that blinded 
assessors show more agreement when evaluating the quality of papers. Furthermore, 
blinded and non-blinded assessors score differently when evaluating the quality of papers, 
because we think that the blinded assessors are less distracted by the study results than 
the non-blinded assessors.
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MeTHodS
We performed a randomised trial on published blood management interventions in 
orthopaedic surgery. Each article was randomised in twice blinded and ones non-blinded 
for study results. Four assessors, aware of the study design, received the articles in blinded 
or non-blinded for study results when evaluating risk of bias in studies (Table 1).
Trial identification
We searched standard databases MEDLINE (Pubmed), EMBASE and The Cochrane Central 
Register of Controlled Trials on two distinct orthopaedic topics. The keywords used were: 
“Arthroplasty, Replacement, Hip” OR “Hip Prosthesis” OR “Arthroplasty, Replacement, 
Knee” OR “Knee Prosthesis”. We focused our search to human, English-language, 
randomised controlled trials and studies published between January 2000 and September 
2010 (additional file 1). We did not use any terms on blood conservation in the primary 
search strategy to prevent loss of articles.
Studies selection
Two independent assessors (BT, WV) selected articles based on title and abstract. Inclusion 
criteria were: primary outcome blood management, full-text in English, study performed 
on human subjects and randomised studies. Disagreement between the two assessors was 
resolved by discussion and consensus. When no consensus was found a third assessor (RP) 
decided to include or exclude articles. SRs and MAs discussing blood management were 
checked for relevant references. The full text articles of the potentially relevant titles were 
retrieved.
Randomisation and blinding
This section was completely performed by one author (BT) who also scored all articles in 
a non-blinded fashion to prevent bias. All selected articles were placed in a random order, 
based on their reference ID, generated by Reference Manager (version 12.03, Thomson 
Reuters, New York, USA). A computer program (www.randomization.com) randomised 
each article (for the randomisation program ‘a random patient’ in the units (‘treatment 
labels’): blinded, blinded and non-blinded for study results, like a crossover design. The 
assessors (WV, CP and SW) had a fixed position in the crossover and were not aware of 
the randomisation plan. So each assessor received articles in a “blinded” or “non-blinded” 
fashion, depending on the randomisation (Table 1). Blinding for the study results was 
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 performed by covering/hiding the abstract, results and discussion sections on a hard copy 
of the article, which was then recopied. If necessary, the title was also blinded for the 
assessors.
Table 1 Randomisation schedule
Article option Assessor 1 Assessor 2 Assessor 3
1 1 Blind Non-blind Blind
2 2 Non-blind Blind Blind
3 3 Blind Blind Non-blind
4 2 Non-blind Blind Blind 
5 1 Blind Non-blind Blind
And so on for 132 articles
Each article was randomised in one of the three options in a random order. Assessor WV, CP and SdW had a fixed 
position respectively assessor 1, 2 and 3. Assessor BT scored each article non-blinded.
outcomes
Each article was assessed by four independent assessors (BT, WV, CP and SW) in two different 
manners (blinded and non-blinded for study results). Out of all instruments available and 
validated we decided to choose two instruments, Jadad and Chalmers, to assess risk of bias. 
The choice of these two instruments was made because no full articles (no abstract, results 
and discussion section) were available for the blinded assessors so the quality assessment 
had to be measured from the materials and methods section.13,14 Furthermore, we wanted 
instruments that had the same amount and equivalent items.
The Jadad instrument (Table 2) focuses on randomisation (2 points), blinding for treatment 
(2 points) and patients account (1 point). This scale gave a deduction of 1-point if the items 
randomisation or blinding were inappropriate.13
The Chalmers instrument (Table 3) also consists of three items (treatment assignment, 
selection bias and blinding for treatment) on which a maximum of 9 points was possible. 
Each item was divided in four options (0 to 3 points) with increasing points for better 
methodology.14
The items per instrument have different names but they are measuring the same subject. 
However, the criteria of the items between the instruments differ, detailed information 
is found in Table 2 and 3. We used the following terms during analysis, “randomisation”, 
“blinding” and “selection”.
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Statistical analyses
The blinded assessors had the possibility to give the answer “unknown” if data regarding 
the item “selection” was not available in the methods section of the article. This led to only 
30 articles that could be evaluated. For this reason the item “selection” was not taken into 
account when calculating the sum score of the instrument.
Our primary outcome was level of agreement between assessors of the same kind, 
blinded or non-blinded for study results. Kappa statistics (ĸ) was utilized to check level of 
agreement between the two assessors of the same kind. For this agreement Fleiss criteria 
were used: 0-0.20 as poor, 0.21-0.40 as fair, 0.41-0.60 as moderate, 0.61-0.80 as good, 
and 0.81-1 as very good agreement.15 Kappa confidence intervals were estimated using 
1.000 bootstrap replications in the software STATA version 12.1. Secondary outcome was 
the so-called blinding effect, which was defined as the difference in scoring between the 
assessors blinded versus non-blinded for study results. A sum score per instrument per 
assessor was calculated, in which we excluded the item “selection”. The sum scores of the 
same assessor were summed and divided by two (called “difference”). Then the groups 
(blind versus non-blind) were compared using the Wilcoxon rank test. Data were analysed 
using IBM SPSS Statistics 19.0 (IBM SPSS Statistics, Chicago: SPSS Inc.).
Table 2 Jadad instrument, classification per point13
Randomisation +1 Randomisation is mentioned
+1 The method of randomisation is appropriate (computer-generated ran-
dom number list, coin toss or well-shuffled envelopes)
-1 The method of randomisation is inappropriate (alternate assignment, by 
birthday, hospital number, or day of the week)
Blinding +1 Blinding is mentioned (conducted in a double-blind fashion)
+1 The method of blinding is appropriate (use of identical tablets or injecta-
bles)
-1 The method of blinding is inappropriate (incomplete masking)
Patients account +1 The fate of all patients in the trial is known. If there are no data the rea-
son is stated. 
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Table 3 Chalmers instrument, classification per point14
Treatment 
Assignment
3 The treatment assignment process was deemed to have been truly ran-
domised, as with a telephone or computer system, and the investigator 
was unlikely to have been able to predict (or identify) the assigned treat-
ment prior to trial entry. When a study was stated to be randomised and 
double-blind/masked (but the method of assignment to the treatment 
group was not described), three points were given only if the summary 
report also presented adequate data to suggest that the treatments could 
not be distinguished from each other and that the treatment groups were 
similar with regard to prerandomisation risk factors.
2 The study was stated to have involved randomisation, but the method of 
assignment was not described, or when assignment was made by envelope 
or by some other method that made it unlikely (but still possible) that the 
treatment to be assigned could be known or suspected by the investiga-
tors.
1 The study was stated to have involved randomisation, but the method of 
assignment was not described and the investigator was not “blinded” at 
treatment assignment.
0 Randomisation was not mentioned explicitly or when the investigators 
could easily have predicted or influenced the treatment assignment. 
Control of 
Selection Bias 
3 The report stated that all patients entered in the trial and assigned treat-
ment were included in the analysis, or if any withdrawals from the trial had 
been listed and the results analysed both by original treatment assignment 
and by treatment received.
2 Withdrawals had actually been listed in the report and the results had 
been analysed by original treatment assignment only.
1 Reports did not mention withdrawals or the results had been analysed only 
by treatment received.
0 Withdrawals had occurred but were not described in the report and 
the results were analysed only by treatment received, or if withdrawals 
accounted for more than 15% of the sample of randomised patients.
Blinding of 
 Participants and 
Investigators
3 The study was reported to have been double-blinded, such that (1) 
patients, (2) care givers, and (3) investigators assessing outcome were all 
kept unaware of the treatment assignment.
2 The investigator assessing outcomes had been blinded to the treatment 
assignment or if two of the three categories listed above had been blinded.
1 Blinding was impossible or when it was impossible to judge whether it had 
been attempted.
0 When a study could have been conducted as double-blinded, but had not 
been.
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ReSulTS
Our search yielded 3016 articles in the three databases after duplicates were removed. 
Based on title/abstract the two assessors had an agreement of 99.3% when in- or excluding 
an article, 206 (6.8%) articles passed to the next stage of inclusion. Twenty-two studies 
(0.7%) had to be viewed by the third assessor (RP) for in- or exclusion, of which 14 were 
included. In the eleven systematic reviews and meta-analyses about blood management 
16 relevant references were checked. Based on the full text, over 100 articles were excluded 
for several reasons; i.e. the study was not randomised, full-text was non-English. A total of 
132 articles were selected (Figure 1). Characteristics of the selected articles are presented 
in Table 4.
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The blinded assessors had good agreement on the Jadad item “randomisation” compared 
to a moderate agreement of the non-blinded assessors (Table 5). The Jadad item “blinding” 
showed a moderate agreement for both types of assessors (blinded and non-blinded). 
The Chalmers items showed lower agreement of all assessors per item compared with the 
Jadad items. The Chalmers items “randomisation” and “blinding” both scored moderate 
agreement for the blinded assessors and fair agreement for the non-blinded assessors. As 
mentioned earlier, the item “selection” was not interpretable for the blinded assessors. For 
the non-blinded assessors, a poor agreement was found for the “selection” item on the 
Jadad and Chalmers instrument.
Table 5 Kappa agreement between the two assessors of the same kind 
Jadad Chalmers





















Data are presented as κ value (95%CI).
All κ values have a significant difference of P-value <0.001; $P-value = 0.718, ^P-value = 0.004
Thus, blinded assessors had better agreement on each single item of the two instruments 
than the non-blinded assessors. Furthermore, the agreement on the Jadad items was 
higher in comparison with the agreement on the Chalmers items.
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A mean overall score per instrument is presented in Table 6. The blinded assessors had a 
significantly higher mean score 2.23 and 3.66 points on respectively the Jadad and Chalmers 
instrument, compared to 2.13 and 3.38 points for the non-blinded assessors. However, sum 
score for the Jadad instrument ranged between 53-56% of the total possible points (4) 
and on the Chalmers instrument the values ranged between 56-61% of the total possible 
points (6).
Table 6 Sum score per instrument according to assessor type
Jadad Chalmers
Blinded 2.23 (2.04-2.42) 3.66 (3.42-3.90)
Non-blinded 2.13 (1.95-2.31) 3.38 (3.15-3.61)
Difference 0.10 (0.01-0.19) 0.28 (0.14-0.42)
P-value (Wilcoxon Ranks Test)* 0.047 0.000
Data are presented as mean (95%CI). Jadad and Chalmers could contain a maximum of respectively 4 and 6 
points. * Theoretical median tested: difference equal zero.
dISCuSSIon
Assessors blinded for study results are more optimistic in their judgement on bias of primary 
articles than non-blinded assessors, suggesting that when the risk of bias is evaluated, 
blinding assessors for study results could be valid. Furthermore, the overall risk of bias 
judgement with the Jadad instrument showed more agreement than with the Chalmers 
instrument.
To our knowledge no similar research design has been published on the topic of blinding 
assessors for study results when judging the risk of bias. The studies that focus on blinding 
integrate this aspect in their study design (blinded for treatment or during analyses) or 
focus on its effect in the review process (blinded reviewers) for a journal. The latter is 
widely studied with contrary results. As concluded from studies in the editorial face there 
is no evidence for an open, transparent, review process. Especially because unblinding 
the information about the reviewers and authors has influence on the amount of possible 
reviewers and the acceptance of a study.16-18
Misclassifications of the quality of studies, related to observer bias can be characterized 
by “optimism error” and “intervention preoccupation”. These are unpredictable; since 
they are subjective and vary between studies.4 Within our data we detected superior 
agreement if the assessors were blinded for results, compared to non-blinded assessors. 
This underscores the conclusions from clinical studies that found that the odds ratio point 
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estimate of the effect size was higher (i.e. more in favour or optimistic on the treatment), 
when outcome assessors were non-blinded.2,4 In our study this is seen as the blinding effect, 
the result that blinded assessors had higher mean scores on the instruments than the non-
blinded assessors. However, the question remains which of the assessors (blinded or non-
blinded) are correct and if this difference yields systematically different results. Despite 
statistical significant results the sum score between the blinded and non-blinded assessors 
remains small which makes blinding for study results methodologically irrelevant.
Morissette et al. performed a systematic review about blinding for basic study characteristics. 
This review also concluded that there was discordance between blinded or non-blinded risk 
of bias assessments. However, the best approach could not be defined in which the time 
consuming aspect of blinded assessments could be crucial in making a choice.12
Strengths of our study include the fact that we randomised each paper like a crossover 
design, for both blinded and non-blinded assessors, which makes the interpretation of 
our results more valid. By randomising, the risk of bias by a specific assessor is minimised. 
To further minimise the bias during assessment of the quality of the papers, the review 
process was validated with specific instructions (both written and oral). Furthermore, the 
outcome of the first five reviewed papers were evaluated with the first assessor (BT). As 
studied by others, training has only a slight impact on the quality of peer reviewing.19-21 
However, we think that this contributes to a better usage of the instruments, but we are 
aware of the fact that each tool and its instruction is an interpretation of a specific person.
Various instruments for assessing risk of bias are available, which makes the generalizability 
of our results for other instruments less valid. The Cochrane risk of bias tool is mostly 
used in the review process. Unfortunately, this tool was not possible to use in this study 
because some of the domains are only presented in the results section. The domains 
“sequence generation”, “allocation concealment” and “blinding of participants, personnel 
and outcome assessors” are partly covered by the Jadad and Chalmers items. This is 
one of our study limitations, assessing other instruments would perhaps lead to other 
conclusions. Jüni et al. illustrated this in their study where 25 scale-based instruments were 
compared and concluded that the overall quality scores of these instruments could not be 
extrapolated because of the heterogeneous nature of the instruments.1,8 For this reason we 
only looked at the individual items of each instrument. This, however, creates controversies 
as well, if different quality assessment scores are compared. For example, in the Jadad item 
“selection bias”, one point is earned if a statement is made regarding withdrawals and 
dropouts, whereas the Chalmers-item “selection bias” has more subcategories. The latter 
also scores the method of data analyses (as treated or per protocol). Especially these items 
on “selection bias” showed poor agreement between assessors in our study.  Furthermore 
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data were missing to a considerable extent in the blinded group. The latter can be explained 
by the fact that this item is mostly covered in the results section of a paper and was thus 
not available for the blinded assessors in the current study design. In addition, the superior 
agreement on the Jadad instrument could possibly be explained by the subgroups of the 
items. The Jadad instrument has a more simple interpretation of the different items that 
makes the assessment easier in comparison with the Chalmers instrument. Our study had 
some more limitations. First, the agreement on quality score in this research was only 
based on two assessors. As mentioned earlier observer bias can despite the blinding of 
assessors still be present, more assessors would give a better interpretation of results, 
but is in reality not possible, due to its time consuming aspect. Secondly, one person 
(BT) was not randomised for blinded or non-blinded because someone had to blind the 
study sections. In addition, the assessors could accidentally be non-blinded for a specific 
study when they already knew the published paper. This has not been checked, but may 
be limited because none of the assessors (WV, CP, SW) was working in this specific field. 
Thirdly, one specific field (patient blood management in orthopaedic surgery) was explored 
in this study. It is unknown if these results can be extrapolated to other fields. Apart from 
this the field investigated is known to have blinding difficulties in study design, however 
this would have minor or no influence of this study because the focus is on another type of 
blinding. Fourthly, the relationship between the score and the study results is not examined; 
because another subjective outcome is than introduced with the expert based opinion if 
the study results found were to be expected.
With increasing numbers of published articles, assessment of study quality is important, 
thus numerous quality assessment scales and checklists have been published.22 The 
Cochrane Collaboration is still debating on the best way, how to incorporate the quality 
assessment in the interpretation of the study results (unpublished abstract Cochrane). The 
GRADE working group made an effort to develop clear guidelines to assess trial quality with 
special focus on the specific context in which the evidence is used.6
In conclusion, the assessment of methodological quality may be biased when assessors are 
aware (i.e. non-blinded) of study results. This study showed that the blinded assessors were 
more optimistic about the study quality measured with the Jadad and Chalmers scale than 
the non-blinded assessors. However, if this could influence a systematic review remains 
unclear and the optimal approach could not be defined. In studies regarding risk of bias 
assessment there should be more focus on how articles are presented to the assessors. 
Especially if a new research instrument for quality assessment is being tested. Further 
research has to be performed to evaluate its impact when conducting a systematic review.
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ABSTRACT
We hypothesized that heterogeneity is a major problem in patient blood 
management (PBM) studies, more specific with respect to outcome in drainage 
studies in orthopaedic surgery. The aim was to identify heterogeneity for the blood 
transfusion trigger in hip and knee arthroplasty. The latter is directly associated with 
the outcome transfusion percentage as well as number of units of blood.
A search strategy on drainage strategies in elective total joint surgery (no drainage, 
closed suction (CS) drainage and autologous blood transfusion (ABT) drainage) was 
done. MEDLINE, EMBASE and The Cochrane Central Register of Controlled Trials 
were used for data extraction. Studies were scored with respect to transfusion 
policy, methodological quality and quality of reporting.
Fourteen studies (64%) reported presence of both a transfusion trigger value as well 
as transfusion policy. In 57% of the included studies an allogeneic blood transfusion 
was given based on non-defined “clinical” symptoms. Furthermore, none of the 
studies gave additional information neither on the transfusion trigger decisions nor 
on the “clinical” symptoms.
Transfusion percentages ranged from 0 to 64%. Nine studies (45%) had a transfusion 
rate of <20%, five of these studies reported a transfusion threshold of <8 g/dL, while 
four studies (44%) did not report a transfusion trigger. Presence of no transfusion 
trigger resulted in a risk difference (RD) of 0.05 (95%CI: -0.05, 0.14) in allogeneic 
transfusion events compared to a RD -0.09 (95%CI: -0.16, -0.02) when a transfusion 
trigger was reported. Methodology scores showed good (r=0.61, p<0.05) and 
moderate (r=0.44, p<0.05) correlation for respectively the CONSORT NPT and 
Chalmers scale with the year of publication.
Larger heterogeneity exists on the transfusion trigger and policy; the latter has 
impact on interpretation of outcomes in patient blood management studies of total 
joint (hip and knee) surgery. Studies should include transfusion trigger decision 
rules in order to make valid comparisons possible. An intention-to-treat (ITT) and 
as treated (AT) principle flow chart for transfusion trigger decisions will improve 
interpretation of outcome results between studies.
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InTRoduCTIon
Patient blood management (PBM) in orthopaedic surgery is important for quality in patient 
care. In PBM the use of closed suction drains and autologous blood transfusion (ABT) drains 
have been studied extensively in many randomized clinical trials (RCTs) and with several 
systematic reviews or meta-analyses in the last decade.1-5 However, data from these studies 
are still not conclusive for neither clinical nor economic benefits. Furthermore, large 
differences in both allogeneic transfusion needs and study groups are reported. Although 
the study designs appear comparable, these large differences in outcome are hard to 
explain by known risk of bias aspects. Heterogeneity between the studies could be the 
driving factor for this variety in conclusions.
Heterogeneity can be subdivided in clinical, methodological and statistical heterogeneity. 
Variability in participants, interventions and outcomes studied can be described as 
clinical heterogeneity, and variability in study design and risk of bias may be described as 
methodological heterogeneity. Statistical heterogeneity manifests itself in the observed 
intervention effects that are greater than would be expected solely on random errors, which 
is a consequence of clinical or methodological diversity, or both.6 These different types of 
heterogeneity are closely intertwined, however this relationship is not straightforward, but 
depends on the differences or covariates present in a study.7
For example in orthopaedic surgery, the possible differences in drainage could arise 
from drain duration, number and position of drains. These factors seem obvious, but 
another major flaw in PBM studies may be inference with the reason for allogeneic blood 
transfusion, such as the different definitions on outcome, the use of a transfusion trigger 
value, the number of units of blood that have to be transfused, and the percentage of 
cases that are actually treated by these predefined trigger values. Although, an allogeneic 
blood transfusion seems a “hard” endpoint the reason for transfusion can be less objective, 
because an allogeneic blood transfusion is often tailored to the patient’s needs.8 This 
tailoring can be regarded as a weak link in clinical studies on PBM since the interpretation 
of clinical symptoms remains subjective and no clear objective parameters are available 
besides the haemoglobin level.9
We hypothesized that results from pooled data from randomised controlled trials in a meta-
analysis are negatively biased, mainly due to clinical heterogeneity for blood transfusion 
indications (e.g. trigger value, transfusion indication) between studies, which makes the 
generalizability impossible. For this reason a systematic review and illustrative meta-
analysis was performed to give insight in the difference in transfusion trigger strategies 
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and subsequent impact on pooled outcomes. Thus, the aim was to identify presence of 
heterogeneity for the blood transfusion trigger in hip and knee arthroplasty. The latter is 




We conducted a systematic review and illustrative meta-analysis to describe the 
heterogeneity of randomized controlled trials on blood drainage in hip and knee 
arthroplasty. We followed the PRISMA statement for reporting of systematic reviews. An 
electronic search of MEDLINE, EMBASE and The Cochrane Central Register of Controlled 
Trials was conducted. The key words used were: “Arthroplasty, Replacement, Hip” OR “Hip 
Prosthesis” OR “Arthroplasty, Replacement, Knee” OR “Knee Prosthesis”. We limited our 
search to human, English-language, randomized controlled trials and published between 
January 2000 and January 2013. We did not use any term on blood conservation in the 
primary search strategy to prevent loss of articles. English-language inclusion was pragmatic 
chosen because we needed additional information from the full text article, which could 
not be found in the abstract of these studies.
eligibility criteria
Two reviewers (BT, WV) independently scanned the titles and abstracts of the identified 
articles for potential relevance and eligibility. Eligible studies included those reported as 
randomized, performed on human subjects with focus on blood drainage, full text article 
available in English and published between 2000 and 2013. Also the systematic reviews 
and meta-analyses of this topic were checked for relevant articles.1-3,5 If there was any 
disagreement, consensus was reached through discussion with a third person (RWP). A log 
of all excluded articles and the reasons for exclusion was kept. Blood drainage was defined 
as studies with focus on closed suction (CS) drains and/or autologous blood transfusion 
(ABT) drains, the eligible studies could make an in-between comparison or a comparison 
with no drainage.
Heterogeneity assessment
Two independent reviewers (BT, WV) extracted data. Relevant descriptive data included 
(1) year of publication, (2) type of journal, (3) body region (hip, knee or both), (4) number 
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of centres (single or more) (Table 1). Specific data regarding PBM policy were collected 
and registered (Table 2). All these factors were compared to give an overview of the 
heterogeneity between studies.
Methodological Quality Assessment
The CONSORT NPT checklist was used to assess the quality of reporting in studies.10,11 This 
checklist, which comprises 25 items, is developed as a reporting guideline and endorsed by 
many journals. Each item received 1 point when information was available; if no information 
was available no points were given. Thus, the total possible score was 25 points. Further 
two scale-based instruments, Jadad et al. and Chalmers et al., were used to evaluate 
utilization of methodological safeguards (risk of bias).12,13 Jadad focuses on randomization 
(2 points), blinding (2 points) and patients account (1 point). A deduction of 1-point was 
given if the items randomization or blinding were inappropriate.12 Chalmers also consists 
of three items (treatment assignment, selection bias and blinding) on which a maximum 
of 9 points can be scored. Each item was divided in four options with increasing points for 
better methodology (0 to 3 points).13
Statistics
Descriptive data were used as background information. Binominal and categorical data 
were expressed as proportions.
Data pooling was only performed to show that the interpretation and pooling of drain 
studies has limited or no additional value when these features are not taken into account 
despite the random effects model. The data were pooled using Review Manager (RevMan), 
version 5.2 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012). 
Studies with three or more treatment arms were excluded when data were pooled based 
on the transfusion trigger. For each study, we calculated a risk difference (RD) for allogeneic 
transfusion need with 95% confidence intervals (CIs) with a random effects model to 
forestall the empty cell problem and heterogeneity. Furthermore, 2005 was used as a 
cut-off point for the evaluation of methodological quality and quality of reporting. This 
arbitrary cut-off was taken since this was the year of implementation of a new PBM policy 
in the Netherlands.
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Excluded, n = 79 
n = 4, meta-analysis 
n = 5, abstract/duplicate 
n = 18, no RCT 
n = 19, other blood conservaon 
n = 33, other drain focus 
 drain clamping (n = 13)  
other blood saving comparisons (n = 10) 
 blood quality (n = 4) 
 compression, sucon and ming of removal (n = 5) 
 bilateral cases compared (n = 1) 
4246 arcles 
Topic: blood management 
n = 291 
Topic: drainage 
n = 109 
Included   
n = 30 
Finally included  
n = 22 
Non-English excluded 
n = 8 
Figure 1 Flowchart of included and excluded articles
ReSulTS
The literature search yielded 4.246 potentially relevant articles after removing the 
duplicate articles. Title and abstract screening eliminated 3.955 articles that did not have 
blood conservation as the primary outcome. The 291 remaining articles were screened for 
eligibility based on drainage comparison. A total number of 22 articles were included in the 
analysis (Figure 1, Table 1). Five meta-analyses were screened for missing references, but 
they included no new references that fulfilled our inclusion criteria.1-5
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Different drain comparisons were made in the included studies; no drainage vs. closed 
suction drainage (CS drainage) (n=10), no drainage vs. autologous blood retransfusion 
drainage (ABT drainage) (n=3) and CS drainage vs. ABT drainage (n=7). Two studies compared 
three different treatments (no drainage vs. CS drainage vs. ABT drainage).
The forest plots (Figure 2, 3 and 4) represent the several drain comparisons in the studies 
with exclusion of two studies because they only reported transfusion units as outcome 
measure.14,15 The no drainage group has a 12% lower risk (RD -0.12, 95%CI -0.21, -0.03) 
(Figure 2) for an allogeneic blood transfusion compared to the CS drainage group. The 
comparison between no drainage and ABT drainage showed no difference in allogeneic 
blood transfusions, the risk difference was 0.04 (95% CI -0.02, 0.09 (Figure 3). Fewer 
allogeneic blood transfusions, with a risk difference of 0.12 (95% CI, 0.06-0.18), were also 
found when the ABT drainage group was compared with the CS drainage group (Figure 4).
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Figure 4 The risk difference of allogeneic blood transfusions between CS drainage and ABT drainage
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Clinical heterogeneity
The literature search included primary THA and TKA surgeries, though some studies used 
more specific in- and/or exclusion criteria. One study reported only uncemented hip 
arthroplasties by the postero-lateral approach, one study only included cemented hip 
arthroplasties, and others reported a mix of cemented and uncemented arthroplasties.15,16
With respect to the drainage devices eleven different drain-systems were used and 
in five studies (23%) no information was reported on the kind of drainage system.15,17-20 
Furthermore, several drainage techniques were used, studies reported on drainage for 
48 hours, while some reported only six hours postoperative drain use.16,21-24 While others 
depended the drainage time on the volume drained or even no specific information was 
presented.25,26 Two studies (9%) included other blood saving alternatives (Table 2) as 
well.27,28 Ten studies excluded patients using anticoagulation therapy for cardiovascular 
problems. Only ten (45%) studies reported a formal sample size calculation. However, six 
different endpoints were used in the included studies to calculate this sample size: blood 
loss, adverse events, length of hospital stay, haemoglobin level at different time points, 
reduction in the number of allogeneic transfusions and wound problems.
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Table 2 Characteristics of included studies
























no drainage vs. CS drainage
Dora, 200714 THA 100 18 / 2 / 5 Complica-
tions
- - - - -0.1 U - - Redon 1 - - Mean age 66 years CS +
Esler, 200321 TKA 100 9 / 1 / 3 Other - Hb<10 g/dL - - 24 - - Medinorm 1 IA - Drain in situ >48hr CS -
Gonzalez, 200420 THA 104 12 / 0 / 4 - - - - - 4.6 - - - 2 FL - Pilot study CS -
Jenny, 200119 TKA 60 6 / 1 / 3 LOHS - Ht<30% Yes 4 - - - - - - Drain in situ >24hr, antico-
agulation excluded
CS -
Li, 201018 TKA 100 11 / 1 / 2 Blood loss 13.2 / 12.9 Hb<10 g/dL - - 42 - - - - - - No mobilisation during drain 
in situ
CS -
Matsuda, 200727 THA 40 19 / 3 / 4 Hb 13.6 / 13.4 Depending on Hb, 
blood loss and col-
lected blood
Yes 0 - - SBVac 2 FL Yes Conclusion not based on 
primary outcome, excessive 
blood loss intraop excluded
CS +
Niskanen, 200015 Both 96 8 / 1 / 3 - - - - - 0.9 U - - - - - - Anticoagulation excluded CS -
von Roth, 201217 THA 80 14 / 2 / 4 Blood loss - - - - 0 - - - - FL - Ratio men:women not 
standard
CS -
Walmsley, 200528 THA 577 17 / 4 / 5 Complica-
tions
13.6 / 13.4 Hb<8 g/dL 2 units Yes 6.6 - - Redivac 1 - Yes 4 deaths in drainage group CS -
Widman, 200236 THA 22 12 / 1 / 1 Wound - Hb<8 g/dL - Yes 3 - - Bellovac - - - Hematoma on scintigraphy CS -
no drainage vs. ABT drainage
Cip, 201237 TKA 140 22 / 4 / 5 Transfusion - Hb<8 g/dL - Yes 0 - - OrthoPAT - - - No info of the 11 exclusions ABT -
Dutton, 201223 TKA 48 18 / 2 / 5 Transfusion 13.3 / 13.7 - - - 1.4 - - Bellovac 
ABT
- - - >6hr drain removed ABT -
Horstmann, 201224 THA 100 19 / 3 / 5 Hb 13.9 / 13.9 Hb<8 g/dL 1 unit  - -4 - - Bellovac 
ABT
- - - Ward doctors blind?, >6hr 
standard drainage
ABT -
CS drainage vs. ABT drainage
Abuzakuk, 200726 TKA 104 18 / 3 / 7 Transfusion 13.5 / 13.6 Hb<9 g/dL - - 1.9 - - Bellovac 
ABT 
1 IA - After 150mL collected 
retransfusion, average of 
2.3 PC transfused
ABT -
Amin, 200838 TKA 178 19 / 2 / 4 Transfusion 13.4 / 13.2 Hb<8 g/dL - Yes -2.1 - - Bellovac 
ABT
1 IA - Expected reduction of 50% ABT -
Atay, 201016 Both 77 14 / 1 / 3 Transfusion 13.1 / 13 Hb<8 g/dL - Yes -30.5 - - Transolog - - - Exclusion Hb <12 g/dL, drain 
in situ 48hr 
ABT +




- -22.6 - - Donor - - - Drain in situ >24hr ABT +
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Moonen, 200740 Both 160 20 / 3 / 6 Transfusion 14 / 14 Hb<8 g/dL 1 unit - -13 - - Abdovac 
and Bello-
vac ABT
2 IA and 
SC
- Inclusion Hb 13-14.6 g/dL, 
>6hr standard drainage
ABT +
Smith, 200729 THA 158 20 / 3 / 4 Hb 13.6 / 13.6 Hb<8 g/dL 2 units Yes -12.8 Yes - Medi-
norm and 
ABTrans





TKA 60 12 / 1 / 3 Transfusion 13.8 / 14 Hb<9 g/dL - Yes -17 - - Gish Ortho-
fuser 
- - - 1 PC was standard given 
after surgery
ABT +
no drainage vs. CS drainage vs. ABT drainage 
Cheung, 201025 THA 153* 19 / 2 / 5 Transfusion 14 / 13.7 / 
13.6
- - Yes 24, 4.5 
and 
-19.5
- - Medinorm 
and Bello-
vac ABT




Kleinert, 201222 THA 120* 19 / 4 / 6 Hb 13.6 / 14 / 
14.2 
Hb<8 g/dL - Yes 0, -6 
and -6
- - Redon and 
Bellovac 
ABT
2 FL - Drain in situ 48hr, mean age 
66 years
Both -
Data collection of the reviewed articles, cells with a dash were not recorded or presented as ‘no’ in the article.
Sample size is overall study size (* in three groups), quality report presented as CONSORT NPT / Jadad / Chalmers. 
Trigger level shows the value when a transfusion was justified for the specific study. Policy describes the action 
taken when the trigger level was reached. Clinical symptoms represents the studies in which this was an escape.
Reduction is percentage allogeneic blood transfusions. Reduction is calculated as intervention – control. In the 
three arm comparisons the first value is none vs. CS, second is none vs. ABT, third is CS vs. ABT.
Transfusion checked, blind and alternatives used were binominal (yes/no) answered. Conclusion is answered as 
positive results or not for a specific drain type.
ABT = autologous blood transfusion; Conc = conclusion; CS = closed suction; FL = fascia lata; Hb = haemoglobin; 
Ht = haematocrit; IA =intra articular; LOHS = length of hospital stay; QR = quality and methodology report; SC = 
subcutaneous; SS = sample size; THA = total hip arthroplasty; TKA = total knee arthroplasty; U = unit
Table 2 Continued
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Transfusion percentages and trigger values
Fourteen studies (64%) reported a transfusion trigger policy as well as the threshold value 
for the transfusion trigger. Administrating only a single unit of allogeneic blood when the 
set trigger value was reached was not common practice; three studies gave routinely two 
units when the trigger reached the value of 8 g/dL. Two-thirds of these fourteen studies 
were performed before 2005 (defined as cut-off point regarding implementation of a 
restrictive transfusion policy in the Netherlands). Eight of the fourteen (57%) studies that 
reported a transfusion trigger had an additional ‘clinical symptom’ escape for justifying 
allogeneic blood transfusion. In none of the studies the transfusion decision was blinded. 
Furthermore, only one study (4%) checked post hoc whether the transfusion decisions 
were made correctly, by looking both at the transfusion trigger as well as the recorded 




























































































Comparator 1 Comparator 2 Comparator 3
Figure 5 Transfusion percentages per study comparison
Comparator 1 is no drainage vs. CS drainage, comparator 2 is no drainage vs. ABT drainage and 
comparator 3 is CS drainage vs. ABT drainage. The line represents the control (lowest end) and the 
intervention group (highest end) with the point as average allogeneic blood transfusion percentage 
per study. Niskanen and Dora excluded.14,15
Figure 5 demonstrates the large range of transfusion percentages between studies. 
Especially in the no drainage vs. CS drainage and the CS drainage vs. ABT drainage studies, 
the transfusion percentages differ largely between groups. Seventy percent (n=14) of 
the studies had a low variability (difference between groups <20%). Comparing studies 
evaluating “no-drainage vs. CS-drainage” had lowest transfusion variability. Nine of the 
twenty studies (45%) with a low transfusion rate (≤20%) had the transfusion trigger set at 
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No trigger < 8 g/dL < 10 g/dL  < 9 g/dL 
Figure 6 Transfusion percentages per type of transfusion trigger
The line represents the control (lowest end) and the intervention group (highest end) with 
the point as average allogeneic blood transfusion percentage per study. Niskanen and Dora 
excluded.14,15
Reporting of a transfusion trigger value showed that the treatment effect of the experimental 
group (CS drainage and ABT drainage) estimate became smaller, with a risk difference of 
-0.09 (95% CI: -0,16, -0.02) to no significant difference when no trigger is reported, risk 
difference of 0.05 (95% CI: -0.05, 0.14, Figure 7). The pooled risk difference was -0.05 (95% 
CI: -0.10, 0.01) indicating that there is no beneficial effect for using a drain system.
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Figure 7 The effect of using a transfusion trigger on the magnitude of the treatment effect
For the three arm studies the comparison no drainage vs. CS drainage was used. Niskanen and Dora 
excluded.14,15 The experimental group includes the CS drainage and ABT drainage groups
Methodological quality and report quality
The quality of reporting (measured with the CONSORT NPT) had a median overall score 
of 17.5 points (70% of the total). The year of publication had a good correlation (r=0.61, 
p<0.05) with the CONSORT score, 12 points vs. 18 points in respectively years before 2005 
and after 2005 (Table 3).
The risk of bias assessment (methodological quality) showed lower percentages on the mean 
overall score, respectively 40% (2 points) and 44% (4 points) on the Jadad and Chalmers 
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instrument (Table 3). The CONSORT NPT and Chalmers showed a significant improvement 
between studies published before and after 2005, respectively P-value of 0.005 and 0.047. 
The correlation of Chalmers with the year of publication was moderate (r=0.44, p<0.05).
Table 3 Quality of the included studies
ConSoRT nPT JAdAd CHAlMeRS
All studies 17.5 (12-19) 2 (1-3) 4 (3-5)
drainage comparison
None vs. CS drainage 12 (9.5-16.3) 1 (1-2) 3.5 (3-4)
None vs. ABT drainage 19 (18.5-20.5) 3 (2.5-3.5) 5 (5-5)
CS drainage vs. ABT drainage 19 (16-20) 3 (2-3) 4 (3.5-5)
Year of publication
< 2005* 12 (8.5-14.5) 1 (1-2.5) 3 (3-4)
> 2005$ 18 (14-19) 2 (2-3) 4 (4-5)
Three arm studies are excluded. Median and IQR (interquartile range) are presented. The instrument had a 
maximum of respectively 25, 5 and 9 points on CONSORT NPT, Jadad and Chalmers.
* based on 7 studies
$ based on 13 studies
dISCuSSIon
Key findings
We found that despite the significant improvement of methodological quality (risk of 
bias) and reporting of studies on wound drainage (no-drainage, CS or ABT drainage) in 
orthopaedic surgery over the last decade, great variation in transfusion percentages 
remain. An important confounder for the latter is high variability in the actual reason to give 
an allogenic blood transfusion: either different trigger values are used or only non-defined 
clinical reasons for transfusion are used. Since this has a direct impact on the outcome 
variable transfusion (i.e. number and percentage) only studies with comparable transfusion 
triggers can be compared irrespective of the devices used. This is also true for any study 
on patient blood management irrespective of the PBM modality or patient group studied. 
We found several potential confounders in the studied articles: (1) different levels for 
transfusion trigger (or even, no defined triggers) (2) non-specific clinical symptoms as pre-
defined possible escape for a transfusion (3) absence of post hoc check on the transfusion 
decisions for validity (4) heterogeneity on study demographics (population, devices, surgical 
procedures and transfusion practice) (5) non-blinded transfusion decisions. Most studies 
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lack information on these factors, causing problems in the interpretation of outcome of 
these studies on allogeneic blood transfusions.
Strengths and limitations
The strength of our systematic review is that we performed a comprehensive search in 
duplicate without specific PBM limitations. Further the specific focus on the transfusion policy 
is another aspect that has not been studied yet. Since this extensive clinical heterogeneity 
focus could be combined with the methodological and statistical heterogeneity of these 
trials.
Limitations were that we excluded non-English papers that could have influenced the data. 
This exclusion was pragmatic chosen because we needed additional information from 
papers. Only drainage studies in orthopaedic surgery are evaluated, if these data could be 
generalized to other medical specialities is unknown and if these findings are also present 
in other PBM studies in orthopaedic surgery is questionable. Further we evaluated and 
screened each paper thoroughly but did not contact authors for additional information 
ignoring potential publication bias, because only published information has given us 
feedback on the study. We are aware that the CONSORT NPT is not a tool to measure quality, 
but it evaluates and improves the reporting of a study. Over the years more journals have 
endorsed the CONSORT statement, which is also seen by our study results with a positive 
correlation between the year of publication and the CONSORT score.
Previous literature
A critical review of the conducted meta-analysis makes the generalizability of these studies 
difficult. Markar et al. and Haien et al. compared CS drainage vs. ABT drainage. However, 
Markar et al. only reported on TKA while Haien et al. reported on both TKA and THA. Zhang 
et al. and Kelly et al. had another scoop; they compared CS drainage with no drainage. But 
Zhang et al. in TKA patients whereas Kelly et al. in THA.3,5 An important finding was that 
Markar et al. excluded studies with focus on both joints (THA and TKA).1 Haien et al. stated 
that RCTs were included without consideration of primary or revision replacements.2 It is 
known that revision arthroplasty have other bleeding kinetics than primary arthroplasty. 
Only Zhang et al. and Kelly et al. made a statement regarding clinical heterogeneity and 
thereof stated that the results should be used with caution because not all variables are 
favouring the same procedure.3,5
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Sharma et al. also checked the methodological quality by the Detsky scale and concluded 
that the reporting in blood conservation trials between 2000 and 2007 was poor. However, 
other items for evaluation were used but findings in our study support this information.30
Implications for future research
Our data showed that the reporting of a transfusion trigger influenced the overall effect 
estimate of the studies. However, our results also showed that a transfusion trigger might 
be seen as a real confounder, because adjustment of the outcomes for the used trigger 
value was not possible since large variation in outcomes exists throughout the different 
trigger groups. Despite, these findings we think that information of the transfusion trigger 
in a study report has additional value for the reader when statements regarding allogeneic 
transfusion are made.
Implications for clinical practice
The transfusion trigger threshold and adherence to this trigger in allogeneic blood 
transfusions varies considerably in PBM studies. This can have an impact on the 
interpretation of PBM strategies. All PBM modalities like erythropoietin, cell saving and 
drains are influenced by the decision to transfuse, since this is the endpoint in most studies. 
The transfusion trigger is part of the causal relation between symptoms and allogeneic 
blood transfusion decisions and by this responsible for the decision when to transfuse and 
how much to transfuse. We found that 57% of the studies had clinical symptoms added as 
possibility for transfusions. This is on the one side the tailoring of PBM but on the other 
side probably the weakness of PBM studies since clinical symptoms are subjective. The 
question remains whether blinding, a proven method to improve quality of the trial is the 
solution to solve this problem in PBM studies.31 The decision maker still has to navigate on 
the information given by the caregiver and can only judge if the symptoms are part of the 
anaemia present. This remains a rather subjective part of the treatment indicating a need 
for more objective measurement tools.
Surprisingly, the transfusion rates in the studies varied largely regardless of the trigger value 
set. Thirty percent of the studies had a large bandwidth, >20% difference in transfusion 
rate, between the two compared groups. This makes the studies difficult to compare, the 
trigger level influences the amount of transfusions because the higher the trigger the more 
transfusions are given in both the experimental and control group. This is also seen in the 
preoperative haemoglobin values of patients, a lower preoperative Hb level is prone for 
more allogeneic transfusions.32
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Based on our study, only adding the transfusion trigger seems not enough. More detailed 
reporting on the followed transfusion practise, i.e. at what trigger and with which 
symptoms transfusions were performed is needed. The aspect ‘clinical symptoms’ should 
suggest information on (patho) physiological parameters like blood pressure and heart 
rate to validate a transfusion.8,9 None of the included studies in this systematic review 
gave detailed (patho) physiological information of the actual patient’ situation when a 
transfusion was given. An idea on the potential bias of the latter could be analysed by 
dividing the transfusions given based on the predefined trigger by the total amount of 
actual transfusions in a study. In this respect the concept of intention-to-treat (ITT) versus 
as treated (AT) could be used for making an assessment of the validity of the transfusion 
decisions. This could probably discriminate between what was to be expected based on 
the haemoglobin level and the true level of transfusion and gives more insight information 
about the adherence to the study protocol and how clinical symptoms are associated.
Results of the Focus trial and a posthoc analysis of an RCT support a more restrictive 
transfusion policy (<8 g/dL) in orthopaedic surgery.33-35 However, the question remains 
of this restrictive transfusion policy is actually implemented in the evaluated studies. 
A transfusion trigger between 8 and 10 g/dL for a single unit allogeneic blood in non-
complicated elective total hip and knee arthroplasty could nowadays be seen as liberal and 
thus giving a larger difference between groups.
Conclusion
Heterogeneity exists on the transfusion trigger, the latter has impact on interpretation of 
outcomes in patient blood management studies in drainage studies of total joint (hip and 
knee) surgery. Studies should include transfusion trigger decision rules in order to make 
valid comparisons possible. An intention-to-treat (ITT) and as treated (AT) principle flow 
chart for transfusion trigger decisions will improve interpretation of outcome results 
between studies. As for the methodological quality of the reported studies, this improved 
over time.
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geneRAl dISCuSSIon And FuTuRe PeRSPeCTIVeS
In total hip and total knee arthroplasty patients both patient pain management (PPM) and 
patient blood management (PBM) significantly improved throughout the last decades. 
Since the end of the previous century more awareness on potential hazards of the existing 
liberal blood transfusion policy arose, resulting in the introduction of more rational blood 
transfusion guidelines (single unit; 4-5-6 mmol/L rule) and several blood saving alternatives, 
like the use of erythropoietin, tranexamic acid, cell saver and postoperative blood reinfusion 
devices. Besides the restrictive transfusion policy, pain management in patients care had 
a special focus because it is seen as one of the key performance indicators for health care 
quality. More specific, prevention of the side effects of an analgesia regimen was the focus, 
to enhance postoperative recovery and reduce morbidity to the patient.
Patient Pain Management
In the 19th century cocaine, ether and chloroform were the first real agents used to sedate 
patients.1 Since then, local anesthetics have been widely used for many indications, 
most commonly for local and regional anesthesia. Despite optimising both surgical and 
anaesthesia techniques functional changes in the human body still occurs after an 
intervention, which are believed to be mediated by trauma-induced endocrine metabolic 
changes and activation of several biological cascade systems.2 The reduction of this surgical 
stress response is now seen as the most important part of the postoperative outcome 
and thus of a successful surgical procedure. The introduction of this term by Kehlet in the 
seventies has shifted “regular” anaesthesia to a multimodal approach for the patient, which 
is used to control undesired sequelae after surgery impeding recovery.3 Thus addressing 
this surgical stress response patient recovery after a surgical procedure will be enhanced.
The use of peripheral nerve blockade offers several advantages when compared to general 
anaesthesia or local anaesthesia. However, muscle weakness, i.e. quadriceps muscle 
weakness after a femoral nerve block, is often mentioned as a potential disadvantage 
for early ambulation of the patient.4-7 To counteract, this problem of the motor block, an 
optimal dose for good pain relief was necessary (chapter 2). A further improvement of 
anaesthesia techniques was the introduction of local infiltration techniques with local 
anaesthetics, local infiltration analgesia (LIA) was developed specifically to avoid motor 
nerve blocks and facilitate rapid physiological recovery after lower limb arthroplasty in 
order to enable early mobilization and hospital discharge. Several LIA variations have been 
described in the last decades, with different routes of administration, types of anaesthetics, 
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and the  combination of intraoperative infiltrations with postoperative catheters. Presently 
no uniformity exists with regard to the most optimal LIA technique. A pharmacokinetic 
analysis of LIA should be a research field to optimise the use of this technique.
Combining LIA and retransfusion drains could be a potential danger to the patient, since 
the shed blood from the retransfusion device is collected in the same area where high 
concentrations local anaesthetics are injected. Although we showed (chapter 3, 4) that 
the combination was safe, formal analysis of the anaesthetic concentration is mandatory. 
Eektimmerman et al. found a so-called ‘flip-flop model’ implying that the absorption of 
ropivacaine from the tissues around the knee into the systemic circulation is a rate-limiting 
step in drug elimination.(submitted data)
Patient Blood Management
Patient blood management encompasses a lot of different alternatives of which usage of a 
trigger rational is probably the most important.8 In this thesis we focussed on the following 
alternatives: erythropoietin, per-operative cell saving and postoperative retransfusion 
devices.
Erythropoietin is widely studied with effective results on transfusion avoidance.9-11 In 
chapter 5 we showed in a RCT that erythropoietin was superior in mildly anaemic patients 
compared with a postoperative retransfusion system at that time. Although the efficacy 
of erythropoietin is superior to retransfusion drains the costs related to this treatment 
are enormous and should be questioned. It significantly exceeds (5-10 fold) the direct cost 
of allogeneic blood transfusions.12 In chapter 6 we calculated the costs associate with 
routine administration. We found that introducing erythropoietin alpha (EPO) as a standard 
treatment in our hospital setting would increase the costs by a factor 6. The generalizability 
of the results on erythropoietin in the Dutch setting should be questioned, looking at the 
low general transfusion percentages reported by Dutch hospitals over the last few years 
the efficacy of EPO is questionable.13,14
In a recent review from Voorn et al. was shown that 69% of the Dutch clinics were using 
retransfusion drains on at least regular basis.15 Although there is lack of evidence to support 
the use of drains, retransfusion drains are still used in many hospitals. It seems traditions 
keep them in place.15 Our results in chapter 7 and 8 could be added to this evidence.
In chapter 8 we studied the efficacy of a new disposable perioperative cell saving device in 
total hip arthroplasty surgeries. In this study we found a 12% allogeneic blood transfusion 
rate in the control group were a percentage of 21% was expected. Therefore the study 
turned out to be underpowered and was prematurely terminated. In a review on cell 
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salvage, Carless et al. reported that cell salvage reduces the need for allogeneic blood 
transfusions of donated blood in cardiac and orthopaedic surgery. However, this can be 
questioned for the Dutch situation since low transfusion percentages are reported in the 
Netherlands.12 In 2011 80% of the Dutch hospitals reported to have less than 10% blood 
transfusions in TKA and less than 20% in THA, which was also found in a Dutch multicentre 
study on over 2200 patients (11%).12-14
In chapter 10 we tried to find an explanation for the large heterogeneity of published data 
in drainage studies. This variation in transfusion numbers can be explained by several 
factors, but the most crucial one is the lack of an uniform transfusion policy. Probably the 
most important blood saving strategy is the use of a restrictive blood transfusion policy 
and continuous education.12,16 In the Netherlands, PBM is an important part of patients 
care in hospitals. Sanquin, the Dutch blood bank, invests a lot in basic research and on 
knowledge about PBM not only by transfusion specialists but also anaesthesiologists and 
other medical specialties (e.g. gynaecology, orthopaedic surgeons). The transfusion figures 
in the Netherlands declined over the last decade but the used transfusion alternatives 
are still very divers. This is caused by the physician’s behaviour and traditions present in 
hospitals as well as the “success” of introducing transfusion alternatives.15 The introduction 
of a transfusion trigger came in many cases along with the implementation of transfusion 
alternatives, which makes it difficult to relate the reduction in allogeneic transfusions to one 
specific item. As mentioned before, transfusion percentages between hospitals are very 
divers and for that reason a critical appraisal of these studies is necessary to considerate an 
extrapolation of the results to a specific hospital.
Currently a Dutch study is under its way, with the aims to change the blood management 
behaviour of orthopaedic surgeons and anaesthesiologists in primary elective total hip 
and knee arthroplasties, using a tailored intervention strategy for de-implementation 
of erythropoietin and postoperative blood salvage.17 This study will lead to generalized 
knowledge regarding relevant factors for the de-implementation of non-cost-effective 
interventions and insight in the differences between implementation and de-implementation 
strategies.17
Conclusion and future perspectives
Today there is still place for the use of PBM alternatives, however the number of valid 
alternatives is declining because surgical techniques have improved and a trigger rational 
(single unit; 4-5-6 mmol/L rule) is used in a vast majority of the hospitals.
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Erythropoietin is one of the most conflicting alternatives. Studies in the past have shown 
that erythropoietin was effective to prevent preoperative anaemia and by this reducing the 
chance on an allogeneic blood transfusions. But the costs for routine administration largely 
exceed the reduction in allogeneic blood transfusions and average transfusion rates have 
gone down questioning whether the previously published results are still valid.
Another alternative is tranexamic acid (TXA), most meta-analysis show reduced blood loss 
and blood transfusion requirements in patients undergoing orthopaedic surgery, with no 
increase in the risk of DVT.18,19 However, this alternative is still little used in daily practice, 
despite its low costs.
The evidence on the efficacy of drains is clearly in favour of not using drains in primary 
elective total hip and knee arthroplasty. The evidence for retransfusion drains is more 
conflicting.12 However, the large study presented in chapter 7 and other studies in hospitals 
with a restrictive blood transfusion policy lack the evidence to support its use.
The limited adherence to trigger values of physicians and the clinicians’ interpretation of 
“clinical symptoms of anaemia” might be important explanations for the heterogeneity 
found in PBM studies. Critical review of the literature in combination with analysis of the 
hospital’s transfusion numbers is therefore mandatory.
Paradigms on PBM must be modified and, more specifically the quest for a universal 
transfusion trigger, the holy grail of transfusion medicine, must be abandoned as is 
proposed by others.20-22 All allogeneic transfusions must be tailored to the patient’s needs. 
To a certain extend this has been done by the identification of high and low risk groups in 
the transfusion guideline. But more objective tools are necessary for tailoring the patient’s 
needs, as rational for allogeneic transfusions.23
The introduction of a transfusion trigger had an enormous impact on transfusion 
numbers in the Netherlands in elective orthopaedic surgery and further adaptation of 
this transfusion rational throughout the world would probably reduce blood transfusions 
worldwide. Nevertheless, stricter adherence to this transfusion trigger is still necessary, 
without jeopardising individual patient care. This could probably be obtained by educating 
clinicians on general (patho) physiology of the cardiovascular system and to give more 
inside in transfusion medicine.
The clinical heterogeneity in blood transfusion studies (“what is the transfusion trigger”) 
presented in chapter 10 seems to be an obvious finding, but is still present in the majority 
of articles and since it has a great effect on outcome of these studies showed by all authors. 
Patient blood management studies should clarify the ‘need’ for an allogeneic transfusion 
in their articles, especially when the set transfusion trigger is waved. Parameters like blood 
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tension and heart rate should be reported. Finally, reporting the reason for transfusion 
and the percentage of adherence to a transfusion trigger value (according to an intention-
to-treat principle) will help interpreting the results in PBM studies and improvement of 
the evidence. A study that looks at the intra- and interobserver variations of transfusion 
decisions could be helpful to find an explanation for differences in transfusion percentages 
within and between randomised trials.
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Chapter 1 gives a general introduction on postoperative local analgesia and patient blood 
management. This chapter divides the thesis in two sections, patient pain management 
(PPM) and patient blood management (PBM). The PPM section starts with a study (chapter 
2) performed to find the optimal dose for good pain relief and lowest side effects that would 
hamper early mobilisation when using a femoral nerve block for postoperative analgesia. 
The three dose regimes tested in this study (0.1%, 0.05% and 0.025%) indicated no apparent 
advantage in decreasing the concentration of ropivacaine administered as bolus injections 
via the femoral nerve catheter below 0.1% on the patient’s ability to actively participate 
in the rehabilitation programme after total knee arthroplasty (TKA). In fact, the lowest 
studied concentration (i.e. 0.025%) resulted in a lower patient’s satisfaction with the pain 
treatment, while not improving recovery after TKA.
In chapter 3 the safety of LIA (local infiltration analgesia) combined with retransfusion 
of shed blood was evaluated. TKA patients received two peri-articular injections during 
surgery followed by continuous infusion, both with ropivacaine (567 mg). Ropivacaine 
plasma concentrations were determined in blood samples taken at 0, 3, 6 and 24 hours 
postoperatively. The collected shed blood was not retransfused instead retransfusion was 
modelled by estimating the cumulative plasma concentrations at 6 hours postoperative. 
Total and unbound ropivacaine plasma concentrations ranged respectively from 0.08 
to 1.9 mg/L and 0.003 to 0.11 mg/L. An average of 13.1 ± 3.7 mg unbound ropivacaine 
would have been returned to the patient. The estimated cumulative ropivacaine plasma 
levels showed that instant retransfusion would have led to plasma levels below 0.26 mg/L, 
which is the minimum safety level for systemic toxicity. Thus, it appears to be safe to 
transfuse autologous blood in combination with LIA if an actual plasma concentration of 
infused anaesthetics is performed. In chapter 4 the plasma concentrations of ropivacaine 
in twenty-two TKA patients that received three peri-articular injections with ropivacaine 
(300 mg) during surgery were analysed. Plasma and shed blood samples were taken at 0, 
1, 3, 6, 7 and 24 hours postoperatively. The calculated (modelled) estimation regarding 
the maximum unbound ropivacaine plasma concentration showed a median value of 
0.114 mg/L (IQR: 0.09, 0.12 mg/L). All concentrations were well below reported toxicity 
thresholds. The combination of LIA and shed blood retransfusion is considered safe. 
However, differences in pain protocol (i.e. amount, kind and concentration of anaesthetic) 
lead to changes in the presented safety evaluation. Compared with previous studies, the 
technique of administration is of greater importance for the effect on unbound ropivacaine. 
The latter pharmacokinetic mechanism is unclear.
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The RCT in chapter 5 showed that erythropoietin alpha (EPO) was superior in mildly 
anaemic patients compared with a postoperative retransfusion system. In mildly anaemic 
patients, preoperative haemoglobin levels between 10 g/dL and 13 g/dL at screening, the 
preoperative haemoglobin level increased to a higher level by EPO and reduced the likelihood 
of receiving an allogeneic blood transfusion. Although the efficacy of erythropoietin is 
superior to retransfusion drains the costs related to this treatment are large. Furthermore, 
currently the number of patients in need for blood transfusion in elective orthopaedic 
surgery is much lower than at the time of this study.
In chapter 6 the costs associated with routine administration of erythropoietin alpha were 
calculated. We found that introducing EPO as a standard treatment in our hospital setting 
would increase the costs by a factor 6. It was showed that health care indicators on PBM 
could be positively influenced by money from the extramural setting. Even more important, 
the generalizability of the results on EPO in the Dutch setting should be questioned, looking 
at the low general transfusion percentages reported (‘zichtbare zorg’) by Dutch hospitals 
over the past few years.
In chapter 7 the percentage of allogeneic blood transfusion requirement was evaluated 
in a randomised controlled trial (RCT), in 575 patients, comparing three arms: no drain, 
autologous blood transfusion (ABT) drain with removal after 6 hours (effective ABT time) 
and ABT with removal the postoperative morning. Secondary outcomes were postoperative 
haemoglobin (Hb) values, length of hospital stay and adverse events. This study showed a 
low percentage (6-8%) of transfused patients, with no differences between the three groups 
(P=0.857). The mean preoperative Hb value in the transfused group was 12.8 g/dL versus 
14.3 g/dL in the non-transfused group (P<0.001, 95% CI: 1.08-1.86 g/dL). Postoperative the 
median of retransfused shed blood in patients with a THA was 280 mL (IQR 150, 400 mL) 
and in TKA patients 500 mL (IQR 350, 650 mL) (P<0.001). ABT drains had no effect on the 
percentage of transfused patients in primary THA and TKA. Also the secondary outcomes 
were comparable between groups.
In Chapter 8 we studied the efficacy of a new disposable perioperative cell saving device 
(Sangvia™) in total hip arthroplasty (THA) surgeries. The blinded interim analysis included 
in the protocol concluded that the original power analysis (outcome percentage of allogenic 
blood transfusions) was based on a too high percentage of patients in need for blood 
transfusion from literature data. The setting turned out to be underpowered. The latter 
resulted in a premature termination of the trial. For that reason the study was not able to 
draw general conclusions on efficacy. A 12% allogeneic blood transfusion rate was found in 
the control group, compared to an expected percentage of 21% from literature data.
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Blinding is one of the methodological safeguards to improve the internal validity of a study. 
Furthermore, it has impact on the effect sizes measured. In chapter 9 we evaluated the 
impact of blinding assessors for study results when interpreting risk of bias. This type of 
blinding could have influence on the evaluation of studies for a systematic review or meta-
analysis. A randomised, crossover trial was performed between four assessors judging 
articles in either a blinded or a non-blinded way. A total of 132 articles were selected. The 
differences in agreement and sum scores on the scales between the assessors suggest that 
risk of bias judgement may be biased by awareness of study results. However, it remains 
questionable if this bias is methodologically relevant when performing a systematic review. 
Further research has to be performed to evaluate its impact when conducting a systematic 
review, especially in studies regarding the screening of methodological quality.
Heterogeneity is a major problem in PBM studies, especially in drainage studies in 
orthopaedic surgery. In chapter 10 a systematic review was performed with focus on the 
effect of confounders in PBM on the interpretation of outcome results. To this end clinical 
and methodological quality was checked in all included studies, with special focus on the 
presented information on the transfusion policy in the studies. In 57% of the included 
studies an allogeneic blood transfusion was given based only on “clinical symptoms” 
without a properly defined trigger level. Furthermore, none of the studies gave additional 
information on the decision when to transfuse blood. The latter was neither based 
on a specific haemoglobin value nor on specific clinical symptoms. For that matter, this 
heterogeneity on the reason for blood transfusion in PBM studies severely obscures the 
possibility to draw conclusions from studies on whether to use either regular or autologous 
blood transfusion (ABT) drains. A first step in further improvement on PBM policies lies 
in clear-cut reporting of transfusion trigger information, possibly the use of quantitative 
physiological transfusion parameters (e.g. adequately monitor tissue oxygenation and 
haemodynamic stability) in order to compare PBM strategies.
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Hoofdstuk 1 begint met een algemene inleiding over postoperatieve lokale analgesie en 
bloedmanagement. Dit hoofdstuk verdeelt dit proefschrift in twee secties, Patiënt Pijn 
Management (PPM) en Patiënt Bloed Management (PBM). Het onderdeel PPM begint met 
een zogenaamde dose-finding studie (hoofdstuk 2). Hierin zijn we op zoek naar de optimale 
dosis van een femorale zenuwblokkade voor postoperatieve analgesie die een goede 
verlichting van de pijn geeft en de minste bijwerkingen heeft die vroege mobilisatie kan 
belemmeren. De drie geteste dosisregimes (0,1%, 0,05% en 0,025%) geven geen duidelijk 
voordeel in het verlagen van de concentratie van ropivacaine, toegediend als bolusinjecties 
via de femorale zenuwkatheter, onder de 0,1%. In feite, de laagst onderzochte concentratie 
(0,025%) resulteerde in een lagere patiënttevredenheid over de pijnbehandeling, zonder 
een verbetering in het herstel na een totale knieprothese (TKP). 
In hoofdstuk 3 wordt geëvalueerd of LIA (lokale infiltratie analgesie) veilig gecombineerd 
kan worden met retransfusie van opgevangen wondbloed. De patiënten ontvingen 
twee peri-articulaire injecties in de knie tijdens de operatie, gevolgd door continue 
infusie aldaar, beide met ropivacaine. In totaliteit werd 567 mg ropivacaine gegeven. De 
plasmaconcentraties van ropivacaine werden bepaald in bloedmonsters van de patiënt, 
afgenomen op 0, 3, 6 en 24 uur postoperatief. De patiënt kreeg zijn opgevangen wondbloed 
niet intraveneus terug, daarentegen werd retransfusie gemodelleerd door een schatting 
te geven van de cumulatieve plasmaconcentraties 6 uur na de operatie. De totaal en 
ongebonden ropivacaine plasmaconcentraties varieerden respectievelijk tussen de 0,08 
en 1,9 mg/L en 0,003 en 0,11 mg/L. Als het opgevangen wondbloed teruggegeven zou 
worden aan de patiënt zou hier gemiddeld 13,1 ± 3,7 mg ongebonden ropivacaine in zitten. 
De geschatte cumulatieve ropivacaine plasmaspiegels na retransfusie zou geleid hebben 
tot plasmaspiegels onder de 0,26 mg/L, het minimale veiligheidsniveau voor systemische 
toxiciteit. Hiermee is aangetoond dat deze LIA-concentraties veilig zijn om te gebruiken in 
combinatie met een autoloog bloedretransfusiesysteem bij TKP patiënten. 
In hoofdstuk 4 werden de plasmaconcentraties van ropivacaine in tweeëntwintig TKP 
patiënten geanalyseerd, die drie peri-articulaire injecties met ropivacaine (300 mg) tijdens 
de operatie kregen. Plasma van de patiënt en wondbloedmonsters werden afgenomen 
op de volgende 6 tijdsmomenten; 0, 1, 3, 6, 7 en 24 uur postoperatief. De berekende 
(gemodelleerde) maximale ongebonden ropivacaine plasmaconcentratie toonde een 
mediane waarde van 0,114 mg/L (IQR: 0,09, 0,12 mg/L). Alle individuele concentraties 
waren duidelijk lager dan de gerapporteerde toxiciteitsdrempels. De combinatie van LIA en 
wondbloed retransfusie wordt als veilig beschouwd. De verschillen in 
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pijnprotocol (zoals hoeveelheid, soort en concentratie van anesthesie) kunnen leiden tot 
veranderingen in de gepresenteerde veiligheidsevaluatie. Dit gecombineerd met eerdere 
studies blijkt dat de methode van toediening van groter belang is dan de concentratie, dit 
vanwege het effect op de ongebonden ropivacaine hoeveelheid. Het farmacokinetische 
mechanisme hierachter is nog onduidelijk. 
Uit de RCT in hoofdstuk 5 bleek dat erytropoëtine alpha (EPO) superieur was in mild 
anemische patiënten in vergelijking met een postoperatief retransfusiesysteem. Bij mild 
anemische patiënten, preoperatieve hemoglobine niveaus tussen 10 g/dL en 13 g/dL bij 
screening, werd het preoperatieve hemoglobinegehalte hoger door EPO, wat de kans op 
het ontvangen van een allogene bloedtransfusie verminderd. Hoewel de werkzaamheid 
van erytropoëtine alpha superieur is aan een retransfusie zijn de kosten van een dergelijke 
behandeling hoog. Bovendien is het aantal patiënten dat een bloedtransfusie nodig heeft 
na electieve orthopedische chirurgie nu veel lager dan op het moment dat dit onderzoek 
werd uitgevoerd. 
In hoofdstuk 6 worden de kosten in verband met routineus toepassen van erytropoëtine 
alpha in de praktijk berekend. Wij vonden dat indien EPO als standaardbehandeling zou 
worden ingevoerd in ons ziekenhuis, de kosten toe zouden nemen met een factor 6. Daarnaast 
is het mogelijk om gezondheidszorgindicatoren over PBM positief te beïnvloeden door geld 
uit te geven dat komt uit de extramurale setting. Maar nog belangrijker, momenteel kan men 
vraagtekens zetten over de generaliseerbaarheid van de EPO resultaten in de Nederlandse 
setting., dit kijkend naar de lage algemene transfusiepercentages gerapporteerd (‘Zichtbare 
Zorg’) door Nederlandse ziekenhuizen in de afgelopen jaren. 
In hoofdstuk 7 is het percentage allogene bloedtransfusies geëvalueerd in een 
gerandomiseerd gecontroleerd onderzoek (RCT) bij 575 patiënten. Deze studie had drie 
behandelarmen: geen drain, autologe bloedtransfusie (ABT) met verwijdering van de 
drain na 6 uur (effectieve ABT tijd) en ABT met het verwijderen van de drain de eerste 
postoperatieve ochtend. Secundaire uitkomsten waren postoperatief hemoglobine (Hb) 
niveau, de duur van verblijf in het ziekenhuis en bijwerkingen tot 6 weken na operatie. Deze 
studie had een laag transfusiepercentage (6-8%) met geen verschil tussen de drie groepen 
(p=0.857). De gemiddelde preoperatieve Hb-waarde in de transfusiegroep was 12,8 g/dL 
versus 14,3 g/dL in de niet-transfusiegroep (p <0,001, 95% CI: 1,08-1,86 g/dL). De mediaan 
van geretransfundeerd bloed bij patiënten met een THA was 280 mL (IQR: 150, 400 mL) 
en in TKA patiënten 500 mL (IQR: 350, 650 mL) (p <0,001). Ook de secundaire uitkomsten 
waren vergelijkbaar tussen de groepen. ABT-drains hebben geen effect op het transfusie 
percentage van patiënten in primaire THA en TKA. 
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In hoofdstuk 8 hebben we de werkzaamheid van een nieuw disposable perioperatief 
bloedsysteem (Sangvia™ Bloed Management System, AstraTech AB, Mölndal, Zweden) bij 
totale heupprothese (THA) chirurgie onderzocht. De tussentijdse analyse, die uitgevoerd 
werd volgens protocol, toonde aan dat de oorspronkelijke berekening van groepsgrootte 
gebaseerd was op een te hoog percentage patiënten die een bloedtransfusie nodig hadden. 
De studie bleek underpowered om de verwachte uitkomst aan te tonen, dit resulteerde 
in het voortijdig stoppen van de inclusie van nieuwe patiënten in het onderzoek. 
Om die reden was de studie niet in staat om algemene conclusies te trekken over de 
werkzaamheid maar alleen te kijken naar kwaliteit van opgevangen bloed. Het percentage 
allogene bloedtransfusies was 12% in de controlegroep vergeleken met een verwacht 
percentage van 21% vanuit de literatuur. De complicaties na het gebruik van dit systeem 
waren vergelijkbaar tussen de twee groepen en de lab waarden toonden geen onveilige 
bloedwaarden aan waardoor de veiligheid van het systeem verder is aangetoond.
Blindering is een van de methodologische kernpunten om de interne validiteit van een studie 
te waarborgen c.q. verbeteren. Bovendien heeft blindering invloed op de effectmaten die 
worden gemeten. 
In hoofdstuk 9 evalueerden we de impact van beoordelaars, die blind waren voor de 
studieresultaten, op hun interpretatie van het risico op bias in een studie. Deze vorm van 
blindering kan invloed hebben op de evaluatie van studies voor een systematisch review 
of meta-analyse. Een gerandomiseerde, cross-over studie werd uitgevoerd tussen vier 
beoordelaars die 132 artikelen beoordeelden op ofwel een geblindeerde of een niet-
geblindeerde wijze. De verschillen in de overeenkomst en somscores op de schalen tussen 
de beoordelaars suggereren dat het risico op bias beïnvloed kan worden door het bewustzijn 
van de studieresultaten. Het blijft echter de vraag of dit methodologisch relevant is bij het 
uitvoeren van een systematisch review. Verder onderzoek moet gedaan worden om de 
impact hiervan bij het uitvoeren van een systematische review te beoordelen, vooral in 
studies die de focus leggen op screening van methodologische kwaliteit. 
Heterogeniteit is een groot probleem in PBM-studies. In hoofdstuk 10 werd een 
systematisch review uitgevoerd met focus op het effect van verstorende factoren in PBM 
op de interpretatie van de uitkomstmaten. Daarnaast werden klinische en methodologische 
kwaliteit gecontroleerd in de geïncludeerde studies, met speciale aandacht voor de 
gepresenteerde informatie over het gevoerde transfusiebeleid. In 57% van de geïncludeerde 
studies bestond de mogelijkheid een allogene bloedtransfusie te geven gebaseerd op 
“klinische symptomen”. Bovendien presenteerden geen van de studies aanvullende 
informatie over de beslissing wanneer allogeen bloed getransfundeerd werd. Om die 
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reden is het lastig om in PBM-studies conclusies te trekken wat betreft de waarde van een 
gewone of autologe bloedretransfusiedrain op het percentage allogene bloedtransfusies. 
Een eerste stap in de verdere verbetering van het PBM-beleid ligt in duidelijkere rapportage 
van transfusie trigger-informatie, mogelijk het gebruik van kwantitatieve fysiologische 
transfusieparameters (bijvoorbeeld een adequate zuurstofvoorziening van de weefsels en 
de hemodynamische stabiliteit te bewaken) om PBM-strategieën te vergelijken.
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A
eleVAToR PITCH
What is already known on this topic
Local infiltration analgesia in combination with a multimodal pain approach helps for 
adequate postoperative pain control.
Blood saving alternatives should be implemented in the process of primary total hip and 
knee arthroplasties.
The endpoint in patient blood management studies is usually Transfusion.
What this thesis adds
Local infiltration as defined in this study can be used safely in combination with an auto-
logous blood transfusion drainage system.
Key clinical components of a randomised trial are frequently inadequately taken into 
account when performing a systematic review.
The endpoint transfusion in patient blood management studies needs additional information 
to make it a strong endpoint.
What is necessary in the future
More evidence based practice, use the correct available evidence in the light of your own 
hospital figures, in patient blood management.
More adequate reporting of and explanations for the transfusion decisions made in patient 
blood management trials.
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